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ABSTRACT 
Background: Hepatocellular cancer [1] is increasing worldwide. The majority are 
detected too late for curative surgery as effective identification of the at risk 
population and their subsequent surveillance is inadequate. My specific aims were to 
study and characterise our own patients, evaluating the known and predicted 
biomarkers for HCC in patients with non-alcoholic fatty liver disease and exploring 
novel biomarker methodologies for the detection of either cirrhosis or HCC 
complicating it.  
Methods: Details of all HCC patients presenting to the Newcastle 
hepatopancreatobiliary (HPB) multidisciplinary team were recorded in an NHS 
intranet database, and a subset were consented for tissue collection.  Established and 
candidate biomarkers were assessed in serum by western blotting and/or ELISA assay 
and the role of microarray analysis of HepG2 cells, and 2D-gel electrophoresis of 
immunodepleted serum in novel candidate biomarker identification were explored. 
Results: 
The number of HCC cases referred has increased dramatically over the last decade, as 
has the numbers arising in a background of non-alcoholic fatty liver disease 
(NAFLD). In our cohort, patients with earlier stage cancers detected by either -
surveillance or incidentally had a better prognosis, but only 10% were eligible for 
definitive treatment.. While HCC patients treated with liver transplant had an overall 
5 year survival was 62.1%, the median survival of the transplant cohort was 137 
months.  Exploration of serum levels of Glypican 3, Squamous Cell Carcinoma 
Antigen-1 and follistatin were poor surveillance biomarkers, but the combination of 
Alpha-fetoprotein and Protrhombin induced by vitamin-K absence was encouraging. 
Serum proteomic analysis in a small subgroup identified four isoforms of 
apolipoproteins as well as CD5L as differentially expressed between patients with no 
cirrhosis, cirrhosis and HCC, although subsequent CD5L ELISA failed to confirm its 
ability to specifically detect HCC.   
Discussion: 
While the incidence of HCC is increasing, the prognosis for those affected remains 
poor.  Biomarkers identifying both the at risk individuals and those with cancer are 
urgently required. 
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CHAPTER 1.  INTRODUCTION 
1.1 Hepatocellular Carcinoma (HCC) 
Hepatocellular carcinoma is a major health problem worldwide. It is the fifth 
commonest neoplasm in the world, and the third most common cause of cancer 
related death[2]. More than 500,000 new cases are currently diagnosed yearly, with an 
age adjusted worldwide incidence of 5.5 – 14.9 per 100,000 population. The incidence 
of HCC has been reported to be rising during the last 5-8 years    [2-6]. Commonly but 
not exclusively, HCC (60-80%) develops in a setting of liver cirrhosis[7]. Liver 
cirrhosis has a very diverse aetiology which includes chronic hepatitis B and hepatitis 
C infection, alcohol excess, non-alcoholic fatty liver disease (NAFLD), diabetes, 
certain medications  (e.g. imipramine, phenothiazine, tolbutamide, phenytoin) genetic 
metabolic diseases as well as toxic exposures including dietary aflatoxins. The annual 
incidence of HCC in cirrhotic patients ranges from 2-8% with a cumulative 5 year 
incidence rate ranging from 15% to 20%[8, 9]. 
Cirrhosis development is characterized by inflammatory cell infiltration, hepatocyte 
regeneration, necrosis and parenchymal remodelling. Residual hepatocytes are 
stimulated to proliferate and this is eventually associated with remodelling of the 
hepatic sinusoids and subdivision of liver parenchyma by fibrous tissue. 
Hepatocarcinogenesis is a multifactorial, multistep process in which external stimuli 
induce genetic changes in key growth regulatory genes in hepatocytes. This can lead 
to changes in cellular proliferation, cell death and the emergence of clonal populations 
with a genetic damage induced survival advantage. These clonal cells may become 
dysplastic hepatocytes, evolving into dysplastic nodules[10]. These grow more rapidly 
and have a tendency to acquire additional genetic damage, progressing into higher 
grade dysplastic nodules. High grade dysplastic nodules are considered premalignant 
in nature. No consistent pattern of genetic damage at different evolutionary stages of 
HCC has been described. This may be because the molecular pathways leading to 
HCC differ according to the underlying aetiology. 
As cirrhosis is clearly a major factor pre-disposing to HCC development, one would 
hope that monitoring of individuals with known chronic liver disease would increase 
the likelihood of early HCC detection, facilitating effective treatments, and improving 
prognosis. While surveillance programmes are thought to aid the diagnosis of early 
HCC (single tumour less than 5cm or not more than 3 tumours and none more than 
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3cm) in 30 – 60%, the benefit is restricted to those patients with known cirrhosis, 
already in surveillance programmes, largely in developed countries [11]. The reality is 
that in up to 80% of patients, an HCC is detected at an advanced stage and prognosis 
for those presenting after the onset of symptoms, is dismal. The overall survival for 
HCC patients is 0-10% at 5 years [12], with many surviving just a few weeks or 
months after diagnosis.  This failure is attributed in part to the lack of effective 
surveillance tools in patients with cirrhosis, but also because of our inability to 
satisfactorily identify the at risk population with chronic liver disease who would 
benefit from regular follow-up. 
1.2 The surveillance population – individuals with cirrhosis 
Progressive hepatic fibrosis with the development of cirrhosis is a feature of all 
chronic liver diseases. Development of fibrosis is a step by step process starting from 
minimal fibrosis limited to the portal tracts, followed by more extensive fibrosis with 
septa extending into the liver parenchyma, that can form bridges between portal tracts. 
On this background, nodules of regenerating hepatocytes further distort the liver 
architechture. Studies on the natural history of the disease suggest that advanced 
fibrosis and cirrhosis develop in about 20 – 40% of patients with chronic hepatitis B 
or C and in a similar proportion to those with alcoholic and non-alcoholic 
steatohepatitis[13-15]. The progression of chronic liver disease through liver fibrosis 
to cirrhosis may take years to decades to develop and needs the perpetuation of the 
underlying injury. Up to 80% of patients  with HCC have an underlying cirrhosis. One 
factor important in a successful HCC surveillance programme is the identification of 
the at risk population. This population includes individuals with chronic hepatitis B, 
hepatitic C virus hepatitis as well as those with cirrhosis of any cause. This suggests 
that staging of hepatic fibrosis is of paramount importance to assess the risk of disease 
progression as patients with necro-inflammation and fibrosis are at highest risk for 
end stage liver disease and hepatocellular carcinoma. To diagnose the aetiology of 
liver disease and stage the severity of  fibrosis or confirm the presence of cirrhosis, a 
liver biopsy with subsequent histopathological assessment is the recommended 
procedure[16]. However, for a number of reasons there is a lot of interest in 
developing non-invasive methods as alternatives. 
Liver biopsy has been used as the ‘‘gold standard’’ for almost all studies evaluating 
noninvasive markers of liver fibrosis[17]. Liver biopsy has the advantage of allowing  
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the acquisition of diagnostic information in making a diagnosis in chronic liver 
diseases, but also plays a key role in the staging of the disease and in their follow up. 
For both the physicians and the patient, the decision to proceed with a liver biopsy is 
not a trivial one due to the risk of complications. Following a liver biopsy 1-5% of 
patients experience severe adverse events needing hospital after care  prolonged by 
more than one day with a reported mortality rate between 1:1000 and 1:10,000[18-
22]. Furthermore, many patients are reluctant to have repeated biopsies, which limits 
our ability to monitor disease progression and the effects of treatment. 
Moreover, a needle liver biopsy only removes 1/50,000
th
 of the liver and hence carries 
the risk of substantial sampling error and cirrhosis can be missed on a single blind 
liver biopsy in 10-30% of cases[23-25]. Review of the available data on the accuracy 
of needle liver biopsy to define the stage of fibrosis is affected by significant 
interpretative error[17]. Interpretation of the sample can also be affected by sample 
size as Scheuer concluded that bigger specimens are more conclusive [26]. Colloredo 
et al also concluded that an adequate specimen should be at least 20 mm in length 
with at least 11 complete portal tracts[27]. The current British guideline considers that 
most hepatologists are satisfied with a biopsy containing more than 6 – 8 portal 
triads[28]. The need for obtaining an adequate liver sample contrasts with the patient 
needs of limited pain and reduced haemorrhagic risks and in fact this procedure could 
be particularly risky for advanced liver disease[29, 30].  The different adverse factors 
associated with biopsy, along with intra/ interobserver variability [31] and 
considerable sampling variability[32], limits the role of liver biopsy in regular 
surveillance. It is also a practice that should not be widely employed as a surveillance 
or screening tool for wider populations. The development of potential non-invasive 
markers, with high sensitivity and specificity, that can be repeated at regular intervals, 
without adding any risk to the patient, are being actively pursued. 
Presently, non-invasive markers for fibrosis can be broadly divided into those that are 
serum based, and those that are imaging based. Assessment of liver fibrosis by a 
combinations of serum markers have shown encouraging results, and the ideal 
characteristic of a serum biomarker as defined by Sebastiani G et al [33] will: (1) be 
specific for fibrosis in the liver; (2) provide measurements to stage the fibrosis and 
fibrogenesis activity; (3) not be influenced by co-morbidities; (4) have a known half-
life; (5) have a known excretion route; (6) be sensitive and reproducible. They can be 
divided into ‘direct’ and ‘indirect’ markers. 
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Direct markers of fibrogenesis are defined as measurable biochemical markers in the 
peripheral blood which reflect the turnover of extracellular matrix of the liver. 
Examples include several glycoproteins (laminin, hyaluronan), the collagen family 
(procollagen III), collagenases and their tissue inhibitors (metalloproteinases, tissue 
inhibitors of matrix metalloproteinase) and cytokines associated with fibrogenesis 
(TNF-β, TGF- β1). These markers have the potential to clinically assess the stage and 
progression of fibrosis, but also to monitor response to treatment. As yet, this has not 
been achieved, but progress has been made. 
Indirect marker of fibrosis are defined as single or combined haematological or 
biochemical parameters that reflect the stage of liver disease, rather than the process. 
Of the direct markers, hyaluronic acid has been studied in all the common forms of 
chronic liver disease and shows an overall good accuracy to discriminate early from 
significant fibrosis. However, the studies had very small cohorts and needed 
validation in larger studies. In 2004, Rosenthal et al in a multicenter cohort study with 
1021 patient samples developed an algorithm combining age with direct markers of 
fibrogenesis i.e. hyaluronic acid, amino-terminal propeptide of type III collagen, and 
tissue inhibitor of matrix metalloproteinase along with markers for inflammation and 
extracellular matrix degradation. The results were compared with tissue samples and 
it detected severe fibrosis with sensitivity of 90% and also accurately detected the 
absence of fibrosis in patients with alcoholic and non-alcoholic fatty liver 
diseases[34]. This algorithm is now described as the ‘Enhanced Liver Fibrosis 
Panel’(ELF). Two studies so far has validated the ELF panel of markers in detecting 
fibrosis in adult and paediatric patients with non-alcoholic fatty liver disease. It is 
restricted by the limited capacity to diagnose the intermediate stages of fibrosis i.e. 
can diagnose cirrhosis. Regarding the ability to predict clinical outcomes in patients 
with chronic liver disease, a prospective study with a 7 year follow up, reported its 
efficacy to be similar to liver biopsy. However, more data is required from 
longitudinal studies to evaluate the performance of these non-invasive markers in 
evaluating disease progression or regression. 
Indirect markers can predict fibrosis either as independent markers like ALT/AST 
ratio (aspartateaminotransferase ratio)[35] or as multicomponent indirect fibrosis test. 
Of the latter, the ‘Fibrotest’ is the most extensively studied. This test which uses a 
combination of five blood tests including γ glutamyl transferase, haptoglobin, 
bilirubin, apolipoproteinA1, α2 macroglobulin, was initially proposed by Imbert-
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Bismuth and colleagues in 1999[36].The data from different studies suggest that the 
Fibrotest  performs well in detecting the two extremes of stages of liver fibrosis but is 
again less accurate in detecting the intermediate stages of fibrosis[17, 37]. 
Radiological or imaging methods considered as liver fibrosis detection methods 
include CT, ultrasound and MRI. Subjective measures such as ‘an irregular liver 
edge’ are poorly reproducible. More quantitative attempts have identified that the 
right lobe exhibits relatively greater shrinkage, while the caudate lobe undergoes 
relative enlargement, and that the ratio of the transverse caudate lobe width to the 
transverse right lobe width can separate cirrhotic livers from the non-cirrhotics ones 
[38]. Using these technique, cirrhosis could be correctly diagnosed with a sensitivity 
of 84%, specificity of 100% and a diagnostic accuracy of 94%. The lower sensitivity 
is attributed to these morphological changes only being present in those with more 
advanced disease[17]. Aube et al studied 11 ultrasonographic variables (in 243 
patients with chronic liver disease), including measurements of liver morphology, 
assessment of portal venous flow, spleen size and liver nodularity and detected a 
diagnostic accuracy of 82-88%. Here, the limitation was significant interobserver 
variability and inability to gain all the required measurements in all patients due to 
anatomic constraints [39]. Comparing ultrasonography to clinical and biochemical 
parameters, Oberti et al found that USS had a diagnostic accuracy of only 70% as 
compared to biochemical parameters which correctly diagnosed cirrhosis in 91 – 94% 
of patients with chronic liver disease, with serum hyaluronidate appeared the most 
sensitive marker for screening[40].  
Another non-invasive imaging modality that is gaining popularity in the assessment 
and staging of liver fibrosis is Hepatic ultrasonic transient elastography/Fibroscan, 
first reported by Sandrin L et al in 2003 [41]. The Fibroscan includes a probe, an 
electronic analysis system, and a control unit installed on a computer. The technique 
uses both ultrasound (5mHz) and low frequency (50Hz) elastic waves whose 
propagation velocity in the liver tissue is directly related to the elasticity of the tissue. 
A metanalysis in 2009 showed that Transient Elastography can be performed with 
excellent accuracy in the diagnosis of cirrhosis irrespective of the aetiology [42]  
However, it is again less accurate in differentiating the different stages of liver 
fibrosis [43]. The results of the test can also be limited by obesity, especially  
increasing waist line/central obesity and also by the experience of the operator [44].  
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In summary, liver biopsy cannot be generally applied for fibrosis detection, and 
although some of the non-invasive methods being explored show promise, none has as 
yet been widely adopted as an alternative.   
1.2.1 Poor sensitivity and specificity of surveillance for HCC 
During the last 30 years, there have been enormous advances in the understanding of 
the mechanisms of carcinogenesis. However, these advances have not seen a parallel 
improvement in the treatment of cancers[45]. A surveillance programme in cirrhotic 
patients has the potential advantage of detection of HCC in its early stages. Early 
detection of HCC is the only way to avoid mortality as the disease is always fatal 
when diagnosed too late for surgical and / or ablative treatments. However, to 
diagnose HCC early and appropriately has proved to be very difficult.  The 
complexity of cancer disease can be attributed to be one of the important causes of 
impediment to this process. It is also known now that the response of individual 
tumours to various forms of treatment is often not possible to predict by histological 
evaluation of tumour tissue alone. An important mission in cancer research is the 
identification of accurate biological markers that can be used to diagnose a disease 
early, as well as predict prognosis and response to treatment options. 
A biological marker is defined as a ‘‘characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathological processes  or 
pharmacological responses to therapeautic intervention’’. An ideal marker would be a 
protein or protein fragment that can be easily detected in the patient’s blood or urine, 
but not detected in a healthy person. Today the most common use of biomarkers is for 
detection of early and recurrent disease [46]. Despite the large number of 
investigations devoted to their identification, reliable biomarkers are still elusive in 
many malignant diseases, including HCC. 
Biomarkers can be grouped into three different classes[47]: 
(1)Diagnostic: These are used to aid histopathological tumour classification. Accurate 
diagnostic markers can aid in screening helping early diagnosis of tumours and 
optimal treatment choices. Diagnostic markers include Calcitonin – elevated in the 
serum of patients with thyroid medullary carcinoma; and PSA( Prostate Specific 
Antigen) – elevated in the serum of patients with prostate cancer [48]. Diagnostic 
markers can also aid the detection of tumour recurrence, especially if the treated 
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primary tumour secreted a particular marker, such as CA-125 (ovarian carcinomas), or  
CEA ( colorectal carcinomas) [46].  
(2)Prognostic: These provide information about the malignant potential of the 
tumours, and can be instrumental in optimum treatment choice. An adequate 
evaluation of the metastatic spread is of particular importance. Examples include 
hormone receptors, proliferation markers, markers of angiogenesis (VEGF), growth 
factor receptors (HER-2/neu) and p53. Her-2 oncogene expression in tissues and 
serum is the most commonly used predictive biomarker for breast cancer. Expression 
of HER-2 is significantly related to positive lymph nodes, poor nuclear grade, lack of 
steroid receptors and high proliferative activity and has been shown to identify a 
subgroup of patients node-specific breast cancer patients with poor prognosis [49-51]. 
Absence of oestrogen and progesterone receptors, upregulation of Ki-67 (MiB1) 
antigen are additional indicators of poor prognosis [52-54]. For ovarian cancer cyclin 
D1 overexpression is related to an aggressive phenotype and poor prognosis  
(3) Predictive: These can also guide alternative treatment modalities. Breast cancer 
patients that exhibit oestrogen receptor positive tumours are usually treated with anti-
oestrogen compounds, as the presence of the marker predicts their response to that 
therapy. Similarly, patients with tumours positive for the Her-2 poor prognostic 
marker, respond to treatment with Herceptin, a monoclonal antibody that binds the 
Her-2 epidermal growth factor receptor isoform, blocking its mitogenic signalling to 
tumour cells[46, 47]  
An assay that is used to determine the presence or absence of disease must be 
validated using a series of analyses that determines how well the test performs in 
diagnosing the disease (since no test is 100% accurate). The simplest measures are 
sensitivity (true positive rate) and specificity (true negative rate), which are inversely 
related. The diagnostic accuracy of a test further relies on the prevalence of the 
disease in the population and can be ascertained by the positive and negative 
predictive values, i.e. the rates at which positive and negative results are correct. The 
Youden index (sensitivity + specificity – 1) can be used to give an estimate of the 
efficiency of the test, free of the influence of the disease incidence. 
Current surveillance tests for HCC are divided into two categories: serological and 
radiological tests 
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1.2.2 Surveillance - Serum biomarkers 
1.2.2.1 Alpha-foetoprotein 
Alpha foetoprotein is a glycoprotein produced primarily by the foetal liver. Its 
concentration falls after birth and its production is repressed in adult life. Since its 
discovery in 1963 [55], and its recognised association with the presence of HCC [56], 
serum alpha –fetoprotein has become the most commonly performed serological test 
for hepatoma screening and surveillance in cirrhotics  patients.  
Trevisani et al reported, using Receiver Operating Characteristics (ROC) for AFP, 
that with a normal serum level below 10ng/ml, 20ng/ml reportedly showed the 
optimal balance between sensitivity and specificity.  20ng/ml is currently considered 
the limit above which investigations for HCC are needed[57]. However, at this level 
the specificity is not particularly good and the sensitivity is only 60%, which is 
inadequate for general use. At higher cut-offs, the specificity is increased, but 
progressively fewer HCC are detected. If the AFP cut-off is raised to, e.g., 200 ng/mL 
(This is the level set by the European Association for the Study of Liver Disease 
(EASL) for HCC diagnosis in a cirrhotic patient with a typical hypervascular mass on 
imaging)  the sensitivity drops to 22%[58]. Some investigators have suggested that the 
usefulness of AFP for HCC detection in viral hepatitis is even worse, and that it 
should be reserved for detecting HCC of non-viral etiology. [59] Certainly transient 
increases and fluctuations in serum AFP may occur in chronic liver disease and 
cirrhosis, especially during exacerbations of hepatitis. Moderately raised levels in 
some patients with uncomplicated chronic liver disease contributes to a relatively low  
specificity of AFP [60].  Therefore some increases can be misleading and all patients 
need retesting at a fortnight after a raised result, especially if obtained in the absence 
of positive imaging. It is a persistently elevated serum AFP, or one steadily rising, that 
alerts to the presence of a tumour.  In specialist liver clinics, where the prevalence of 
HCC among cirrhotic patients is high at approximately 5%, serial testing still has a 
role, even though its inadequacy as a screening test is widely acknowledged 
[57].Serum AFP estimation may be useful in monitoring response to therapy despite 
its poor performance as a surveillance diagnostic marker. Indeed, there is preliminary 
evidence that changes in serum AFP may be a more accurate and sensitive way of 
determining the degree of response to treatment than conventional imaging 
procedures that rely on physical determination of tumour size[61]. 
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Total AFP can be divided into three different glycoforms, namely AFP-L1, AFP-L2 
and AFP-L3, according to their binding capabilities to lectin lens culinaris agglutin. 
AFP-L1, as the non-LCA bound fraction, is the major glycoform of AFP in the serum 
of non-malignant hepatopathy patients. On the contrary, AFP-L3, is the LCA bound 
fraction, is the major glycoform of AFP in the serum of HCC. Some researchers 
suggest that the sensitivity of AFP can be improved by measuring the glycoforms of 
AFP. Measurement of the lens culinaris agglutin-reactive fragment of AFP (AFP-L3) 
has been developed and reflects HCC related changes in the AFP carbohydrate side 
chain[62]. Early studies suggested that the AFP-L3 assessment could be used to detect 
early HCC in patients with cirrhosis [63, 64] and that AFP-L3 could be used as an 
adjuvant to imaging and AFP in the surveillance for HCC[65]. These studies had the 
advantage of being prospective in nature but they were under powered (patient 
numbers ≤ 51) and performed only in single centre studies.  However, a large phase 2 
biomarker case control study which included 417 cirrhosis controls and 419 HCC 
cases showed that AFP-L3 was not sensitive in detecting early HCC. The study 
concluded that for the diagnosis of early stage HCC, AFP-L3% was not useful, partly 
because of the need for an elevated total AFP,  which limits its effectiveness [66]  
AFP-L3 could possibly be used as a prognostic marker. According to a study by 
Kumada et al, the tumour doubling time is shorter in patients with high levels of AFP-
L3 and failure of AFP-L3 to fall after treatment could signify residual disease. 
Recurrence of HCC is likely if AFP-L3 starts to rise after returning to baseline after 
treatment.[67]. It has also been found that relapse with multifocal HCC and portal 
vein invasion is more frequent in patients with elevated AFP-L3 as compared to the 
patients with re-elevation of AFP-L3 after treatment[67]. Unfortunately, as the 
sensitivity of AFP-L3 is suboptimal it is unlikely to improve surveillance strategies if 
widely accepted. The assay of AFP-L3 is not routinely available, [68] which is also a 
limiting factor in its routine use. 
1.2.3 Surveillance - Imaging modalities 
 a) Abdominal Ultrasound (USS) of the liver is the most commonly used test 
for surveillance of HCC because it is simple and non-invasive [69, 70]. Lesions can 
take on a number of appearances. The lesion can be echogenic because of the fat 
content, or give a hypoechogenic or target lesion appearance. None of these 
appearances are specific. The sensitivity of ultrasound has been reported to be 
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between 65 and 80% with a specificity of 90% when used as a screening test for HCC 
in patients with cirrhosis[71]. In patients with cirrhosis a positive predictive value to 
detect HCC has been reported to be 78%[72]. However, a study by Sherman et al 
showed a positive predictive value of only 14% when ultrasound was used for 
screening in chronic HBsAg carriers [73].  Thus, the value of USS is highly variable. 
The major drawback is that its performance depends on the experience of the 
examiner and the physical size of the patient. Although these performance 
characteristics are not ideal, they are superior to any available and validated 
serological test. 
Further development in ultrasound technology can improve the efficacy of the 
technique in screening. Colour Doppler imaging provides real time imaging of the 
haemodynamics of liver tumours, and power Doppler imaging has added to a better 
detectability of blood flow. However, limitations in the detection of slow flow and 
vessels located deeply from the skin surface have prevented the use of these modes 
regularly in the evaluation of tumour haemodynamics. Against this background the 
development and use of micro bubble contrast agents was expected to provide a stable 
enhancement effect that are useful for the detection and characterisation of liver 
tumours. Recent literature suggests that contrast enhanced ultrasound has a reported 
sensitivity of 98 – 100% and specificity of 63 – 93% in discriminating benign from 
malignant liver lesions. The use of contrast enhanced ultrasound to characterise 
nodular lesions in cirrhosis has been recommended by the clinical practice guidelines 
issued by the European Federation of Societies for Ultrasound in Medicine and 
Biology and the American Association for Study if Liver Diseases. However, 
contrast-enhanced US has not resulted in any significant improvement in the ability of 
US to detect small tumour foci, since a comprehensive assessment of the whole liver 
parenchyma cannot be accomplished during the short duration of the arterial phase 
[74].  Secondly, contrast enhanced ultrasound is not cheap and is not routinely 
available. 
 b) Computerised Tomography (CT) is suggested when there is suspicion of 
HCC by ultrasound in a patient with cirrhosis of the liver[75]. Evaluating spiral CT 
alone Kim et al showed that the sensitivity of HCC detection was up to 100% from 
results of imaging with the four phase CT in tumours greater than 2cm in size, 93% in 
tumours 1-2cm in size and 60% in tumours less than 1cm in size[76]. Comparing 
ultrasound with CT scan in a screening programme Chalasani et al reported a 
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sensitivity of 59% with ultrasound and 91% with CT scan[77]. In another study 
comparing the two modalities for evaluation before liver transplantation sensitivity to 
detect HCC was reported to be 79.4% for ultrasound and 81.6% for CT scan[78]. 
Teefey et al, however, mentioned that the sensitivity of ultrasound (89%) was much 
higher than CT (67%) and magnetic resonance imaging (56%). Given the poor 
performance of alpha foetoprotein and the observer dependant variation with 
ultrasound some groups have suggested the use of CT for surveillance. This however 
poses a number of logistic problems. First, a screening test is usually not the 
diagnostic test of choice. Second, the performance characteristics of CT scanning 
have been developed in diagnostic/imaging studies and the performance 
characteristics of CT scanning in HCC surveillance are unknown. Furthermore, if CT`
 ` scan is to be used as a screening test, i.e. every 6-12 months over many 
years,  there is a significant radiation exposure [58], as well as significant increase in 
costs to be considered. Current practice is to use CT for surveillance only in poor 
sonar subjects e.g. markedly obese individuals, or in those where a suspicious nodule 
on USS or mid to moderately raised AFP, suggests a higher individual risk of 
developing HCC. 
c)  Magnetic Resonanace Imaging (MRI) of the liver has a sensitivity of 40-70% for 
detection of early HCC [79, 80]. The arterial phase is critical for detection of 
HCC[81]. Lesions more than 1cm which are hyperintense in the T2 phase of imaging 
are likely to be malignant which helps to differentiate from dysplastic nodules and 
regenerative nodules which are T2 hypointense [82]. These characteristics make it a 
useful tool for diagnosis of HCC but this modality is expensive with a poor sensitivity 
which does not make it an ideal imaging for surveillance. 
d)  2-[fluorine-18]fluoro-2-deoxy-D: -glucose Positron Emission Tomography 
(FDG-PET) detects increased glucose metabolism associated with neoplastic lesions, 
provides high accuracy in most cancer imaging. Only 30-50% of HCC show 18F FDG 
uptake above background levels [83] which limits its application in the evaluation of 
HCC. To improve visualisation of these lesions an alternative tracer (11-acetate) has  
been used in conjuction with FDG [84]. The degree of differentiation determines its 
relative avidity for one of the two probe molecules. This can be used as a diagnostic 
tool but the limited availability and and high cost do not make it an effective 
surveillance tool.  
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1.2.4 Current practice of surveillance 
Our current practice for HCC surveillance is to use six monthly USS with serum AFP 
measurements. HCC screening is recommended in the high risk patients as mentioned 
below[85] 
 Hepatitis B carriers (HBsAg positive) 
 Asian males >40 years 
 Asian females >50 years 
 All cirrhotic hepatitis B carriers 
 Family history of HCC 
 Africans over age 20 years 
 Nonhepatitis B cirrhosis 
 Hepatitis C 
 Alcoholic cirrhosis 
 Genetic haemochromatosis 
 Primary biliary cirrhosis 
 Possible α1-antitrypsin deficiency, non-alcoholic steatohepatitis, autoimmune 
hepatitis 
The cost effectiveness of this programme is still debatable. The detection rates with 
this practice are increased, but so also the costs and false positive rates. AFP alone 
had false positive rate of 5% and ultrasound has a false positive rate of 2.9% but when 
used together the false positive rate rises to 7.5%[86]. The study by Izzo et al 
supported the six monthly surveillance by AFP and USS for patients with severe 
chronic active hepatitis and liver cirrhosis[87]. Fasani et al reported that patients with 
multiple risk factors the six month surveillance might be inadequate and a tailor made 
surveillance programme might be required [88], complicating matters further. 
Two randomised controlled trials from China have reported contradictory findings. 
Investigating 5581 patients with chronic hepatitis infection Chen et al reported that 
biannual screening with AFP and USS resulted in earlier diagnosis of HCC but the 
gain in lead time did not result in overall reduction in mortality[89]. Zhang et al, 
however, in a study of 18816 patients with HBV or chronic hepatitis, reported that in 
the screening group patients the HCC related mortality was reduced by 37%[90]. 
Examining their surveillance programme based on six monthly AFP and USS in a 
European cohort Bolondi et al  reported that the cumulative survival for the 61 
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patients with HCC detected through the surveillance programme was significantly 
better than that of controls not participating in any surveillance programme[71]. Other 
non-randomised trials and observational studies have also shown survival benefit in 
patients diagnosed with HCC in 6-12 monthly surveillance programme using AFP and 
USS[91, 92]. Studies have also shown a survival benefit in those diagnosed with 
small and early tumours[93].  
Surveillance programmes benefit the population if the increased survival with early 
diagnosis is associated with gains in lead time when compared to those diagnosed 
with the disease in late stages. If there is no gain in survival time beyond the time 
when death would occur if diagnosed late then the apparent gain is called a ‘‘lead time 
bias’’. The above mentioned, not so well controlled studies, suggesting improved 
survival by surveillance are plagued by lead time bias, differential tumour growth and 
poor compliance with surveillance. However, a recently reported study by Tong et al 
reported that surveillance for HCC identifies patients with a smaller tumour burden 
after correction for lead time bias these patients show improved survival as compared 
to patients presenting with symptomatic HCC [94]. Another study reported a overall 
reduced survival with delayed diagnosis of HCC irrespective of lead time bias[95]. 
The above mentioned studies are heterogenous but there is some evidence that 
surveillance for HCC may have a positive impact on survival. Due to the availability 
of curative therapy for early HCC it would be difficult to plan further randomised 
trials to accurately evaluate the effect of lead time bias on the survival of patients with 
HCC diagnosed through surveillance versus symptomatic patients. On the basis of 
available data surveillance is performed as per EASL guidelines on a 6 monthly basis 
in the liver units. There is little doubt, however, that the performance needs to be 
improved. It is hoped that more sensitive biomarkers and improved imaging 
technologies will facilitate this.  
1.2.5 Diagnosis of HCC 
HCC is commonly diagnosed with non-invasive methods. For lesions more than 2cm 
or more on a background of cirrhosis the diagnosis of HCC is made using the EASL 
imaging criteria of the presence of typical imaging features showing areas of early 
arterial enhancement and delayed washout in the venous phase of multidetector CT or 
dynamic enhanced MRI. For lesions measuring 1-2cm the diagnosis is made by 
characteristic imaging findings in one or two modalities. For lesions less than 1cm the 
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lesions should be imaged in 4 months later in order to note a change in size or the 
presence of new imaging characteristics[96]. In difficult cases PET-CT is another 
modality which is now being used in specialised centres. In patients where imaging is 
inconclusive for lesions more than 1cm biopsy is suggested in the EASL guidelines. 
1.2.6 Staging of HCC 
An effective staging classification of HCC should help to decide the choice of therapy 
and also predict survival. In addition it is an important research tool which permits 
comparison between differenrt research groups. Well defined staging systems are 
available for almost all cancers. In HCC however, standard tumour staging systems, 
such as the widely adopted tumour, node metastases (TMN), are not helpful as they 
do not take into account the co-existent liver disease.  There are a number of HCC 
specific prognostic scoring systems, which include Cancer of the Liver Programme 
(CLIP), Barcelona Clinic Liver Cancer (BCLC), Chinese University Prognostic Index 
(CUPI) and Japanese Integrated System (JIS) and Okuda Scoring systems. All these 
staging systems use permutations of different variables including number and size of 
the liver lesions, spread of the disease to the portal veins or systemically, as well as 
having a measure of the severity of background liver disease. Largely because of the 
variability in the latter, HCC has proved somewhat of an exception in that here is no 
consensus as to which one to be used universally.  Some groups have adopted the 
BCLC staging system (figure 1.1) as this system aids management by stratifying 
patients into treatment groups, according to the extent of the disease, underlying liver 
function and performance status (PST). 
Figure 1.1(below) showing the BCLC staging of HCC 
Stage                                   Tumour status 
PST         Tumour stage      Okuda                 Liver function 
O very early HCC 0 Single <2cm I No portal hypertension, 
normal bilirubin 
 
A early HCC 
A1 
 
A2 
 
0 
 
0 
 
Single 
 
Single 
 
I 
 
I 
 
No portal hypertension 
and normal bilirubin 
Portal hypertension and 
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A3 
 
A4 
 
0 
 
0 
 
Single 
 
3tumours <3cm 
 
I 
 
I-II 
normal bilirubin 
Portal hypertension and 
abnormal bilirubin 
Child-Pugh A - B 
 
B Intermediate HCC 0 Large 
multinodular 
 
I-11 Child-Pugh A-B 
C Advanced HCC 1-2 Vascular 
invasion or 
extrahepatic 
spread 
 
I-11 Child-Pugh A-B 
D End stage HCC 3-4 Any 
 
III Child-Pugh C 
 
Another commonly used staging system is the CLIP score, which uses a mathematical 
score based on the Child Pugh criteria for assessing liver function, tumour 
morphology, AFP and the presence of vascular invasions. This scoring system has 
been analysed in a prospective manner and has been suggested as the best documented 
and analysed staging system for prognostic purposes[97]. Using a combination of two 
staging systems is an acceptable alternative and many centres prefer this. 
1.2.7 Current treatment modalities  
Therapies for HCC can be broadly classified into 4 categories: 
Surgical  
Resection 
Transplantation 
Percutaneous ablative techniques 
Radiofrequency Ablation (RFA) 
Percutaneous ethanol injection (PEI) 
Microwave ablation 
Experimental strategies 
High intensity focussed ultrasound 
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Electroporation 
Radiofrequency based treatment with nano particles 
Local embolic therapies 
Transarterial chemoembolisation 
Transarterial embolisation 
Radioembolisation 
Systemic  
Chemotherapy 
Molecular targeted therapy 
 
a. Surgical  
Surgical intervention is the treatment of choice for HCC, as resection and 
transplantation provide the curative options in well selected patients. 
Resection is the preferred modality of treatment for patients with HCC without 
concomitant liver cirrhosis and in selected patients with Child-Pugh A cirrhosis. 
Because of the prevalence of cirrhosis, however, surgical resection is suitable for less 
than 5% of western patients with HCC. In contrast, it is offered in up to 40% in Asian 
countries, where HBV is endemic and HCC in the absence of cirrhosis is 
common[98]. 
Historically, resection was associated with significant mortality, most commonly due 
to post-operative haemorrhage, liver failure and sepsis but the reduced operative 
mortality to <5% reported by major centres in recent times has made resection a first 
line therapeutic option [99, 100]. Pre-operative assessment of the liver remnant after 
resection is an important predictor. The Makuuchi algorithm uses the Indigo-Cyanine 
Green retention rate (ICG). An ICG 15, value of less than  20% confers better 
prognosis [101]. Patients with oesophageal varices, splenomegly, high bilirubin (> 2 
mg/dl) and a low platelet count are poor candidates for liver resection. On the 
contrary, hepatic venous wedge pressure of <10mm Hg and single tumours afford the 
lowest mortality [102] 
Refinements of surgical techniques, understanding of the Couinaud’s segmental 
anatomy of the liver, development of ultrasonic dissectors and vascular staplers have 
aided in reducing blood loss and thereby have played a significant role in reducing 
post resection morbidity [103]. 
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The selection of patients for resection and the margin of resection vary on a case to 
case basis but in general the tumour is considered unresectable if the tumour is large 
with insufficient hepatic remnant after resection, the tumour is multifocal and bilobar, 
there is extra hepatic metastases, portal vein thrombosis, or hepatic vein or inferior 
vene cava involvement [104]. Tumour size also predicts survival and outcome.  A 
tumour size of 5cm also appears to be a prognostic factor: 5-year survival is 32% for 
tumours more than 5cm compared to 43% when less than 5cm [105, 106]. 
Other studies have also reported favourable results for solitary tumours with the five 
year survival reported to be 35 -50% for all resections [107] but more than 50% for 
small, solitary HCC with preserved liver function [99, 108].  Another major clinical 
problem after resection is tumour recurrence in 50% to 80% of patients after 5 years. 
Accurate identification of disease free survivors based on clinico-pathological 
characteristics continue to be a challenge. It has been suggested that neo-adjuvant or 
adjuvant therapy which can decrease or delay the incidence of intrahepatic recurrence 
may improve the result of liver resection[109], and the international STORM 
(Sorafenib as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular 
Carcinoma) study aims to investigate the role of the VEGF inhibitor in reducing 
tumour recurrence after radical surgery. If carefully selected liver resection and liver 
transplantation may act in a complimentary way to achieve the best outcome. 
Liver transplantation for HCC has evolved over the last two decades and is now 
considered the optimal therapeautic option for the disease arising in a cirrhotic liver as 
confirmed by the Organ Procurement Transplant Network data [110]. The potential 
advantage of this modality over resection is that it not only removes the tumour but 
also the liver with the background disease and thereby reducing the chances of 
recurrence. With a limited supply of life saving organs and with post-transplantation 
outcomes dependant on the complex relationship between tumour and 
immunosuppression, choosing the patient who will receive maximum benefit is of 
paramount importance[109].  
The commonly used criteria for liver transplantation in HCC was initially proposed by 
Mazzafero et al in 1996 [111] and is now routinely referred to as the Milan criteria. 
(Table1.2) The reported 4 year survival rates are more than 70% with recurrence rates 
of less than 15%.  
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Table 1.2 Milan criteria for consideration of OLTx in HCC 
One HCC smaller than 5cm in diameter 
or 
Up to three HCC nodules less than 3 cm in diameter 
In the absence of extrahepatic disease or macroscopic vascular invasion. 
  
As the number of patients with HCC falling outside the Milan Criteria is increasing 
these criteria have since been challenged with suggestions that these criteria are too 
restrictive and expansion of these could  achieve comparable survival rates. In 
2001,Yao et al proposed to expand the criteria  by including solitary tumours up to 
6.5cm or three or less nodules with the largest not more than 4.5cm and the combined 
diameter is not more than 8 cms. They reported a five year mortality of 75.2% [112], 
thus proposing the UCSF criteria. The dilemma this criteria presented was that the 
results were based on explant tumour characteristics rather than on the preoperative 
characteristics based on imaging.This study was corroborated at UCLA by Duffy et al 
who even demonstrated the use of pre-operative imaging as opposed to explant 
histology to expand the criteria for transplant. They noted in a retrospective study that 
tumours which were beyond the Milan criteria showed a 5 year survival rate near or 
above 50%with a mean follow up of 7 years [113]. Other critical studies using 
different expanded criteria include the studies from Tokyo [114], Kyoto [115] and 
Hangzhou[116]which report five year survival rates up to 87%. Though the data is 
limited but it presents an opportunity for consideration of extension of the criteria for 
transplantation. Following the success of the expanded criteria indications for LT in 
the UK have been revised allowing patients with a solitary lesion between 5–7 cm to 
be considered provided this has not increased bymore than 20% over 6 months. The 
new criteria also allow for up to 5 tumours – all < 3 cm in size. 
The discrepencies between radiological and pathological data for HCC prompted a 
search for more reliable morphological data and Toso et al evaluated total tumour 
volume (TTV) for transplant assessment[117]. A TTV of > 115cm
3
 was used as cut-of 
and the radiological accuracy increased to 91% (69% and 75% for Milan and UCSF 
criteria respectively). A score combining TTV >115cm
3
 and an alpha-fetoprotein 
level >400ng/ml provided the best predictive outcome in a group of 6478 adult 
recipients of liver transplantation.  
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Liver transplantation is the best treatment option for HCC and with the expanded 
criteria an increasing number of cases of HCC are being considered for 
transplantation. This generates a constant struggle to strike a balance between the 
HCC and non-HCC recipients of liver transplantation. There is also the discrepancy  
between demand and supply of livers, which results in a drop out rate from the 
waiting list between 25 – 37.8% in twelve months owing to disease progression[118]. 
It is because of these constraints that hepatologists and hepatobiliary surgeons are 
obliged to follow a strict selection criteria. As a consequence patients with HCC who 
fall outside selection criteria are considered for alternative therapeutic options. To 
reduce these drop out rates during the waiting time, bridging therapies like 
transarterial chemoembolisation (TACE) and percutaneous ablation techniques are 
used, but there is no consensus at present as to the optimal bridging therapy before 
transplantation. 
  Live Donor Liver Transplantation (LDLT) for HCC has developed as an 
acceptable alternative to cadaveric transplantation over the last decade because of 
organ shortages, increasing waiting time and the expectation that many patients listed 
for liver transplantation will die while they are waiting for suitable organ. LDLT, 
however, is a complex procedure that is associated with a morbidity of 20 – 40% and 
a donor mortality of 0.3 – 0.5% [119, 120]. Donor safety is of paramount importance 
but the mortality data in donors raises some ethical and legal issues. Currently there is 
no consensus about an acceptable donor risk and an acceptable recurrence risk.  
Three studies have reported higher rates of tumour recurrence after live related liver 
transplantation though overall survival rates are not significantly different[121-123]. 
The difference in recurrence could be a result of selection bias as the longer waiting 
time for cadaveric transplants results in drop out of patients with aggressive HCC but 
when live related transplant is offered on a fast track basis it is conceivable that many 
patients with aggressive HCC did not wait long enough for the biological behaviour of 
the tumour to be assessed. 
As for the criteria for selection, the data is not clear as to whether the centres should 
use the same criteria for DDLT and LDLT or use extended criteria for LDLT. 
In many regions deceased donation rates are poor. In these areas live related liver 
transplant may offer the only chance of cure and should be considered a private gift. 
But there are conceptual reasons for concern about coercion and potential harm to the 
donor when only LDLT is offered for HCC.This is a difficult balace to achieve and 
26 
 
centers preferentially offering LDLT for HCC should prospectively monitor and share 
data for both donor and recipient outcomes and balance their responsibility to protect 
the living donor with their respect for autonomy[124]. 
 
b. Local ablative techniques  
Image guided tumour ablation is now a conventional treatment for tumours less than 
3cms. Ablation induces rumour necrosis by injection of chemicals e.g ethanol or by 
temperature modification by radiofrequency, microwave or cryoablation and most of 
these procedures can be performed percutaneously.  
Percutaneous ethanol injection, introduced in the 1980’s was the most commonly 
studied. For single tumour upto 5cm or < 3 tumours measuring <3cm the five year 
survival is 50% but for single tumours less than 3cm a 80% response is seen. This 
procedure is limited by a high recurrence noted to be up to 43%.  Radiofrequency 
ablation has rapidly evolved, and is considered potentially curative for small HCCs. 
PEI involves injecting absolute alcohol into the liver lesion under ultrasound 
guidance, while RFA is a thermo ablative technique, inducing temperature changes by 
applying high frequency alternating current through electrodes placed in the tumour. 
RFA can be applied laparoscopically or percutaneously under ultrasound guidance. 
Randomised trials suggest that RFA is superior to PEI in the treatment of HCC of < 
3cm, both in terms of tumour response and long term survival [125-127] and a recent 
meta-analysis confirms the same [128]. This meta-analysis also concluded that RFA 
was superior to ethanol injection in ablating all viable tumour tissue and creating an 
adequate tumour free margin. 
For tumors less than 2cm, RFA can achieve a 5-year survival of 68% with the 
preservation of liver parenchyma and thereby present a challenge to liver resection for 
this cohort of patients. Cho et al concluded that RFA and hepatic resection are to be 
considered equally effective for the treatment of HCC less than 2cm. Therefore, in 
patients with HCC measuring less than 2cm RFA can be offered a first line treatment, 
with resection reserved for individual variables, including tumour location, would 
make RFA not feasible or unsafe. For tumours larger than 2cm the the published data 
comparing RFA with resection is controversial. A randomized trial comparing 
resection with RFA including patients with tumours less than 5cm and Childs A 
disease of the liver failed to show any statistical difference in overall and disease free 
survival [129]. However another randomized trial comparing the two modalities in 
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patients of HCC whose disease conformed to the Milan criteria suggested that 
resection may provide better survival and lower recurrence rates than RFA[130]. The 
quality improvement guidelines for radiofrequency ablation of liver tumours suggest 
that the target tumour should not be more than 3cm in its longest axis to achieve the 
best rates of complete ablation [131] 
Microwave ablation (MW) is emerging as an effective alternative to RFA for thermal 
ablation for HCC. This modality heats matter by agitating water molecules in the 
tissue producing friction and thereby inducing cell death by coagulation 
necrosis[132]. Microwave ablation when compared with RFA show consistently 
higher intratumoral temperatures, larger tumour ablation volumes and faster ablation 
times.This modality is less affected by tumour proximity to vessels as compared to 
RFA [133]. However, a RCT comparing MW with RFA found no statistically 
difference in effectiveness of the two procedures [134]. 
A new, non-chemical, non-thermal image guided technique currently undergoing 
clinical investigation for management of HCC less than 3cm is irreversible 
electroporation (IRE). This modality induces disruption of cell membrane by 
changing the transmembrane potential, resulting in cell death without the need for 
additional pharmacologic injury [135]. This modality has the ability to to sharply 
delineate the treated from the non-treated tissue. There appears to be complete 
ablation to the margin of blood vessels with no compromise to the functionality of 
blood vessels [135]. With all the suggested benefits of this technique clinical trials 
required to determine its clinical effectiveness 
c. Local embolic therapies 
Transarterial embolisation(TAE) is a loco-regional modality for palliation of HCC not 
suitable for surgical resection or curative therapy but have relatively preserved liver 
function, absence of cancer related symptoms and no evidence of vascular invasion or 
extrahepatic spread [58]. Once the HCC is vascularised the blood supply is from the 
hepatic artery and not from the portal vein. TAE induces tumour necrosis by hepatic 
obstruction and when chemical agents mixed in lipiodol as the embolising agent then 
it is termed as Trans Arterial Chemoembolisation (TACE). The most commonly used 
agents are adriamycin and cisplatin [136]. Response rates of 16 – 60% are noted with 
TACE [12, 137, 138]. A meta-analysis of RCTs comparing TAE/TACE to a control 
group showed only a modest effect in terms of survival due to the advanced nature of 
the disease [138]. Tumour factors specifically related to good prognosis include 
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tumour less than 5 cm, replacement of liver by tumour tissue of less than 50% and 
unilobar tumour [109]. Unfortunately even for this palliative treatment, a study 
reported that only 12% of patients were eligible. 
An ideal TACE regime should achieve sustained concentration of the 
chemotherapeutic agent in the tumour with minimum systemic exposure.This has led 
to the introduction of embolic microspheres that have the ability to actively sequester 
doxorubicin from the solution and release it in a controlled and sustained fashion 
locally to the tumour with minimal amount of the agent reaching the systemic 
circulation as compared to the standard TACE[139].Results of the PRECISION trial 
indicate that TACE with drug eluting beads are better tolerated with significant 
reduction in toxicity. Significantly improved objective response rates were also noted 
in this trial [140]. A trial comparing TACE with drug eluting beads with TAE showed 
significantly lower tumour progression with the drug eluting beads [141]. 
Radioembolization is emerging as another form of tumour embolization. The most 
popular radioembolization technique uses microspheres coated with yttrium 90, a β-
emitting isotope. Given intra-arterially the injected microspheres are preferentially 
delivered to the tumour bearing area selectively emitting high energy radiation to the 
tumour with minimal collateral damage [142].  Salem et al reported in a 
comprehensive analysis of 291 patients with HCC that yttrium microspheres could be 
an effective loco-regional treatment option especially in patients with portal vein 
thrombosis when TACE is not an option [143].  The results suggest that a well 
controlled trial is required to compare radioembolization with conventional TACE to 
establish its role in clinical practice.  
d. Systemic chemotherapy 
Systemic chemotherapy is useful in a select few as a palliative option.  The response 
is limited and is dictated by the underlying state of cirrhosis. Until recently, no phase 
3 trial had demonstrated a survival benefit for HCC patients. This changed in 2007. 
The SHARP trial reported a modest but significant survival benefit for patients with 
advanced HCC treated with the RAF-kinase / VEGF-2 antagonist, sorafenib [144]. 
This drug has limited availability for NHS patients in the UK, although it has 
increasingly been adopted by regional cancer drug advisory groups under the 
‘Intermediate Cancer Drug Fund’ introduced by the coalition government elected in 
2010. Numerous other trials of targeted biological agents, either alone or in 
combination with surgical or ablative therapies, are ongoing and it is likely that more 
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medical treatments will become available.  As this happens, it is even more important 
that  
we diagnose these cancers early enough to treat patients effectively, 
We learn how to employ relevant staging systems and biomarkers to help to choose 
the best therapy for each patient. 
1.2.8 The need for biomarkers 
 In the absence of markers for early detection of this disease, HCC continues to 
be diagnosed largely at a late stage. While advanced HCC has a dismal prognosis, 
there are therapeutic and even curative options for those detected earlier.  Thus we 
urgently need to improve our means of performing surveillance in known at risk 
populations. 
While improvements in radiological imaging advance in parallel, our own focus is on 
the identification of new serum biomarkers. The ideal serum surveillance marker for 
HCC would be specific for HCC and not detected in the individuals with predisposing 
liver disease (i.e. cirrhosis, regardless of the cause). The ideal marker should also be 
sensitive, enabling the detection of HCC at an early stage, when curative treatment is 
possible. It should be easily measurable, and the test highly reproducible, minimally 
invasive, and acceptable to both patients and physician[145].  
Recent developments of gene-expression microarrays, proteomics and tumour 
immunology have raised the possibility of screening thousands of genes or proteins 
simultaneously. Whilst we struggle to handle the huge amount of data generated by 
these techniques, it is anticipated that they will play a role in the identification of new 
biomarkers for HCC within the in the next decade. 
1.3 Experimental biomarkers 
1.3.1 Proposed biomarkers 
Serological tests that have been suggested for surveillance are PIVKAІІ (Prothrombin 
Induced by Vitamin K Absence), glycipan3 and the 8900Da fragment of Vitronectin. 
However none of these have been validated as surveillance tests for HCC. These and 
other novel proposed serum markers will be discussed in turn. 
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a.Des-gamma carboxy prothrombin/Prothrombin induced by vitamin K absence 
(DCP/PIVKA-II) 
PIVKA-II is an inactive prothrombin deficient in γ-carboxyglutamic acid and is 
produced by malignant hepatocytes. Recent evidence suggests that the elevated levels 
of PIVKA-II in patients with HCC is influenced by the increased production of 
PIVKA-II / DCP not only by the cancerous tissue but also by the surrounding  non-
cancerous tissue [146]. PIVKA-II results from an acquired post-translational defect in 
the vitamin K dependant carboxylase system. PIVKA-II  production is independent of 
vitamin K deficiency, although pharmacological doses of vitamin K can suppress 
production of PIVKA-II in some tumours[147]. PIVKA-II has been reported to be a 
growth factor which increases the expression of angiogenic growth factors like 
VEGF, TGF-alpha and β-FGF in HCC cells which suggests its role in the progression 
of HCC [148]. 
Liebman et al in 1984 first reported the use of des-gamma carboxy (abnormal) 
prothrombin / PIVKA in the detection of hepatocellular carcinoma[149]. They 
detected des-gamma-carboxy prothrombin in the serum of 69 of 76 patients (91 per 
cent) with biopsy-confirmed hepatocellular carcinoma (the mean level of the 
abnormal prothrombin was 900 ng per millilitre). In contrast, levels of the abnormal 
prothrombin were low in patients with chronic active hepatitis (mean, 10 ng per 
millilitre) or metastatic carcinoma involving the liver (mean, 42 ng per millilitre), and 
undetectable in normal subjects. Using a cut-off value of 40mAU /ml, Cui et al 
reported a sensitivity and specificity of 51.7% and 86.7% in discriminating HCC from 
cirrhosis and also found that 36.84% of patients with small HCC also had a raised 
serum PIVKA-II values [150]. Marrero et al used a cut off value of 125mAU/ml in 
American patients and found PIVKA-II to have a sensitivity and specificity of 89% 
and 86.7% in discriminating HCC from, non-malignant hepatopathy [151]. However, 
regarding the role in detecting early tumours, Koike et al in 2001 in a study on 227 
patients found that the serum DCP level is the most useful predisposing clinical 
parameter for the development of portal venous invasion.[152].  Other studies also 
confirm that HCC with raised PIVKA-II values are associated with higher frequency 
of HCC with indistinct margin, large nodule more than 3cm and moderate to poor 
differentiation [153, 154]. This would suggest that it detects late disease and not early 
disease, which doesn’t make it a good candidate for surveillance. Similar to AFP, 
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PIVKA-II is an excellent marker for monitoring treatment efficacy, with changes 
correlating with clearance of HCC after curative treatment, and  its subsequent 
recurrence.[68] Since PIVKA-II and total AFP are independent of each other in the 
setting of HCC and neither one is an ideal marker of HCC, Grazi et al find that the 
combination of the two is better because in their study, the sensitivity, specificity, and 
diagnostic accuracy for PIVKA-11 alone and total AFP alone are 53.3, 88.1 and 
71.1% and 54.9, 97.4 and 76.6%, respectively but on combining the two markers 
these figures become 74.2, 87.2 and 80.95 respectively [155]. Other studies also have 
concluded that combination of the two markers increases the sensitivity as well the 
specificity[156-158] 
b.Glypican 3 
The name glypican has been assigned to a family of heparin sulfate (HS) 
proteoglycans that are linked to the cell membrane by a glycosyl-phosphatidylinositol 
anchor. To date, six family members of this family have been identified in mammals 
(GPC1 to GPC6). Glypicans play an important role in cell growth, differentiation and 
migration [159, 160]. Although down regulation of these proteins are noted in several 
tumours and cell lines, a study in 2001 showed increased glypican 3 (GPC3) 
expression at the mRNA levels in HCC as compared to healthy livers and benign 
hepatic lesions  [161, 162]. 
Glypican 3 may enhance the growth of HCC by stimulating the canonical wnt 
pathway[163]. In 2003, studies showed the increased expression of GPC3 at the 
protein level in HCC. In one such study Capurro et al reported that GPC3 is elevated 
in more than 71% of HCCs but not detected in healthy livers and benign liver diseases 
[164, 165]. In addition GPC3 is detected in the serum of subset of patients with HCC.  
Nakatsura T et al in 2003 detected GPC3 in the sera of 40% of HCC patients. It was 
reported negative in 13 patients of liver cirrhosis, 34 patients of with chronic hepatitis 
and 60 healthy individuals, giving it a specificity of 100% [165]. Capurro et al also 
noted elevated serum levels of GPC3 in 50% of patients with HCC but in only 1/20 
patient of chronic viral hepatitis [164]. In most cases of HCC no correlation was noted 
in the serum levels of  GPC. These two markers in combination could improve the 
sensitivity to detect HCC[164] [166].                                                          
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 GPC-3 and AFP has also been reported to be elevated in patients with testicular germ 
cell tumours [167]. Overall, however, the sensitivity of GCP-3 in isolation as a 
biomarker of HCC has been a little disappointing. The elevated levels in other 
malignancies also necessitates further studies needed to validate its usefulness as a 
surveillance tool 
c. 8900Da fragment of Vitronectin 
Paradis V et al identified 8900 Da fragment of vitronectin as a potential marker for 
HCC by serum proteomic profiling of HCC patients. Because they also demonstrated 
that vitronectin gene is down regulated in HCC they postulated that the occurrence of 
the 8,900-Da carboxy terminal fragment in sera of patients with HCC may derive 
from an increase in vitronectin catabolism associated with liver carcinoma[168]. No 
further studies have been published validating the data.  
d. Heat shock protein 27 (HSP27) 
Heat shock protein 27 belongs to a family of heat shock proteins that are ubiquitous 
and highly conserved proteins whose expression is induced in response to a wide 
variety of physiological and environmental insults. As molecular chaperones they 
perform an important role in protein folding, translocation, and refolding of 
intermediates, proteases, such as the ubiquitin-dependent proteasome, which ensure 
that damaged and short-lived proteins are degraded efficiently. 
Heat shock protein 27 (HSP27) is ubiquitously present in many normal tissues[169]. 
Studies have shown that HSP 27 may play a role on thermo-tolerance, cellular 
proliferation and apoptosis, oestrogen response and molecular chaperoning[170-173]. 
Hsp27 can prevent apoptosis downstream of caspase-3(casp.3) activation by 
interacting with caspase-3.[174] The molecular mechanisms responsible for 
overexpression of heat-shock proteins in cancer cells are not known but a plausible 
scenario is that oncogenic mutations create an increased demand for chaperone 
activity within cells expressing protein variants that possess less than optimal folding 
characteristics. This cancer-specific stress response represents an adaptive process 
that allows cells to configure signal transduction pathways in such a way as to permit 
unrestrained proliferation. These oncogenic proliferative signals are tied to apoptotic 
processes that must be circumvented. This requirement may be met by the 
antiapoptotic function of heat-shock proteins[174]. 
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HSP 27 was elevated in the HCC tissues in 28 of 45 tissues and was correlated with a 
poor survival compared to HCC (17 of 45) with low expression of HSP27 [175]. Feng 
et al reported that HSP 27 was elevated in 90% of patients with HCC  and in 2 of 20 
patients with HBV but none in healthy controls[176]. However the cohort in the 
reported study was small and the results need to be validated in a larger group of 
patients. Furthermore, Heat Shock Proteins induced by cell stress are expressed at 
high levels in a wide variety of tumours and are not specific to the liver tissue, which 
does not make it the first choice for a surveillance marker for HCC. 
e.  Alpha-L-fucosidase(AFU)  
Alpha-l-fucosidase is an enzyme which hydrolyses fucose glycosidic linkages of 
glycoproteins and glycolipids. Giardina et al in 1992 reported that serum alpha-l-
fucosidase is a useful marker in detecting HCC, especially in conjunction with AFP 
and ultrasonography. They reported a sensitivity of 76% and a specificity of 90.9% 
for alpha L-Fucosidase. Its activity in patients with HCC was significantly higher than 
that found in cirrhosis, chronic hepatitis, other tumours and controls. They concluded 
that patients with cirrhosis who have a marked increase in serum AFU should be 
closely monitored for HCC development. El-Hosseini ME et al in 2005 also reported 
that adding AFU to measurement of AFP increased the detection of HCC from 68% to 
88.6% [177]. These encouraging findings also, have yet to be validated in an 
independant and larger group of patients before the value of AFU as a surveillance 
tool can be affirmed. 
f. Thioredoxin 
Thioredoxin (TRX), a reductase enzyme, is known to contain an active site with a 
redox-active disulfide and has various biological activities. Tumour cell proliferation, 
de-differentiation and progression depend on a complex pathway of altered 
intracellular processes including cell cycle regulation, excessive growth factor 
pathway activation and decreased apoptosis. Metabolites from these processes result 
in significant oxidative stress that must be buffered to prevent cell death. It has been 
hypothesized that redox-sensitive signalling factors such as thioredoxin and 
thioredoxin reductase may represent central pro-survival factors that allow the tumour 
cell to evade the damaging and potentially cytotoxic effects of endogenous and 
exogenous agents that induce oxidative stress [178]. 
Hepatocellular carcinoma tissue shows increased expression of thioredoxin and 
thioredoxin reductase as compared to controls [179]. It has also been detected in sera 
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of patients with HCC and has been shown to be significantly higher in patients with 
advanced HCC as compared to normal volunteers and patients with chronic hepatitis 
and liver cirrhosis without HCC [180]. Its utility in HCC diagnosis and surveillance is 
unknown. 
 
Squamous Cell Carcinoma Antigen-1 (SCCA-1) 
Squamous cell carcinoma antigen, a member of the high molecular weight family of 
serine protease inhibitor(serpins), is physiologically found in the spinous and granular 
layer of normal squamous epithelium and typically over expressed by the neoplastic 
cells of epithelial origin and so used as a clinical marker. Reports indicate that SCCA 
expression makes cancer cells resistant to several killing mechanisms by inhibiting 
apoptosis involving the caspase 3 pathway and/or upstream proteases.  
Pontisso et al first reported the over expression of SCCA in liver tumours(14/18) and 
not in normal livers[181]. However, the first report of increased serum levels of 
SCCA1 in HCC patients as compared to cirrhotics was published in 2005 by Gianneli 
et al. They suggested that level of SCCA1 was not related to the size or spread of the 
tumours and that it could potentially be an early tumour marker. In a study of 120 
patients with HCC and 90 patients with cirrhosis SCCA1 was found to have 
sensitivity of 84.2% but a specificity of only 48.9% but when combined with AFP a 
correct serologic diagnosis could be made in 90% of patients[182].  This performance 
was detected in patients with viral hepatitis and its value in patients with HCC 
developing against a background of other aetiologies such as alcoholic and non-
alcoholic liver disease is unknown.  
1.3.1 Dissemination of tumour cells in the peripheral blood 
Solid malignancies are characterised by spreading of tumour cells from the tissue of 
origin to distant parts of the body at some point in the course of the disease. This 
spreading or dissemination of cancer cells from the primary tumour is the most 
important factor affecting prognosis in carcinoma patients. Once metastatic spread has 
occurred, the cancer disease is often no longer regarded as curable and medical 
treatment is generally considered palliative. Haematogenous spread of solid tumours 
represent a major challenge in oncology and has a fundamental influence on the 
outcome of the disease.[183]  
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The early seeding of metastatic cells in distant organs can contribute to metastatic 
relapse and is missed by traditional tumor staging. It has, therefore, been hypothesized 
that very sensitive monitoring of single or small clusters of tumor cells that 
disseminate into the blood would allow improvement of individual outcome 
prediction because it addresses metastasis formation more directly. Metastases 
currently are diagnosed by clinical manifestations, imaging studies like computerized 
tomography, and serum biomarker assay such as CEA for colorectal tumours. 
However, these methods are insensitive to the cancer cells at the small cell level or 
small cell clusters. The amount of tumour markers are related to the tumour mass and 
does not reflect viable disseminated tumour cells. Therefore, detection of cancer cell 
dissemination at an early stage could have great impact on cancer mortality, making 
eradication of cancer cells more probable by applying treatment modalities before 
clinically overt metastases appear. Moreover, detection of tumour cells in peripheral 
blood after resection could help early prediction of relapse in comparison to 
traditional tumour markers. 
HCC is a solid tumour and liver being a very vascular organ there is likelihood that 
tumour cells may be shed from the HCC during treatment like Radiofrequency 
ablation, transplantation or resection. However, the number of tumour cells in 
circulation could be extremely small to be detected morphologically. In order to detect   
disseminated tumour cells in blood or bone marrow at an expected frequency of 10
-6
 
or 10
-7
 nucleated haemopoietic cells requires highly sensitive techniques. During the 
last decade molecular techniques such as polymerase chain reaction (PCR) or reverse 
transcriptase polymerase chain reaction(RT-PCR) has been suggested as one of the 
most sensitive techniques. 
Molecular detection methods such as PCR or RT-PCR target nucleic acids as 
discrimination markers between carcinoma and nucleated hematopoietic cells. A 
major drawback in the use of PCR with genomic DNA as starting material is that only 
a few tumor types show characteristic genomic alterations, and high sensitivity 
detection of mutations can only be obtained in cases where these occur in a few 
specific codons of a gene or when the mutation is already known.  
The other main strategy for the detection of occult tumor cells involves detection of 
tissue-specific mRNA. The procedure is known as RT-PCR. This approach is based 
on the fact that malignant cells often continue to express markers that are 
characteristic of or specific for the normal tissue from which the tumor originates or 
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with which the tumor shares the histotype. The appearance of these tissue-specific 
mRNAs at body sites where these transcripts are not normally present implies tumor 
spread[184] Because of the instability of mRNA in the extracellular environment, the 
detection of mRNA in peripheral blood requires the presence of viable tumor cells. 
Matsumara et al (1995) and Komeda et al (1995) using the polymerase chain reaction 
(PCR) to identify tumour-specific gene transcripts showed that the detection of 
isolated tumour cells in a small blood sample is possible and that the method is 
sensitive[185, 186]. Using PCR  to detect target DNA or RNA of tumour cells it is 
possible to detect isolated tumour  cells with a sensitivity of one cell in 10
5
 – 106 
normal cells[187]. The clinical relevance of detecting these peripheral cells by 
molecular techniques has been the subject of ongoing debate. Recent data, however, 
suggest that detection of tumour mRNA in the peripheral blood is associated with a 
increased recurrence and poor prognosis in patients with colorectal or gastric 
carcinoma [188, 189] . In HCC, detection of peripheral tumour cells  predict tumour 
recurrence[190]. 
 The above suggests that if this method is reproducible and correlates with the clinical 
condition then it could possibly be used as a molecular marker to detect HCC, either 
for diagnostics during surveillance, or providing prognostic information post 
treatment. 
1.4 Application of current techniques to identify novel biomarkers 
1.4.1 Genomics 
 Genomics is the study of genes and their function. Recent advances in 
genomics are bringing about a revolution in our understanding of the molecular 
mechanisms of disease, including the complex interplay of genetic and environmental 
factors 
At present, histopathologic evaluation of a tumour and tumour staging are the 
mainstays for guiding therapeutic interventions and predicting outcomes. However, 
the limitations of the conventional methods are obvious. Tumours with identical 
histopathology may progress differently, responding differently to therapy and may be 
associated with different clinical prognosis, suggesting that additional parameters 
should be identified to predict disease outcomes. Gene expression profiles of cancers 
may be able to serve as a complimentary tool providing useful information.  
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Like most solid tumours, the development and the progression of HCC are believed to 
be caused by the accumulation of genetic changes resulting in altered expression of 
cancer related genes, such as oncogenes and tumour suppressor genes, as well as 
genes involved in different regulatory pathways, such as cell cycle control, apoptosis, 
adhesion and angiogenesis[192, 193] Comprehensive analysis of gene expression 
patterns of thousands genes in certain tumour cells and comparison to the expression 
profile obtained from healthy cells and/or other cancer cells of different phenotype 
can provide insight into the consistent changes in gene expression that are associated 
with tumour cellular dysfunction and concomitant regulatory pathways. Current 
cDNA microarray technology enables investigators to measure the expression of 
thousands mRNAs simultaneously in a biological specimen, providing comprehensive 
information which may ultimately aid diagnostic and prognostic methods, as well as 
identify novel therapeutic targets. 
 
1.4.1.1  Microarray  
Microarray technology which was developed to study differential expression of 
thousands of genes simultaneously in complex populations of RNA, allowing 
scientists and clinicians to identify qualitative and quantitative changes at RNA level 
in the development and progression of cancer[194-196]. Spotted arrays are 
manufactured using  robots that deposit cDNA (PCR products) or short 
oligonucleotides onto specially designed glass microscope slides[197]. Spot sizes 
range between 80 and 150μm in diameter, and arrays that contain up to 80,000 spots 
can be obtained. Gene expression sequences to be arrayed are selected from public 
databases and the clones chosen are amplified from appropriate cDNA libraries by 
PCR and purified before spotting on the slide[195] 
 In general, the use of microarrays in HCC can be categorised into three 
purposes: 
1. to define the molecular profile of HCC as distinct from non-cancerous liver and 
other tumour types identifying the tumour and liver specific genes. 
2. to describe gene expression profiles that correlate with clinical subsets, which 
mechanisms of HCC development and progression. 
3. to identify tumour specific molecular markers, which will be helpful for cancer 
diagnosis, prediction of prognosis and response to treatment.[198-200] 
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 We are aware that progression of HCC is a stepwise process that proceeds 
from preneoplastic lesions , including low grade and high grade dysplastic nodules to 
early and then advanced cancer. Although the stepwise molecular changes associated 
with each stage are not clear, genome based research in this field is growing. Suk 
Woo Nam et al, 2005, used DNA microarray to show a clear molecular demarcation 
between dysplastic lesions and overt HCC lesions. They noted a heterogeneity in 
G1(low grade Edmondson grading) HCC suggesting that G1 HCC might border 
between preneoplastic lesion and outright carcinoma representing a transition state 
from dysplasia to carcinoma. They also identified 3,084 grade associated genes whose 
transcript levels were either positively or negatively correlated with tumour 
progression. The majority of oncogenes and tumour suppressors  identified in the 
study demonstrated expression patterns that systemically change from dysplasia to 
carcinoma, and in some cases, with alteration in expression already detectable in the 
pre-neoplastic state. The latter suggests that these genes, acting together or separately, 
could be directly involved in common pathways of HCC pathogenesis [201]. This 
study showed that systemic approaches such as genome wide transcripts and 
regulatory pathways in precancerous lesions and HCCs may help us to gain the much 
needed molecular insight into hepatocarcinogenesis. 
 Microarray technology has also been used in an attempt to predict clinical 
outcome and survival in HCC. Ju-Seog Lee et al characterised gene expression 
profiles in 91 human primary HCC and 60 matched non-tumour surrounding liver 
tissue using cDNA microarray. Hierarchical clustering of data revealed two subclasses 
of HCC strongly associated with the length of survival. The group also noted that 
enhanced activation of ubiquitin-dependant protein degradation may account for 
deregulation of cell cycle control and faster cell proliferation in the poor survival 
group, perhaps indicating that deregulated components in ubiquitin-mediated protein 
degradation may provide attractive targets for novel HCC treatment modalities[202]. 
The data available from the microarray analysis can also be used to predict serum 
biomarkers. Using gene ontology analysis of the microarray data, upregulated genes 
encoding for the secretory or transmembrane proteins could be identified. Using this 
method in the data generated from HBx transgenic mice Quang Sun et al in 2007 
identified four genes encoding TFF3, IGF2, LPL and SPL1 as promising diagnostic 
biomarkers for the detection of HCC in the tissue[203]. This appears to be a very 
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promising new method to mine for biomarkers for diseases both for diagnosis and for 
targeting treatment. 
1.4.2 Proteomics 
 The term ‘proteomics’ was first coined in 1995 by Wilkins and co-
workers[204, 205]. Proteomics may be defined as the direct qualitative and 
quantitative analysis of the full complement or subset of proteins present in an 
organism, tissue, cell under a given set of physiological and or environmental 
conditions[206]. The proteome is the time and cell-specific protein complement of the 
genome, encompassing all proteins expressed in a cell at any given time, including 
protein isoforms as well as co- and post- translational modified forms. The study of 
the proteome is more daunting than the study of the genome for several reasons. 
While the genome of the cell is constant, nearly identical for all cells of an organ and 
organism, and consistent across a species, the proteome is extremely complex and 
dynamic as it continuously responds, at both transcriptional and post transcriptional 
levels to multiple external factors as other cells, nutritional status, temperature, drug 
treatment, to name only a few. Therefore, there is no fixed proteome and the analysis 
of the proteome at any one time is a ‘‘snapshot’’. Serum and tissue are the most 
commonly studied for proteomics. 
There has been significant interest in the study of global protein expression, an 
approach known as expression proteomics. It is well established that for only a subset 
of mRNA does expression significantly correlate with protein abundance. Moreover, 
post translational modifications, including phosphorylation, glycolsylation, and 
degradation, which are aberrantly regulated in many types of cancer, can be predicted 
neither by measuring the amount of RNA, nor by studying nucleoside sequences. 
Therefore, proteomic studies may overcome some of the limitations of global mRNA  
studies. As the functions of proteins are more directly linked to the aberrant 
phenotypes and malignant behaviour of cancer cells, proteomic studies may represent 
a better strategy to investigate cancer. 
The technology of proteomics has generated great interest to apply the technique to 
investigate the proteome of diseased samples, with the very goal of mining 
biomarkers for different disease conditions because it is a non-invasive and can be 
repeated easily. 
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1.4.2.1 Serum Proteomics 
Of all accessible physiological reservoirs of human proteome, human plasma is 
considered one of the richest and most representative, with more than 10,000 distinct 
proteins[207]. Since blood has direct contact with most of the tissues of the human 
body, pathological changes are likely to be reflected with changes in the serum. The 
cancer proteome is an exceptionally complex biological sample containing 
information on perhaps every biological process that takes place in cancer cells, 
cancer tissue microenvironment, and cancer cell-host information. Cancer cells 
release protein biomarkers into the extra-cellular fluid through the secretion of intact 
or cleaved peptides. In addition, cancer-associated circulating biomarkers can be 
contributed by the tumour microenvironment e.g. surrounding host cells such as 
fibroblasts and macrophages. Some of these products can end up in the serum and can 
serve as potential biomarkers. This is one of the important reasons for exploiting the 
human serum in the search for biomarker discovery. However, it is difficult to identify 
these low abundance proteins in the serum. The study of the human serum proteome is 
complicated by the dynamic range of protein expression which may vary by as much 
as 7-12 orders of magnitude as compared to only five orders of magnitude for 
DNA[208, 209]. 
One of the major obstacles in mining these low abundance biomarkers from serum or 
plasma is caused by the fact a small number of proteins, including albumin, α2-
macroglobulin, transferrin and immunoglobulins constitute about 80% of total 
proteins. At present, no single technique in a one-stop operation can provide the 
identification and quantification of all proteins in a complex sample like body fluids, 
cell lystaes or tissue extracts. Therefore, to achieve this objective of analysing the 
complex proteome concerted approach is needed which includes sample preparation, 
protein/peptide separation, mass spectrometric analysis and the use of bioinformatics 
tools for database search and quantification. Currently the tools for resolution and 
analysis of plasma proteins can be broadly categorised into the two-dimensional gel 
electrophoresis (2D-GE) approach and mass spectrometry (MS) based approach.  
The high abundance proteins in the serum and tissues provide a significant 
background and make it difficult to identify the low abundance proteins. Therefore, a 
highly promising first step for most analysis strategies of serum or plasma is to 
deplete as many of the major proteins as possible, followed by pooling and 
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concentration of the low abundant protein fraction to bring its concentration to a level 
consistent with the sensitivity range of current analytical instrumentation. 
1.5 Overview of current proteomic technology 
1.5.1 Elimination of the high abundant proteins 
 A range of methods to deplete high-abundance proteins have been evaluated 
which include Molecular Weight Cut Off Filters (MWCO), Cibacron blue – a 
chlorotriazine dye which has a high affinity for albumin, protein A or G to deplete 
immunoglobulins and the recently developed multiple affinity removal system. 
A.  Low molecular weight cut off filters 
  Georgiou et al in 2001 using 30 kDa cut off membranes attempted to remove 
the high abundant proteins from the plasma following the manufacturer’s protocol. 
They concluded that centrifugal ultra filtration of whole plasma prior to 2-DE does 
not adequately remove proteins and suggested that they are unlikely to be useful[210]. 
However, Tirumalai RS et al in 2003 separated low molecular weight protein using 
centrifugal ultrafiltration with 30kDa cut off molecular weight filters and get 
consistent results. Harper et al in 2004 using 50kDa cut off filters and modifying the 
manufacturer’s protocol were able to successfully separate the high abundant proteins 
from the low abundant proteins efficiently[211]. The numbers of studies using low 
molecular weight cut off filters, however, are limited and this technique has not been 
validated or become routinely applied for removing high abundant protein. 
B. Cibacron Blue 
 Cibacron blue is a chlorotriazine dye which has a high affinity for 
albumin[212, 213]. While these dye based kits bind the majority of albumin they often 
also bind a large number of non-specific proteins, resulting in potential losses. This 
non-specific binding probably includes both proteins that bind to the dye as well as 
minor proteins that bind albumin[214]. Cibacron blue and other dye based methods 
are known to bind proteins with nucleated binding domains as well as via ionic and 
hydrophobic interactions[212]. This multifuntionality may result in the removal of 
proteins of interest through a rather broad and non-specific interaction, which can 
only be partially mitigated by judicious selection of mobile phase conditions 
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C. Multiple affinity removal system (MARS) 
Another approach is the use of antibodies targeted to the common abundant proteins. 
Individual antibody methods have shown to be more specific in depleting targeted 
proteins like albumin and this strategy could be extended to the removal of any 
protein for which specific antibodies or affinity reagents are available[215]. 
Monoclonal antibodies are a promising target choice for their high specificity, but 
since they target a specific epitope of such proteins,  they may not recognise all forms 
of the targeted proteins, e.g. proteolytic fragments, the post translational modified 
forms of the antigen, or proteins where the epitope is occluded  due to protein-protein 
interactions[215, 216]. Polyclonal antibodies are more likely to remove multiple 
structural forms of the protein.  
Ideally for a biomarker discovery it is desirable to deplete as many abundant proteins 
as possible and at the same time minimising incidental losses of the non-targeted 
proteins. Removal of high abundant proteins by multi-component immunoaffinity 
based protein subtraction chromatography introduced by Anderson and co-workers 
specifically for analysis of plasma was in important step towards this process[217]. 
The ability of a commercially available MARS HPLC column to efficiently remove 
the six most abundant serum proteins and to aid in the identification of more low 
abundant proteins efficiently, have been recently published[214]. 
1.5.2 Fractionation of serum low abundance proteins and protein identification 
The next step following sample preparation is the separation of proteins. The most 
common method for separating complex mixture of proteins is called ‘two 
dimensional sodium dodecyl sulphate polyacrylamide gel electrophoresis’ (2D-
PAGE). In  this approach the complex mixture is subjected to two dimensional 
chromatographic separation, using iso-electric focussing as the first dimension which 
separates proteins  according to their isoelectric points and the second dimension is 
SDS-PAGE electrophoresis which separates proteins according to their molecular 
weights.  The differential proteins of interest can be identified by two approaches: 
A)‘Top down’ approach 
B)‘Bottom up’ approach 
A)         ‘Top down’ approach 
A conventional mass spectrometry approach to proteomics is generally initiated by 
one- or two- dimensional(2D)  electrophoretic separation of a protein mixture, after 
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which protein bands are excised from the gel and subjected to reduction, alkylation 
and several washing steps, and finally enzymatic digestion followed by peptide 
extraction[218]. The masses of these peptides are characteristic of the protein, and 
provide a peptide ‘mass fingerprint’ which can be used in database searches to 
identify the protein of interest[219, 220]. The 2-dimensional gel technique has been 
used since 1975 when Klose, O’Farrel and Scheele almost simultaneously published 
the methods of isoelectric focussing in the first dimension and gel electrophoresis in 
the second. This technique has been very successful and will continue to be improved 
and refined. This technique is capable of producing highly reproducible results and 
there is good coverage of proteins with isoelectric point 3-11 and molecular weight 10 
– 100kDa. Since it separates intact proteins, different isoforms of the same protein can 
also be separated and detected. In conjunction with other techniques of fractionation 
coverage of the proteome can be high. When combined with mass spectrometry, 
proteins can be identified and fully characterised [221]. 
2-Dimensional gel electrophoresis is currently the principal technique for the 
separation of  complex protein mixtures[222]. 2-Dimensional electrophoresis not only 
generates information regarding protein information regarding protein modification 
and/or expression level changes but also allows for the isolation of proteins in 
significant amounts for further structural analysis using MALDI-TOF MS or Erdman 
microsequencing techniques[223] 
 However, no technique is without its limitations and there are several practical and 
fundamental limitations associated with the 2-dimesional electrophoresis approach. 
Despite the potential and resolution of 2-dimensional gel approaches it remains a 
labour intensive technique to produce reproducible results. To overcome gel to gel or 
intrinsic biological simple variations, it is considered that, for this type of expression 
proteomics study, at least three different gels of three different samples of the same 
biological state are required. In any case, the total proteome coverage by 2-
dimensional electrophoresis is experimentally limited to proteins with molecular 
weight  in the 10 – 120 kDa range, with neutral – acidic end points. Basic proteins are 
very difficult to focus[224] and this technique rarely displays hydrophobic proteins 
weight[224]. Despite these drawbacks, Kim M and Kim C in 2007 concluded that 
despite a variety a techniques being attempted so far, no generally accepted technique 
has yet been developed for the identification of biomarkers that can replace 2-
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dimensional electrophoresis with regard to its ability to separate and display several 
thousand plasma proteins simultaneously[225] [226] 
 
B) ‘Bottom up’ approach 
A widely used strategy in the bottom up approach is based on the use of isotope coded 
affinity tag (ICAT) reagents by the Aebersold group[227]. This technique consists of 
chemical labelling of protein sulph-hydryl groups with the ‘light’ and ‘heavy’ 
versions of the ICAT reagent followed by mixing of both samples and digestion by an 
endoprotease. The peptides are then fractionated usually using Mud-LC – strong 
cation exchange chromatography followed by reversed phase liquid chromatography. 
Relative abundance of the peptides and their identification is then established by 
MS/MS analysis by tandem mass spectrometry. 
This approach has some inherent disadvantages with it. An important disadvantage is 
that proteins lacking cysteine residue are not detected.[224].  Also, digestion of an 
unfractionated protein mixture greatly increases the number of components to be 
analysed and condenses the peptide mixture into a narrow mass range, thereby 
complicating the task of isolating individual components for subsequent analyses. 
Furthermore, while the identification of only one peptide from a protein digest is 
required to identify that protein unambiguously, provided that peptide is unique to 
single protein, a significant amount of time during the analysis of complex peptide 
mixtures is spent analysing the same peptide ion or different peptides of the same ion. 
The peptide digest often yields significant number of peptide tandem mass spectra 
which are unassignable. Finally, it is inevitable that information is lost when upon 
transformation of an intact protein or protein complex into a family of polypeptides. 
Additionally, the mass of an intact protein or protein complex, which can provide 
important protein characterisation information such as the identity of post-
translational modification, is not directly accessible via the ‘bottom up’ approach[226] 
This technique is also limited to the study of >30 kDa proteins only and there is 
obviously less coverage of the proteome it studies limited to proteins of MW <30kDa. 
[221]. 
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1.5.3 Chromatographic techniques 
1.  Ion exchange chromatography 
Ion Exchange Chromatography relies on charge-charge interactions between the 
proteins in the sample and the charges immobilized on the resin of choice. Cation 
exchange chromatography is a form of ion exchange, in which positively charged ions 
bind to a negatively charged resin  
Cation exchange chromatography retains biomolecules by the interaction of the 
sulfonic acid groups on the surface of the ion-exchange resin with histidine, lysine 
and arginine. Commonly used cation exchange resins are S-resin, sulfate derivatives; 
and CM resins, carboxylate derived ions. The bound solutes are then eluted 
differentially by adding increasing gradient of salt in the mobile phase. 
2. Reverse Phase High Performance Liquid Chromatography (RP-HPLC) 
 Reverse phase chromatography was originally developed in the 1960s for the 
separation of small organic molecules. The separation mechanism in reversed phase 
liquid chromatography depends on the hydrophobic interaction between the solute 
molecules in the mobile phase and the immobilised hydrophobic ligand i.e. the 
stationary phase. Reverse phase chromatography is an adsorptive process by 
experimental design which relies on a partitioning mechanism to effect separation. 
The solute molecules partition between the mobile and the stationary phases. The 
distribution of the solute between the two phases depends on the binding properties of 
the medium, the hydrophobicity of the solute and the composition of the mobile 
phase. Bound solutes are then desorbed from the stationary phase by adjusting the 
polarity of the mobile phase so that bound solutes will sequentially desorb and elute 
from the column. The gradual decrease in polarity ( increasing mobile phase 
hydrophobicity) is achieved by increasing linear gradient from 100% initial mobile 
phase A containing no organic modifier to 100% (or less) mobile phase B containing 
a higher concentration of organic modifier.  
 Modern RP-HPLC utilises a wide selection of chromatographic materials to 
separate proteins and peptides. The choice of packing material has the greatest impact 
on the separation and resolution of proteins or peptides of interest. The separation 
efficiency of the packing material is determined by the particle size, pore size, surface 
area, stationary phase, as well as the chemistry of the substrate surface. The most 
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popular materials for RP-HPLC column packing are based on spherical silica. 
Typically particle size of 3-5μm are used for analytical separation of proteins, 
peptides or other small molecules. Separation efficiency increases by 30-40% when 
particle size is reduced from 5 to 3 μm.[228].  
For this procedure it to be effective for human serum samples the most abundant 
proteins need depleting before subjecting to reverse phase chromatography. The RP-
HPLC when coupled with high resolution mass spectrometry can lead to enhanced 
identification of low abundance proteins[229] . 
1.5.4 Protein Identification 
A. Matrix Assisted Laser Desorption Ionisation (MALDI) 
The proteins in the different fraction from different forms of Liquid Chromatography, 
described above, can be identified with help of Mass Spectrometers. The Mass 
Spectrometers require charged molecules for analysis. Large biomolecules are not 
easily transferred to the gaseous phase and ionised. However, the development of 
Matrix Assisted Laser Desorption of Ionisation (MALDI) and the Electrospray in the 
late 1980s should be credited with most of the success of Mass Spectrometry (MS) in 
life sciences.  
 MALDI was developed by Karas and Hillenkamp in the late 1980s. To 
generate gas phase, protonated molecules, a large excess of matrix material is 
coprecipitated with analyte molecules by pipetting a submicrolitre volume of the 
mixture onto a metal substrate and allowing it to dry. The resulting solid is then 
irradiated with nanosecond laser pulses, usually from small nitrogen lasers with a 
wavelength of 337nm. The matrix is usually a organic molecule with absorbance at 
the wavelength of the laser employed. Work with biomolecules almost exclusively 
uses α-cyano-4-hydroxycinnamic acid or dihydrobenzoic acid(DHB). 
 For MALDI time of flight (TOF) Mass Spectrometry the short burst of ions, 
generated by the laser pulses, are accelerated to a fixed kinetic energy and then they 
travel down a flight tube. The small ions have higher velocity and are recorded on the 
detector [182] before the larger ones, producing the time of flight spectrum. Several 
dozen to hundred of laser shots are averaged to produce the final MALDI spectrum. 
Performance in modern reflector MALDI Mass Spectrometers is typically in the range 
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of a few parts per million in mass accuracy, and only about a femtomole of peptide 
material  needs to be deposited on the MALDI target to produce a signal 
 The mass range below 500 daltons is often obscured by matrix related ions in 
MALDI. The proteins generally undergo fragmentation to some extent during 
MALDI, resulting in broad peaks and loss of sensitivity, therefore MALDI is mostly 
applied to the analysis of peptides. 
 
B. Electrospray and nanospray 
Electrospray mass spectrometry has been developed for use in biological mass 
spectrometry by Fenn et al  [230]. Liquid containing the analyte is pumped at low 
microlitre-per-minute flow rates through a hypodermic needle at high voltage to 
electrostatically disperse, or electrospray, small, micrometer-sized droplets, which 
rapidly evaporate and which impart their charge onto the analyte molecules. This 
ionisation process takes place in atmosphere and is therefore very gentle (without 
fragmentation of analyte ions in the gaseous phase). The molecules are transferred 
into the mass spectrometer with high efficiency for analysis. To stabilise the spray, a 
nebuliser gas or some other device is often employed. 
 Nanospray is a miniaturised version of electrospray that operates without 
pumps and at very low flow rates in the range of a few micro litres per minute[231, 
232]. It is performed in pulled glass capillaries with an inner diameter at the tip of 
about one micrometer. A microliter volume of sample can be analysed for more than 
one hour at full signal strength, which allows complete sequencing experiments to be 
performed[218]. 
The ions can be trapped for analysis in three-dimensional electric fields. These ion 
traps capture the continuous beam of ions up to the limit of their space charge. This is 
the maximum number of ions that can be introduced without distorting the applied 
field. The ions are then subjected to additional electric fields, which eject one ion 
species after another from the trap, and are detected, to produce a mass spectrum. 
A large number of ions can be analysed by the electrospray mass spectrometry; the 
only requirement is that the molecule is sufficiently polar to allow attachment of a 
charge. The large ions are typically multiply charged which bring them into the range 
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of mass-to-charge ratios of typical mass spectrometers. The distribution of charges 
give rise to the typical multiple charged envelope[218]. 
C. Fourier ion transform ion cyclotron resonance 
Another version of ion trapping is embodied in the Fourier Transform Ion Cyclotron 
Mass Spectrometry. This technique was first published in the mid 1950s where it was 
demonstrated for measurement of very small mass differences at very high precision. 
It was applied to proteins only in the late 1980s, when electrospray made it possible to 
ionise the large protein molecules without disintegrating them. 
 In the basic FT-MS instrument the ions generated from the source are passed 
through a series of pumping stages at increasingly high vacuum. When the ions enter 
the cell pressures are in the range of 10
-10
 to 10
-11
 mBar with temperatures close to 
absolute zero. The cell is located inside a spatial uniform static superconducting high 
field magnet (typically 4.7 to 13 tesla) cooled by liquid helium and liquid nitrogen. 
When the ions enter the magnetic field they are bent into a circular motion in a plane 
perpendicular to the field. They are prevented from falling out of the cell by trapping 
plates at each end of the cell. The frequency of the motion is dependant on their 
mass/charge (m/z) ratio. At this stage no signal is observed, because the radius of the 
motion is small. Excitation of each individual m/z is achieved by a swept 
radiofrequency(RF) pulse across the excitation plates of the cell. Each individual 
excitation frequency will couple with the ions natural motion and excite them to 
higher orbit where they induce an alternating current between the detector plates. The 
frequency of this current is the same as the cyclotron frequency of the ions and the 
intensity is proportional to the number of ions. This results in the measurement of all 
the ions simultaneously producing a complex frequency vs time spectrum containing 
all the signals. The signal is then deconvoluted into a deconvoluted frequency vs 
intensity spectrum which is then converted to the mass vs intensity spectrum. Due to 
the ion trap nature of this instrument it is possible to measure the ions without 
destroying them. 
1.6 Statistical Analysis  
Statistical methods are required for analysis of data achieved during research. 
Variability in data is inevitable and to gain any relevant conclusion from this data for 
clinical application an appropriate statistical analysis of the same is essential.  
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Statistical analysis is hence needed to 
 Explore and summarise data 
 Analyse the data and derive conclusions 
 Make relevant decisions 
1.6.1 Types of data 
Data can be classified into 
 Qualitative data 
 Quantitative data 
Qualitative data refers to measured attributes e.g gender, blood groups, social groups, 
racial origin etc 
Quantitative data refers to numerically measured data which can be continuous e.g 
blood pressure, temperature, or discrete e.g. number of admissions to the surgical 
ward. 
1.6.2 Analytical methods 
          Analysis of differences 
For analysis of data it is important to understand whether the data follows a normal or 
not normal distribution. The statistical tests can be either or non-parametric.  
Parametric tests e.g. t-tests, ANOVA ( Analysis of Variance) makes a number of 
assumptions about the data 
 The data is continuous 
 The data has a normal distribution 
 When differences or measures of statistical association are being analysed 
between two or more samples the variance between these samples is not 
significant. 
If the assumptions of a para-metric test are not fulfilled a non-parametric equivalent 
e.g. Mann-Whitney test, Wilcoxon, Kruskall-Wallis test, and for categorical data 
Fisher or Chi-square test is applied. 
The significance of the difference calculated is reported as a probability. The 
probability (p-value), from zero to one, that the results observed in a study could have 
occurred by chance. By convention, the p-value of less than 0.05 is considered 
significant. That means the chance is less than 1 in 20 which is not very likely. 
Multivariate analysis 
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Multivariate analysis consists of a set of dedicated statistical methods used to analyse 
data sets with more than one variable to investigate relationship with the variables. 
Survival analysis 
Survival analysis is concerned with studying the time between entry to a study and a 
subsequent event. The event may death, disease free survival, recovery from illness. 
Two survival curves with the same condition but different treatment options could be 
compared with the log rank test. 
1.6.3 Software package 
The data is statistically analysed with suitable software. The software packages 
commonly used are 
 SPSS (Statistical Product and Service Solutions) 
 SAS/STAT 
 Prism 
 Minitab 
1.6.4 Statistics used in this study 
Linear regression was used to explore associations between two characteristics. The 
diffference between two groups of continuous variables obtained in serum ELISA 
assays were assessed by t-test (paramateric data) and Mann-Whitney test for two 
variables and Kruskall-Wallis test for more than two variables (non-parametric data). 
Differences between categorical variables were assessed by Pearson Chi Square, or 
Fishers Exact tests approximated using a Monte Carlo approach where cells within a 
contingency table of greater than 2x2 contained low numbers (<5). A p-value of <0.05 
was considered significant.  
Survival statistics in the prospective epidemiological study and the study of patients 
receiving liver transplant for HCC was performed using Kaplan-Meier analysis and to 
compare two groups of survival data log-rank test was used. To analyse any 
association of a patient or tumour characteristic with survival univariate analysis was 
performed. In the epidemiological study the factors included in this analysis included 
age, sex, Child-Pugh status, Performance status, mode of presentation, portal vein 
thrombosis,tumour number and AFP values.A cut-off of <0.05 was considered for 
factors to be included in the multivariate analysis. In the analysis for the subset of 
patients receiving liver transplant for HCC tumour characteristics affecting survival 
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which were considered for univariate analysis included aetiology, number of tumour 
nodules, degree of differentiation, AFP values, pre-operative treatment, lobar 
distribution, microvascular invasion and multifocal or unifocal tumour. A p-value of 
less than 0.05 was considered for the factor to be included in the multivariate analysis. 
All statistical analalysis was performed using using SPSS for windows, version 14 
(SPSS Inc. Chicago Illinois, USA), licensed to the Newcastle University. 
1.7  Aims 
The Primary Aim of this thesis is to identify the disrupted genes or proteins in 
primary liver cancer development with a view to identify novel biomarkers for the 
disease. We want to correlate these with the clinical stage of the disease and identify 
those that are diagnostic, or which predict prognosis. We believe that this may 
improve our ability to accurately both diagnose and treat the disease. 
Specific Aims included: 
 The creation of a user friendly database incorporating all relevant patient 
information for exploring staging systems and their correlation with outcome, 
as well as identifying the characteristics and trends within our own patient 
population. 
 To explore known and predicted serum surveillance biomarkers for HCC in 
patients with non-alcoholic fatty liver disease (NAFLD) 
 To explore proteomic strategies for identifying novel serum biomarkers 
identifying advanced fibrosis in patients with NAFLD, as well as HCC in 
those with NAFLD cirrhosis.  
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CHAPTER 2.  PATIENTS AND METHODS 
2.1. Ethical Approval and Patient Recruitment 
  Recruitment of patients to this project was commenced in December, 2004 
after receiving formal ethical approval from the regional ethical committee 
(Appendix D). All patients with suspected or confirmed HCC referred to the 
hepatology clinic were considered for the study. The diagnosis of HCC was made 
according to the EASL guidelines (European Association for Study of Liver 
diseases) as summarised in Table 2.1 and the patients were then staged accurately 
according to the Okuda and CLIP score and the performance status assessed. These 
scoring systems are as summarised in Table 2.2 
 
Table 2.1 EASL criteria for diagnosis of HCC 
Investigation Criteria for diagnosis 
Radiological & 
serum AFP  
Non-invasive criteria is based on imaging techniques obtained by 
4-phase multidetector CT  or dynamic contrast enhanced MRI. 
Diagnosis should be based on the identification of the typical 
hallmark of HCC (Hypervascular in the arterial phase  with 
washout in the portal and delayed phases  and serum AFP 
levels >400ng/ml. While one imaging modality is required for 
nodules beyond 1cm in diameter, a more conservative approach 
with 2 techniques is recommended in suboptimal settings. 
Histopathological For nodules of 1-2cm, HCC diagnosis should be based on non-
invasive criteria of imaging or biopsy proven pathological 
confirmation. However, there is a 30-40% false negative rate 
and a  negative biopsy does not rule out malignancy[233] 
 
Table 2.2 Scoring systems for HCC 
Okuda Score 0 1  
Tumour size <50% of liver >50% of liver  
Ascites No Yes  
Albumin(µmol/l) >30 <30  
Bilirubin (g/l) <35 >35  
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Okuda Stage          Stage 1: score 0; Stage 2: score 1 or 2; Stage 3: score 3 or 4 
CLIP scoring 0 1 2 
Childs Pugh stage A B C 
Tumour 
morphology 
Uninodular and 
extension <50% 
Multinodular and 
extension <50% 
Massive or extension 
>50% 
AFP(ng/ml) <400 >400  
Portal vein 
thrombosis 
No Yes  
 
Barcelona Clinic Liver Cancer scoring is described in Figure 1.1 (Chapter 1) 
The patients were recruited after a fully informed written consent was obtained. 
2.2 Central Database 
 A central database was the key to the study. A Microsoft access database was set 
up in conjunction with the Freeman Hospital information technology (IT) 
department, linked to the hepatopancreatobiliary (HPB) patient database recording 
all new referrals to the Newcastle upon Tyne NHS Trust. Unfortunately, this 
database lacked full functionality and ongoing IT support. Thus, the HPB patient 
database was used to identify all patients with HCC. Subsequently the main 
clinical, epidemiological, pathological and radiological variables were entered into 
a patient proforma (see appendix) and subsequently recorded in an excel 
spreadsheet database on a secured hospital intranet server. All therapeutic options 
were recorded, as was any invasive diagnostic procedure such as a biopsy. Patient 
progress was monitored until death.  
2.3 PATIENT DATA AND SAMPLES FOR ANALYSIS 
For the analysis of the data from the central database 130 consecutive patients with 
HCC referred to the Freeman Hospital between January 2004 and June 2006 were 
considered for analysis. The follow up data was cut off in June 2011. The data 
included demographics, Child Pugh status, CLIP, BCLS and Okuda staging and the 
treatment provided. 
To explore and suggested biomarkers for HCC pre-treatment samples from 50 patients 
with HCC, all of whom had an underlying cirrhosis, were selected for study. Of these, 
31 patients had alcoholic liver disease (ALD) and 19 patients had NAFLD. The serum 
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was immediately separated by centrifugation and frozen at - 80°C. These serum 
samples were compared to an independent group of 41 patients with biopsy proven 
ALD or NAFLD cirrhosis. The diagnosis of NAFLD cirrhosis was made in patients 
who had clinical features and liver biopsies compatible with NAFLD. Females and 
males consuming greater than 14 or 21 units of alcohol per week respectively were 
excluded from this category, as were any individuals with viral or autoimmune liver 
diseases.  
In the proteomics study for HCC serum samples from 5 patients with biopsy proven 
NAFLD without cirrhosis, 5 patients with NAFLD cirrhosis and 5 patients with AFP 
negative HCC were used for immunodepletion and 2 dimensional gel electrophoresis. 
A  novel biomarker identified from the above experiments was assessed in the serum 
of 45 individuals with steatohepatitis-related HCC and compared to levels in 49 
individuals with biopsy proven steatohepatitis-related cirrhosis and 64 patients with 
biopsy proven NAFLD steatohepatitis without cirrhosis or HCC. 
2.4 EDTA blood and serum collection and storage 
At each visit a blood sample was taken from those individuals who had consented to 
ethically approved (by the Newcastle and North Tyneside Ethics Committee) tissue 
collection.  Serum from 5ml of blood was harvested after centrifugation at 3500g 
for 10 min and then stored at -80
o
C for serum proteomic studies and for later 
validation of markers. 5ml of EDTA blood was also taken and stored at -80C for 
preparation of leukocyte DNA. 
. 
2.5 Serum Analyses  
Successful serum proteomics, identifying and comparing quantities of proteins in 
similar serum samples, needs careful preparation.  Collected samples were 
centrifuged and serum stored at -20degrees c within 2h wherever possible.  Within 
1-2 days, linked-anonymised samples were transferred to -80
0
C storage at the 
Northern Institute for Cancer Research Central Tissue Resource.  Protein 
quantification was as described in the Pierce BCA protein assay (section 2.5.1). 
Polyacrylamide gel electrophoresis for separation of proteins in a single phase is 
described (section), as are relevant standard laboratory techniques such as western 
blotting and ELISA assay for specific protein detection.  In addition, for novel 
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protein detection, a methodology to remove the abundant proteins enabling the 
subsequent analysis of the depleted serum for change in any protein(s) to 
characterise a disease condition (which in our study was cirrhosis and 
hepatocellular carcinoma) was required. So we initially explored low molecular 
weight filter as a method for removing the abundant heavy proteins. We 
subsequently explored the use of immunodepletion to remove the top six abundant 
proteins, prior to separating samples by two dimensional gel electrophoresis. Each 
of these techniques are summarised.  
2.5.1 Protein Quantification  
Protein quantification with the Pierce protein assays was estimated relative to a 
standard curve created with Bovine serum albumin (BSA), as summarised below. 
1. The BSA standards provided as vials in the kit were diluted in ‘RIPA’ buffer.   
Vial 
 
Vol of 
dilue
nt 
(RIPA) 
Vol and 
Source of 
BSA 
standard  
Final (BSA) 
mg/ml 
A 0 300(stock) 2 
B 125 375(stock) 1.5 
C 325 325(stock) 1 
D 175 175(vialB) 0.75 
E 325 325(vialC) 0.5 
F 325 325(vialE) 0.25 
G 325 325(vialF) 0.125 
   
2. 10 μl of each standard or blank was placed in quadruplicate wells according to the 
following layout in a 96 well plate, with diluted unknowns (uk) in remaining wells. 
Blank 2 1 0.5 0.125 Uk1 Uk3      
Blank 2 1 0.5 0.125 Uk1 Uk3      
Blank 2 1 0.5 0.125 Uk1 Uk3      
Blank 2 1 0.5 0.125 Uk1 Uk3      
Blank 1.5 0.75 0.25  Uk2 Uk4      
Blank 1.5 0.75 0.25  Uk2 Uk4      
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Blank 1.5 0.75 0.25  Uk2 Uk4      
Blank 1.5 0.75 0.25  Uk2 Uk4      
 
3. The working Pierce reagents were made up according to manufacturer’s 
instructions (50 parts Reagent A and 1 part Reagent B: 19.6 ml of Reagent A to 
400 μl Reagent B in a universal container, followed by gentle inversion). 
4. 190 μl of working reagent was added to each well using a multichannel pipette, 
followed by brief mixing on a plate shaker. 
5. The plate was covered with cling film and placed in a 37
о
C incubator for 30 mins. 
6. The plate was read on a spectra max plate reader at 562 nm, with software creating 
a standards curve and calculating the concentration of protein in each unknown.  
2.5.2 Western blotting 
i) Casting the gels using Biorad 
1. Clean glass plate and spacer plate were slid into the casting frame. After ensuring a 
tight seal at the bottom, the pressure clamps were engaged. The gel cassette assembly 
was then placed in a casting stand. A sample loading comb was placed on top of the 
assembled gel cassette to mark the level up to which the resolving gel is poured. 
2. The resolving gel was prepared from the recipe in appendix 1. The chemical 
‘TEMED’ is added last, just prior to pouring, as in the presence of APS, it helps to 
initiate the solidifying process. A 10% resolving gel was used as it is effective for the 
proteins in the range of 20 – 300 kDa. The solution was then poured up to the mark in 
the casting apparatus taking care to prevent mixing with air. It was then quickly 
overlaid with isopropanol, to keep the top of the gel smooth while setting  
3. The gel was allowed to polymerise for 1h and then the alcohol overlay was 
removed by blotting and replaced with the stacking gel, prepared as per recipe in 
appendix 2. Again, the APS and Temed were added last and the solution was poured 
between the glass plates till the top of the short plate was reached.  
4. The sample loading comb (creates the spaces in which the samples will be placed 
after the loading/stacking gel has set) was then inserted between the plates and the 
stacking gel allowed to polymerise for 45 minutes. 
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5. The comb was gently removed and the wells are rinsed thoroughly with running 
buffer. The gel cassette assembly was then removed from the casting stand and then 
the gel cassette sandwich released from the casting frame and was ready for 
electrophoresis after sample loading 
 
 
 
 
Figure 2.1 below shows the preparation of SDS gel for electrophoresis 
ii) SDS Polyacrylamide gel electrophoresis 
1.  .Running buffer was prepared while the stacking gel was setting. The stock recipe 
is used (appendix 3), diluted 1:10 (900ml distilled water: 100ml of running buffer) 
prior to use. 
2. The prepared serum samples were thawed on ice and 50 μg protein equivalent is 
aliquotted into each eppendorf and RIPA buffer added to make total volume of 15 μl. 
To each of these aliquots 5 μl of SDS loading buffer was added. The aliquots are then 
placed in a preheated hot block at 100ºC for 2 minutes. 
3. Before loading the samples the wells were flushed gently to ensure they were free 
of ‘unset’ acrylamide. The samples were then loaded into the wells, with a record kept 
of their order, relative to the marker loaded into the end well. 
4. The lid was then placed on the tank ensuring that the colour coded plugs 
(determining the direction of current passed) were in the correct orientation. 
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5. Ice was packed around the apparatus. The leads were then inserted into the power 
supply, with volts set as follows:  
 a) 90v for the running in the stacking solution  
 b) 150v for running in the resolving gel. 
6. The Hybond P (Polyvinylidene difluoride, PVDF) membrane to which separated 
proteins would be transferred was prepared by cutting a piece slightly bigger than the 
size of the gel along with two similar sized filter paper while the gel was running. 
Transfer buffer was also prepared using protocol in appendix 4. Two pieces of sponge 
more than the size of the gel was also assembled.  
iii) Protein transfer onto the membrane and antibody fixing 
1. After the electrophoresis was complete, the power supply was turned off, the 
electrical leads disconnected and the gel running assembly removed from the tank. 
The gel cassette was freed, and the gel plates were separated. The gel removed by 
gently floating it in a container of transfer solution. 
2 . For assembling the transfer of proteins from the gel to the hybond P 
membrane, a sandwich of plastic cassette (black side), sponge, filter paper, gel, 
hybond P, filter paper, sponge cassette (red side) was made, as described in the  figure 
below 
 
---------------------------------red (+) 
---------------------------------pad/sponge 
---------------------------------filter paper 
-------------------------------membrane 
-------------------------------gel 
---------------------------------filter paper 
---------------------------------pad/sponge 
---------------------------------black (-) 
 
3. The closed sandwich cassette was then placed in the correct orientation in the 
transfer tank (black side of the cassette facing the black side of the tank) 
59 
 
4. The gel transfer was done at 40mA overnight on the bench using cooling packs 
around it and stirrer within the tank to ensure circulation of the buffer. The transfer of 
the ladder proteins was used to check for transfer. 
5. After removal, antigenic proteins on the transfer membrane were blocked with 
100ml of 5% milk in TBS, shaking gently for 1h. The membrane was subsequently 
washed in TBST 5-10 minutes, repeated 3 times. 
6. Incubating transfer membrane with antibodies was as follows: 
Description Antibody 
raised in 
Dilution 
factor 
Diluted in Incubation 
time 
Incubation 
temperature 
Anti Granulin Rabbit 1:100 5% milk in 
TBST 
Overnight Room 
Anti FST Mouse 1:250 5% milk in 
TBST 
Overnight Room 
7. After the incubation with primary antibody the membrane was washed three times 
with TBST, as it was after secondary antibody incubation.  
 
Description  Dilution 
factor 
Diluted in Incubation 
time (hours) 
Incubation 
temperature 
Anti rabbit 1:1000 5%milk in 
TBST 
1 Room 
Anti mouse 1:1000 5% milk in 
TBST 
1 Room 
 
iv) Developing the ‘Western Blot’ 
1. The inside of the radiographic cassette was lined with cling film. The Pierce West 
Dura Substrate kit was used. The TBST was removed, leaving the membrane in its 
empty wash container.  
2. The membrane was covered with 1ml of ‘Dura’ solution (500μl of stable peroxide 
buffer plus 500μl of luminal enhancer) for five minutes. 
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3. The membrane is then transferred to the clingfilm within the radiographic cassette 
and carefully wrapped and smoothed. 
4. In the dark room, radiographic film was placed over the membrane and the cassette 
is closed for 1min, prior to the film being removed and placed into the automatic 
film developer. On film removal, additional time points for incubation with film 
were chosen pending the initial result. 
 
2.5.3 ELISA (Enzyme Linked Immunosorbent Assay)  
 
Western blotting was used to confirm the presence of discriminatory identified in our 
projects. However, an ELISA assay is a more quantitative technique and a 
background to the technique and summary of our methods are summarised below.   
‘ELISA’ evolved in the 1960s from a radio-immuno assay, with the observation that 
either the antibody or the analyte / antigen could be adsorbed to a solid surface and 
still participate in specific high affinity binding. Engvall and Perlman published their 
first paper on ELISA in 1971 and demonstrated quantitative measurement of IgG in 
rabbit serum using alkaline phosphatase as the reporter label.[234]. The basic purpose 
of an ELISA is to determine whether a particular protein is present in the sample, and 
is so, quantify it. 
In an ELISA, the antigen of interested must be immobilised to a solid surface, which 
is also called the ‘solid’ phase. The antigen is then complexed with an antibody that is 
linked to an enzyme. Detection is accomplished by incubating this enzyme-complex 
with a substrate that produces a detectable product. The most crucial element of the 
detection strategy is a highly specific antigen-antibody interaction. The ability to wash 
away the non-specifically bound materials makes the ELISA a powerful tool for 
measuring specific analytes within a crude sample preparation.  
I) Types of assays 
i)  Direct and Indirect ELISA 
A detector enzyme may be linked directly to the primary antibody (Direct ELISA) or 
introduced through a secondary antibody that recognises the primary antibody 
(Indirect ELISA). The most common enzymes used are Horse radish peroxidise 
(HRP) and Alkaline phosphates (AP).Other options have been used but they have not 
gained widespread acceptance because of limited substrate options. The choice of 
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substrate is also determined by the necessary sensitivity level of the detection and 
instrumentation available for detection (eg spectrophotometer, fluorometer or 
luminometer). 
 
The advantage of direct assay is that it is quick and cross reactivity of secondary 
antibody is eliminated. It has the disadvantage that immunoreactivity may be reduced 
by labelling of the primary antibody. In addition, labelling of the primary antibody is 
time consuming and expensive, with no flexibility in choice of primary antibody label 
from one experiment to another.  
Cross reactivity of the secondary antibody can be a disadvantage with the indirect 
ELISA, but this assay has some significant advantages. Firstly, a wide variety of 
labelled secondary antibodies are available; secondly, the immunoreactivity of the 
primary antibody is not affected by labelling of the primary antibody. Thirdly, the 
sensitivity is increased because each primary antibody has several epitopes that can be 
bound by the labelled secondary antibody allowing for signal amplification.. Lastly, 
different visualisation markers can be used with the same primary antibody. 
ii) Capture ELISA / Sandwich ELISA 
Another commonly used format for ELISA is the sandwich assay. The name is 
derived from the fact that the analyte to be measured is captured between two 
antibodies – the capture antibody and the detection antibody i.e. two antibodies 
directed to two different epitopes of the same protein to prevent interference in 
binding. It is more sensitive and robust.  Either monoclonal or polyclonal antibodies 
can be used.  Monoclonal antibodies have an inherent monospecificity towards a 
single epitope that allows fine detection and quantification of small differences in 
antigen. A polyclonal is often used as a capture antibody to pull down as much 
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antigen as possible, and then a monoclonal antibody is used as the detection antibody 
to provide improved specificity.  
 
 
II) Sensitivity of an ELISA assay 
The antibody is the key to the sensitivity and specificity of an ELISA assay. It is the 
three dimensional configuration of the antigen binding site found in the F(ab) portion 
of the antibody that controls the strength and specificity of the interaction with the 
antigen. The stronger the interaction, the lower the concentration of the antigen that 
can be detected. A competing factor is the specificity of the binding or the cross 
reactivity of the antibody to serum proteins other than the target proteins. 
The sensitivity of the assay can also be compromised by the presence of detergents in 
the coating solution, which can prevent binding of the protein to the plate. Excessive 
concentration of coating protein occasionally lead to less binding, a phenomenon 
known as the ‘hook effect’. This can therefore cause poor detection of the protein in 
the sample. 
III) Detection molecules 
Common detection molecules used are Horse radish peroxidase and alkaline 
phosphatase. 
Horseradish Peroxidase (HRP) Substrates 
Horse radish peroxidase is a 40 kDa protein that catalyses the oxidation of substrates 
(e.g.TMB; tetramethylbenzidine) by hydrogen peroxide, resulting in a coloured or 
fluorescent product or the release of light as a by-product. High turnover rate, low 
cost, wide availability of substrates and superiority of antibody-HRP conjugates in 
comparison to antibody-AP (Alkanine phosphates) makes it the enzyme of choice for 
most applications. 
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Alkaline phosphatise (AP) Substrates 
Alkaline Phosphatase is a 140 kDa protein that catalyses the hydrolysis of phosphate 
groups from a substrate molecule, resulting in a coloured or fluorescent product or the 
release of a fluorescent product as by-product. 
A.  Indirect ELISA for FST and CD5L 
Due to the availability of antibody to only one epitope of our target proteins studied 
(FST and CD5-L), we developed the indirect ELISA.  FST and CD5L recombinant 
protein was used in serial dilution (figure 2.2) to obtain a ‘standard’ graph. After 
measuring serial dilutions of FST and CD5L, the optimum dilution for FST was noted 
to be 1:50, while for CD5L it was 1:2. Reproducibility was confirmed by duplicate 
analyses. 
 
Figure 2.2: The 
standards curve 
generated with 
known concentration 
of the target protein 
Follistatin (FST) 
 
 
The materials are 
summarised below: 
Coating buffer (1 × TBS) (Appendix 6) 
Wash buffer (TTBS; TBS + 0.05% Tween 20) 
Tween 20 = 0.5gm per litre of TBS 
Blocking buffer 
3% BSA (Bovine serum albumin) in TBS 
Dilution buffer 
% BSA in TTBS 
Primary antibody 
Mouse antibody for FST (Sigma Aldrich SAB14025150 
Goat antibody for CD5L (Abgent AT1443A) 
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HRP(Horse raddish peroxidise) secondary antibody 
Anti-mouse antibody for FST 
Anti-goat antibody for CD5L 
Substrate solution (appendix 7) was prepared fresh 
The method developed was as follows: 
Serial dilutions (in coating buffer) of the recombinant protein were placed in triplicate 
in the wells of the ELISA plate. 
Appropriate dilution of the serum (1:10) was made in the coating buffer and 100µl 
was then placed in triplicate wells. The plate was covered for overnight incubation at 
4
0 
C 
The following day the plate was emptied. The plate was then inverted and tapped on a 
paper towel.  
Each plate was  rinsed 4 times with wash buffer. 
The primary antibody was diluted (1:250 for FST and 1:500 for CD5L). 50µl of 
primary antibody was then added to each well and the plate incubated for 1h at 37
0
C. 
Step 4 was repeated to wash the plate. 
50µl of HRP antibody (anti-mouse for FST 1:2000 and anti-goat for CD5L 1:5000) in 
dilution buffer was added to each well. The plate was then incubated at room 
temperature for 1h. 
The plate was washed as in step 4. 
100µl of substrate solution was added to each well and then left at room temperature 
for 30 minutes. A blue colour should develop. 
The reaction was stopped by adding 50µl of 1m sulphuric acid, turning the colour 
yellow. 
The plate was then read in the Spectra Max plate reader at optical density (OD) 650 
nm and 450 nm. The reading at at 650nm was then subtracted from the OD reading at 
450 nm. The plates were  read within 30 min of stopping the reaction.  
 
2.5.4 ELISA for PIVKA-II (Prothrombin induced by vitamin-k absence) 
As a part of our project we also analysed known serum biomarkers PIVKA-II and 
glypican 3 in our serum samples, exploring whether they would add any value in our 
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surveillance for HCC in our patients. Custom made ELISA kits were used for these 
analyses, used according to manufacturers instructions, described in appendix B. 
2.5.5 ELISA for Glypican-3 (GPC-3) 
The glypican 3 assay was performed with an ELISA kit manufactured by Biomosaics 
limited (Catalog no B1500) available for research purposes. It is ‘‘sandwich’’ ELISA 
employing two GPC-3 specific antibodies. The assay was performed as per 
manufacturer’s protocol described in appendix C. 
2.5.6 Optimising serum samples for proteomic studies 
 
From the available literature it was obvious that to mine for biomarkers we needed to 
analyse the less abundant proteins. To achieve that objective it was important that 
we optimised a method with reproducible results to remove the abundant proteins 
from the serum samples before subjecting it to two dimensional fractionation.  The 
first step was to assess the effectiveness of low molecular weight cut off filters in 
removing the abundant high molecular weight fractions 
Low Molecular weight filters 
To 100µl serum aliquots 300µl of TBS buffer was added and centrifuged at 10,000g 
for 10 minutes. The supernatant was then applied to the Low Molecular Cut Off 
Filter (Microcon/Millipore) and centrifuged at 10,000g for 30 minutes at 4
o
 C. 
Multiple filtered fractions of the same sera were prepared at the same time and are 
pooled together. The pooled fractions were then concentrated by lyophilisation and 
the protein concentration is checked BCA assay. The retentate from the filters was 
also treated in the same way. 
To check for the efficiency of the cut off filters we subjected the depleted serum and 
also the retentate through one dimensional SDS-polyacrylamide gel electrophoresis 
which was performed as per protocol mentioned in section 2.4.2.(ii). The gel was 
then stained with Coumassie.  
The 30kDa filter showed no low molecular weight protein bands in the filtrate and the 
50kDa revealed low molecular weight bands but could not effectively remove the 
high molecular weight proteins in the filtrate. Two 50kDa filters with the same 
serum sample show different filtration fractions suggesting significant 
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inconsistency. The failure of the low molecular weight cut off filters led us to 
revisit our strategies. 
 
 
Figure 2.3. Picture of gel comparing 
retentate with the filtered fractions from a 
50 kD and from a 30kDa filter. The ladder 
has stained as a control and the raw serum 
shows some protein bands to confirm the 
performance of the PAGE. The filtered 
sera from the 30 kDa filters fail to reveal 
any bands in the gel and the filtrate from 
the 50 kDa filter shows bands from more 
than 50 kDa proteins  
 
2.5.7 Immunodepletion of abundant proteins and 2-dimmensional gel 
electrophoresis 
Following the encouraging reports about the MARS (Multiple Affinity Removal 
System) immunoaffinity column in effectively depleting the top 6 abundant proteins 
with reproducible results we used this as our first step. The serum fraction depleted of 
the top 6 abundant proteins was then subjected to 2-dimensional gel electrophoresis 
for the second dimension.  
 Immunoaffinity Column (Agilent Technologies) 
An 1100 HPLC (Agilent Technologies) apparatus was used for the immunoaffinity 
column. The HPLC apparatus is first purged with Buffer A and B (Proprietary buffers 
for the column). Buffer A is a salt containing neutral buffer, pH7.4, used for loading, 
washing and requilibrating the column. Buffer B is a low-pH urea buffer used for 
eluting the bound high abundance proteins from the serum  A time table is set up in 
the apparatus for the running of the serum samples as mentioned in the manual.  
 
 
 
67 
 
LC method for 4.6×100mm column 
Time   %B Flow Rate 
ml/min 
Max Press 
0.00 0 0.500 120 
10.00 0 0.500 120 
10.10 100 1.00 120 
17.00 100 1.00 120 
17.01 0 1.00 120 
28.00 0 1.00 120 
 
The MARS column is attached after two runs with buffer A the HPLC apparatus, For 
each run, 80µl of serum is prepared by diluting with 300µl of buffer A and then 
centrifuged through a 0.22µm filter at 16,000 for one minute to remove particulates. 
The fraction eluting from between 2.5 min and 6 minutes corresponding to the less 
abundant proteins was collected. The protein quantities were assessed by the BCA 
protein assay kit and then the depleted samples are then stored at -20
o
 C before two 
dimensional electrophoresis. 
Two dimensional gel electrophoresis 
This involves isoelectric focussing as the first dimension and gel electrophoresis as 
the second dimension 
For isoelectric focussing the sample was prepared with a rehydration buffer to 
completely solubilise the proteins, prevent protein modification, remove interfering 
components and maintain protein in solution during the isoelectric focussing. 
Isoelectric focussing was performed using 18cm, 3-10 non-linear strips (GE 
Healthcare Immobiline
TM 
Dry Strip pH 3-10 NL, 18cm). For each strip depleted sera 
with 500µg of protein was prepared by adding rehydration buffer (appendix) (total 
volume 450µl). After incubating in room temperature for 30 minutes the sample was 
pippeted into the strip holder. The non-Linear strip is then placed in the holder with 
the gel side down taking care to avoid any air bubbles 
 After incubating at room temperature for 12 hours, isoelectric focussing was 
performed using high voltage and low current using the following protocol 
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Step Voltage Duration 
(h:min) 
Kilo volt hours 
(KVh) 
Gradient Type 
1 Rehydration 12:00 00  
2 500 6:00 3 Step-n-hold 
3 3500 01:30 3 Step-n-hold 
4 3500 06:00 30 Step-n-hold 
 
After focussing, the strips were stored at -20
o
 C before proceeding to the second 
dimension gel electrophoresis. The second dimension gel electrophoresis required 
the preparation of 25 × 25cm gel and then equilibrating and saturating the strips 
before gel electrophoresis.  To prepare the gel for electrophoresis the 
components in appendix 10 were mixed and degassed. Then Temed (337.5µl) and 
10% APS (3.375µL) were added to the above solution. 10ml of the solution was 
then poured into each gel stack (Amersham Biosciences) and the gel allowed to 
settle. 
 The isoelectric focussed strips were first treated with 15ml of equilibration buffer 
with added DTT (100 µg/10ml) on a rocker for 15 minutes and then with 15ml of 
equilibration buffer with IAA (250µG/10ml) for a further 15 minutes on a rocker. 
The equilibrated focussed strips were then placed over the top of the 1mm gel and 
secured with agarose. The gel in the plates was then placed in the DALT six (
TM
GE 
Healthcare Life Sciences) and electrophoresis was performed using the following 
conditions 
Step Current (mA/gel) Duration (h:min) 
1 10 00:15 
2 20 05:00 
The gel run was stopped within 1cm of the lower edge of the gel and the gels were 
washed with double distilled water. The gels were then stained with Coumassie for 
one hour and then destained with double distilled water overnight. 
Next day the gels were imaged under the scanner at 16 bits and stored for further 
analysis. The gels were then analysed using the software. 
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2.5.8 Microarray data for serum biomarkers 
The complete unravelling of the human genome and the increasing amount of data 
from a DNA microarray of different disease conditions has opened up a new window 
to mine for biomarkers.  Microarray data provides us with a vast amount of 
information about genes expressed in a given tissue. The mining of this data can 
identify genes or clusters of genes which transcribe cell surface or secreted proteins, 
but needs careful and complex statistical analysis. 
 RNA was previously extracted from HepG2 cells (hepatoblastoma cell line) 
stably expressing either empty vector (pBABEpuro) or the KLF6 tumour suppressor 
gene. Proliferation was suppressed in the cells over-expressing KLF6.  The RNA 
obtained from both the cell lines was converted to cDNA and biotin labelled, prior to 
hybridisation to Codelink Bioarrays (Unpublished data from Dr Reeves Group).  The 
Bioarrays were previously scanned using an Axon Laser Scanner and Genepix 
Software, prior to importing the data into Gene Spring version 6 (Silicon Genetics) for 
analysis. 
 My own analysis of this data identified 20 genes with a particularly high basal 
level of expression in HepG2 cells, whose expression was suppressed by at least 2 
fold in the slower growing KLF6 overexpressing cells. Of these, I identified genes 
which were secretory proteins/transmembrane proteins, which were targets of MMPs, 
or involved in regulation of the cell cycle/survival.  I also looked for those to which 
commercial antibodies were available. Consistency with other data sources was also 
explored, including the Stanford university website of HCC microarray data. Finally, I 
chose two genes Follistatin (FST) and Granulin) suspected of having a role in 
hepatocarcinogenesis, which were predicted to be present in serum, for 
characterisation at the protein level. 
 Western blotting was then performed with immunodepleted serum obtained 
from the previous part of the study. The samples were then blotted separately against 
antibodies for Follistatin (FST) and granulin. The results with FST appeared 
discriminatory for HCC and cirrhosis. But granulin was non-discriminatory and was 
discarded from further study. 
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Chapter 3 Results 1. Hepatocellular cancer in the North-East of England 
3.1 Introduction - Approach and management of HCC patients in Newcastle 
With 200,000 cancers diagnosed annually in the UK and 120,000 people dying from 
cancer, cancer treatment has become one of the central priorities for the NHS. It was 
recognised in the 1990s that there were many regional variations in the quality of 
cancer patient care and treatment. In the year 2000, the department of health 
introduced a comprehensive ‘Cancer Plan’ aiming to deliver the fastest improving 
cancer care services in Europe. The plan had four objectives: 
To save more lives 
To ensure people with cancer get the right professional support and care as well as the 
best treatments. 
To tackle the inequalities in health that meant unskilled workers were twice as likely 
to die from cancer as professionals 
To build for the future through investment in the cancer workforce, through strong 
research and through preparation for the genetics revolution, so that the NHS did not 
fall behind in cancer care. 
The success of the plan would rely on reducing the risk of cancer, detecting cancers 
earlier, improving cancer services in the community and ensuring faster access to 
treatment. The goal for faster access to treatment was that no patient should wait 
longer than one month from an urgent referral by their GP with suspected cancer to 
the start of treatment. The progress of the cancer plan has been closely followed 
(www.nhs.uk/nhsengland/NISF/pages/Cancer.aspx) and some of the important 
achievements are outlined below 
Better prevention – A ban on smoking in private places has resulted in a reduction in 
smoking rates 
More early stage cancers are detected through screening – National screening 
programmes for bowel, breast and cervical cancer are considered successful and 
further screening programmes will be introduced. 
Faster diagnosis and treatment – waiting times for cancer have reduced dramatically 
Improved access to better treatment – there has been a major increase in the use of 
drugs approved by the National Institute of Clinical Excellence to treat cancer with 
less variation between cancer networks. 
71 
 
Free prescription charges for patients with cancer – since April 1, 2009, patients 
undergoing treatment for cancer, including the effects of past cancer treatment, have 
been able to apply for medical exemption. 
Building on the success of the Cancer plan 2000, the Cancer Reform Strategy was 
published in December, 2007. It detailed how by 2012 cancer services in England 
could be among the best in the world. The continuing achievement in the early 
diagnosis and treatment of cancer could be facilitated by having dedicated databases 
in trust hospitals with prospectively entered data, with regular monitoring of progress. 
A step in the right direction was taken at Freeman Hospital at the time of the inception 
of the NHS cancer plan 2000, when a Microsoft Excel database was initiated in the 
same year, with the primary aim of auditing the success of radiofrequency 
ablation(RFA) as a recently introduced therapeutic intervention for colorectal liver 
metastases and HCC. In this database a record of interventions and outcomes for 
patients, treated with RFA, was maintained by clinical surgical staff. The majority of 
patients receiving RFA at this time received the treatment for colorectal liver 
metastases rather than primary HCC. 
 In parallel a separate NHS IT staff supported database was set up – the hepato-
pancreatobiliary (HPB) database. This database was central to the newly created HPB 
multidisciplinary team; supporting improved care for cancer patients following the 
government initiated Cancer Plan 2000. All the HPB cancer patients in the Northern 
region are now discussed and managed with agreement of this multidisciplinary team 
– including physicians, surgeons, radiologists, oncologists, pathologists and specialist 
nurses. Details for all patients with primary or secondary liver tumours and pancreatic 
tumours, irrespective of the treatment they received, have been regularly recorded in 
the HPB database. 
 Whilst the HPB database had the potential to be used as a powerful research 
tool, its major purpose was for patient tracking. In addition, the large number of 
patients being discussed and managed in this forum hampered focus on HCC. 
Restructuring of the multidisciplinary meetings, with grouping together of subclasses 
of diseases has improved the efficiency of this service. In parallel an intranet based 
HCC excel patient database has been created. The data entered includes patient 
demographics, baseline blood tests and radiology and facilitates patient staging 
according to Childs-Pugh, Okuda and CLIP score. This database has become a 
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powerful audit and research tool. The maintenance of a central database is key to the 
management of cancer patients as explained in figure 3.1 
 
Figure3.1 (left) 
showing the 
central 
database in 
relation to 
cancer 
management 
 
 
 
 
 
In 2004 we successfully obtained permission to collect and store patient tissues as 
well as data for research purposes, initiating a project entitled ‘The application of 
molecular biology and proteomics to the management of patients with liver cancer’. 
We collected serial blood samples from all patients, as well as any biopsy tissue 
available, hoping to improve the value of the HCC database as a research tool, by 
accompanying it with genomic and proteomic studies.  
3.2 Staging of HCC 
As for any malignancy, clinical staging for HCC is an essential pre requisite as it 
provides the tools for assessment and a guide for therapeutic strategies. We not only 
need it to predict prognosis at the time of diagnosis but a standard validated staging 
system is required for comparing results from trials before we can incorporate them in 
daily clinical practice. However, the assessment for HCC is more complex than other 
tumours as the prognosis and treatment modalities are not only guided by the tumour 
characteristics and extent of spread (local and distal,) but also by the background 
function of the liver, as about 80% of HCC develop in the background of chronic liver 
disease. This complexity of the disease has resulted in the failure to develop a uniform 
standard staging system for HCC management. 
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A staging classification for solid tumours was first proposed by French surgeon, 
Pierre Denoix more than 50 years ago which then formed the basis of the first edition 
of  TNM (Tumour, Node, Metastasis) classification in 1968. This has since then 
undergone modifications and the sixth edition were published in 2003. The 
assessment of the tumours in this system is based on the size of the tumour and the 
extent of local and distant invasion. In HCC, the presence of chronic liver 
disease/cirrhosis prevents accurate assessment. This limitation has resulted in the 
development of different staging systems for HCC with each of them trying 
incorporating different parameters of chronic liver disease. 
The staging systems commonly used in contemporary clinical practice are the Okuda 
staging, the CLIP (Cancer of the Liver Italian Program) score, and the BCLC 
(Barcelona Cancer Liver Clinic) staging. There are other staging systems which are 
used more locally and they include CUPI (Chinese University Prognostic Index), JIS 
(Japanese Integrated Score) and the GRETCH (Groupe d’Etude et de Traitement du 
Carcinome Heaptocellulaire) systems. The Okuda Staging (Table 2.2) was proposed 
in 1985 and included the significant variables of liver function and tumour extension 
[235]. This staging stratified the disease more successfully when patients presented 
with advanced disease (Okuda Stage 3 or more), but in present day practice, with the 
disease being diagnosed early, the Okuda system fails to stage  the disease accurately, 
failing to separate individuals into distinct prognostic categories, therefore failing as a 
tool to guide management [236].     
While the failure of the Okuda staging system to differentiate the disease in the early 
stages suggested the need for more complex staging systems, the Okuda system 
represents an important step forward for HCC staging, suggesting the importance of 
combining liver function with the tumour characteristics. In 1998, the CLIP (Cancer 
of the Liver Italian Program) (please refer to table 2.2) was proposed from a 
retrospective evaluation of 435 Italian patients diagnosed with HCC between 1990 
and 1992 [237]  and includes the Child-Pugh stage, tumour morphology and 
extension, serum AFP levels and portal vein invasion. The CLIP score was then 
prospectively validated internally by the same group in 2000 [237, 238] and also in 
separate series of Italian and Canadian patients[236, 239]. However, in a series of 662 
Japanese patients the predicted mortality rates were significantly different from the 
actual survival which compromised the external validation [240]. A major problem 
encountered with this staging system is the CLIP score of ‘0’ for uninodular tumours 
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with a tumour extent of less than 50%, which is a fairly large tumour in present day 
practice, where more tumours are being diagnosed when small in size, thereby 
compromising the predictability. It has also been reported that CLIP scores of 4, 5 and 
6 have no statistical difference and that it is also not able to stratify treatment option s 
for different CLIP scores [241]. Despite these limitations it has fared better than 
Okuda scoring system and is now commonly used for prognostic assessment but not 
for planning management. 
A further step was taken when the EASL (European Study of Liver Diseases) panel of 
experts recommended inclusion of general condition of the patient and treatment 
efficacy along with tumour stage and liver function status in the prognostic modelling 
of HCC patients which formed the basis of the Barcelona-Clinic Cancer Liver staging 
system. The Barcelona group constructed the BCLC (Barcelona-Clinic Liver 
Cancer) staging (Figure 1.1) system after reviewing survival data of early tumours 
selected for radical therapy and the natural outcome of non-surgical HCC patients. 
This staging includes the variables related to physical status, cancer related symptoms 
along with the tumour stage and functional status of the liver categorising HCC into 
four stages (Stages A – D) with a treatment algorithm. The BCLC has been 
prospectively validated and has been suggested to more accurate than the other 
systems available [242, 243]. However, a recent study, in 2009, concluded that BCLC 
was the ablest in predicting survival in early treated patients but none of the scoring 
systems (CLIP, BCLC and GRETCH) used in the study was able to predict 
confidently survival in individual patients[244]. The authors suggested that a more 
accurate staging system was still needed. 
In our study, we prospectively scored the patients into OKUDA, CLIP and BCLC 
stages, as they are the most commonly used scoring systems, and regularly accrued 
treatment and survival data to assess the prognostic ability of these staging systems 
and comparing them with the available data in the literature. This is an ongoing study 
to recruit a large cohort of patients to continuously monitor patients, analyse response 
to treatment and regularly check the mortality from the disease. 
3.3 Increasing incidence and changing aetiology of HCC in the North East of 
England 
The number of patients included in the study from its inception in January 2004 until 
mid 2006 was 130, and this cohort has been the focus of my research. Comparison of 
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the trends in disease characteristics were facilitated by the inclusion of HPB data from 
2000 until 2004. In addition, a cohort of 69 consecutive HCC patients identified and 
characterised by Dr Mark Hudson between 1993 and 2000, was also available for 
comparison. The most obvious difference is one of numbers, namely 69 over a 7 year 
period pre 2000, versus 130 in a 2.5 year period just 4 years later. The referrals to the 
HPB team documented in figure 3.1 confirm a steady increase from 10 – 12 patients 
per year, to over 50 in 2006. This dramatic increase most likely reflects, at least in 
part, the success of the Cancer Plan 2000, ensuring that all patients in the region were 
referred to specialist team. The increase may also be due to a true increase in the 
numbers of patients with HCC. Certainly a comparison between the 1993 – 2000 and 
the 2004 – 2006 cohorts suggest a dramatic change in the aetiology of underlying 
liver disease in more recent years. Table 3.1 demonstrates a proportional increase in 
the numbers of patients with underlying NAFLD – an entity hardly recognised in the 
previous decade. 
The irony of the Cancer Plan 2000 success for HCC patients was that all too often this 
was a ‘paper exercise’ only, with no treatment to offer the referred patients other than 
best palliative supportive care. With careful characterisation of our 2004 -2006 cohort, 
we aimed to audit care and outcomes, hoping to facilitate improvements in both. 
Table 3.1 (below) comparing the background liver disease in patients with HCC 
between the 1993 – 2000 and 2004 – 2006 cohort 
Aetiology 1993 – 2000 
N = 69 
2004 – 2006 
N = 130 
Alcoholic liver Disease 16 (23%) 50 (38.5%) 
Non-alcoholic liver disease 02 (3.0%) 21 (16.2%) 
Hepatitis B 06 (9.0%) 06 (4.6%) 
Hepatitis C 10 (14%) 08 (6.2%) 
Haemachromatosis 05 (7.0%) 11 (8.5%) 
Autoimmune hepatitis 03 (4.0%) 04 (3.1%) 
Primary Biliary Cirrhosis 06 (9.0%) 04 (3.1%) 
Alpha-antitrypsin deficiency 04 (6.0%) 01 (0.7%) 
Cryptogenic 04 (6.0%) 07 (5.3%) 
Primary HCC without cirrhosis 13 (19%) 18 (13.8%) 
Other 4 (6.0%) 0 (00%) 
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Figure 3.1 showing the trend in HCC from 1995-2006 
3.4 Patient demographics, Childs Pugh status and tumour staging 
Our cohort of 130 patients was followed up until June 2011, completing a minimum 
of five years follow up. There were 22 females and 108 males with a male to female 
ratio of 5:1. The most common aetiology was chronic alcoholic liver disease, 
comprising 38.2% of patients. The demographic, clinical and tumour staging 
characteristics of our set of patients are described in table 3.2 
 
 
 
Table 3.2 (below) showing the demographic, clinical and tumour staging information 
of our cohort of patients with HCC. 
Demographic, clinical and 
tumour characteristics 
Number of 
patients 
% 
  Sex 
Male 
Female 
 
108 
22 
 
83.1 
16.9 
77 
 
Age group 
<40 
 40 - 50 
50 – 60 
– 70 
>70 
 
2 
4 
24 
52 
48 
 
1.5 
3.0 
18.5 
40 
37 
Mode of presentation 
Incidental 
Surveillance 
Symptomatic 
 
55 
34 
41 
 
42.3 
26.2 
34.5 
Child – Pugh score 
A 
B 
C 
 
82 
25 
23 
 
63.1 
19.2 
17.7 
AFP 
       <400 
    400 – 1000 
        >1000 
 
55 
30 
45 
 
42.3 
23.1 
34.6 
 
Portal vein invasion 
None 
Branch invasion 
Main trunk invasion 
 
92 
18 
20 
 
70.8 
13.8 
15.4 
Okuda stage 
1 
2 
3 
 
66 
47 
17 
 
50.8 
36.2 
13.1 
CLIP score 
0 
1 
2 
3 
4 
5 / 6 
 
23 
32 
24 
26 
16 
09 
 
17.7 
24.6 
18.5 
20 
12.3 
6.9 
78 
 
BCLC stage 
A 
B 
C 
D 
 
20 
19 
64 
27 
 
15.4 
14.6 
49.2 
20.8 
 
The primary outcome of our observational study was survival. Follow-up times were 
measured as the number of months from diagnosis of HCC until death or the last 
available information of the patient. The patients were periodically assessed in the 
clinic at Freeman Hospital using clinical and biochemical parameters, and interval 
imaging.  
The cumulative survival was ascertained using the Kaplan-Meier method and the 
differences in survival between different stages in any staging system were 
determined using the Log-Rank test. The Cox-regression model was used to identify 
prognostic value of baseline parameters in predicting survival. A P-value of <0.05 
was considered significant. All analysis was performed using the SPSS 10.0 for 
Windows ( SPSS Inc. Chicago Ill, USA).                                                              
3.4 Results - Treatment strategies and its effect on survival 
The available treatment options in this unit are the following: 
Surgical resection for patients with preserved liver function. Peri-operative 
adriamycin was administered and selective post operative adriamycin was considered 
for tumours with adverse prognostic factors  
Cadaveric liver transplantation with per-operative chemotherapy for patients with 
HCC which met the Milan criteria. Selective post operative adriamycin was 
recommended for tumours with adverse prognostic factors (tumour >2cm, evidence of 
lymphovascular invasion) in patients who were fit for adjuvant chemotherapy four 
weeks post liver transplant. 
Percutaneous ablation using radiofrequency. This technique was considered for 
patients with small volume disease unfit for resection.  It could also be seen as a 
bridge to transplantation. This modality was also used as an adjunct to transarterial 
chemoembolization 
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Transarterial chemoembolization (TACE) was and still is recommended as first line 
palliative therapy for non-surgical patients with intermediate/multifocal HCC who do 
not have vascular invasion or extrahepatic spread. 
The main contraindication to TACE is the lack of portal blood flow (because of 
portal vein thrombosis, porto-systemic anastomoses or hepatofugal flow) and poor 
hepatic functional reserve. Particularly patients with lobar or segmental portal vein 
thrombosis are poor candidates for TACE, as this will cause necrosis of the tumour 
and of the non-tumour bearing liver deprived of its blood supply. This increases the 
risk of treatment-related death due to liver failure. Patients with advanced liver 
disease (Child-Pugh class B or C) and/or clinical symptoms of end-stage cancer 
should not be considered for transarterial embolization and chemoembolization as 
they have an increased risk of liver failure and death 
Hepatic artery adriamycin infusion therapy was considered for patients with 
advanced tumours with portal vein invasion but preserved synthetic function 
Options for patients with more advanced tumours included consideration for entry 
into medical trials or for palliation. Sorafenib is now approved as the first line medical 
therapy for patients with advanced liver cancer and preserved liver function following 
the success of the SHARP trial ( LLovet et al 2007/2009), in which 2 of our 2004 – 
2006 took part. Sorafenib was not available as an NHS treatment during that time and 
will not be discussed further. All the patients receiving treatment other than best 
palliation were followed up at regular intervals by AFP assessment and ultrasound 
and / or CT. Table 3.3 shows the distribution of our cohort of patients with HCC 
receiving any modality of treatment.  Curative therapy in the form of resection or liver 
transplantation was available to only 8.5% (n = 11) of the patients. This small cohort 
had a median survival of 71 months. Of the palliative treatments, a combination of 
TACE and RFA appeared to be more effective than TACE alone. Treatment with 
RFA only was undertaken in 2 patients only and it would be improper to make any 
inference. 
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Table 
3.3(left) 
showing 
the 
different 
treatment 
groups 
 
 
 
 
 
 
Figure 3.2 (left) showing the 
survival curves with the different  
treatment modalities. 
 
 
 
 
 
 
 
3.5 Results - Survival and baseline characteristics 
In the initial univariate analysis performed on the whole set of 130 patients it 
wasconfirmed that the mode of presentation (symptomatic, incidental or surveillance), 
tumour extension in to a branch or main trunk of the portal vein, increasing tumour 
number and rising AFP values were independent predictors for survival. Cox 
regression analysis also confirmed the same parameters in predicting survival. Age, 
sex did not show any correlation with survival. The results of the multivariate analysis 
using different demographic and clinical parameters are shown in table 3.4 
 
Treatment option Number of 
patients 
% Median 
survival 
Transplant 
Resection 
3. TACE  
4. RFA 
5. RFA + TACE 
6. None 
09 
02 
50 
02 
13 
 
54 
6.9 
1.5 
38.5 
1.5 
10 
 
41.5 
55mo 
36mo 
13 mo 
 7 mo 
30 mo 
 
 3 mo 
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Table 3.4 (below) showing the clinical characteristics of our patients with HCC in 
predicting survival 
Parameter Median survival 
(months) 
Univariate Cox regression 
model 
(Multivariate) 
Sex 
Male 
Female 
 
10 
12 
0.575 
 
0.59 
 
Age 
<40 
40-50 
50-60 
60-70 
70+ 
 
10 
13 
08 
13 
11 
0.045 
 
0.058 
 
Mode of 
presentation 
Incidental 
Surveillance 
Symptomatic 
 
 
19 
14 
03 
0.001 0.002 
 
Childs Pugh stage 
A 
B 
C 
 
 
18 
04 
04 
0.001 
 
0.002 
 
Performance status 
0 
1 
2 
3 
4 
 
 
24 
16 
08 
01 
0 
0.002 
 
0.002 
Portal vein 
thrombosis 
 
 
0.001 0.001 
 
82 
 
No thrombus 
Thrombus in a 
branch 
Main trunk 
thrombus 
18 
 
05 
 
03 
AFP 
<400 
400-1000 
>1000 
 
19 
12 
04 
0.001 
 
0.002 
 
Tumour number 
1 
2-3 
4 or more 
 
 
19 
18 
08 
0.001 
 
0.002 
 
 
Table 3.4 shows that patients in whom tumour was diagnosed incidentally or by 
surveillance shows better median survival as compared to the symptomatic patients 
suggesting that intense surveillance with more sensitive biomarkers would diagnose 
tumours early which could improve the median survival of the disease. Regarding the 
patient and basic tumour characteristics, the table shows that deteriorating liver 
function, worsening performance status, increasing AFP levels, portal vein thrombosis 
and multiple tumours are independent poor prognostic markers. 
3.6 RESULTS – Survival and the staging systems 
The long term survival of these patients with or without treatment is calculated using 
the Kaplan-Meir survival analysis. The cumulative five year survival of patients of 
HCC in our series was 8.5% as seen in figure 3.3 and the median survival was 12 
months. 
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Figure 3.3(left) showing 
cumulative survival of 
HCC patients for five 
years in our study. 
 
 
 
 
 
 
 
 
The survival pattern of the patients was then calculated for the different tumour stages 
and any association of survival with any tumour or patient characteristics were also 
evaluated. 
                                                             
 
Figure3.4 (left) 
showing the difference 
in survival with 
different CLIP scores.  
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Table 3.5 (left) showing the 
median survival in each 
CLIP stage and the 
significance in the inter-
group difference in survival. 
 
 
 
 
 
The median survival over 5 years, decreases with increasing CLIP scores (figure 3.4). 
The difference in median survival is statistically significant for stages 0 and 1 and also 
for the advanced stages 5/6. However, the difference in survival between the 
intermediate stages 2, 3 and 4 was not statistically significant. The early CLIP scores 
of 0 and 1 were heterogeneous as they did not identify the patients for curative 
treatment separately from the patients who could only be considered for palliative 
treatment i.e. TACE and RFA.  
The survival pattern of the patients with HCC in different Okuda stages is noted in 
Figure 3.5. The median survival reduces with increasing stage of the tumour but Stage 
1 fails to identify the patients with early tumour who would benefit from the curative 
surgical options. No statistical difference in survival is noted in the median survival 
between stages 2 and 3.  
 
 
 
 
 
 
 
 
CLIP score Predicted Median 
survival 
P-value 
 
0 
1 
2 
3 
4 
5/6 
 
49 
29 
09 
08 
03 
01 
0.001 
 
0.001 
 
0.001 
 
0.082 
 
0.497 
 
0.001 
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Figure 3.5 (left) showing probability 
of survival in different Okuda stages 
in the 130 patients. 
 
 
 
 
 
 
 
 
 
Table 3.6 (left) showing the 
median survival in the 
different Okuda stages and 
the difference in survival 
between the stages 
 
 
 
 
Figure 3.6 (left) showing survival 
probability in different BCLC stages of 
HCC. 
 
 
 
 
 
 
 
 
Okuda 
stage 
Predicted Median 
survival 
( in months) 
Difference 
P-value 
  
1 
2 
3 
 
22 
8.2 
1.6 
  
0.001 
0.001 
0.168 
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The survival pattern in the BCLC stages are shown in figure 3.6 and the median 
survival with the difference in between stages are shown in table 3.7. Stage A 
representing the early tumour shows the best survival among all the three stages due 
to the fact that it contains all the patients who underwent definitive treatment which 
significantly affects survival. It also predicts the poor prognosis of the most advanced 
group in stage C. The staging, however, fails to differentially predict survival in the 
intermediate stages B and C. 
 
 
Table 3.7 (left) shows the 
medial survival in the 
different BCLC Stages and 
the statistical significance 
 
 
 
 
 
Finally, the predicted survivals for each of the stages other than early (CLIP 0, BCLC 
A) was poorer in our cohort of predominantly ALD and NAFLD patients, than that 
predicted by the schemes developed in patients with predominantly HCV. 
3.7 Discussion 
The setting up of the central database for HCC in Newcastle was a key step in 
devising management strategies for patients with HCC and the initial data has shown 
some interesting results. Hepatitis B and C virus infections are the major causes of 
HCC worldwide[245, 246]. However, in our series we note that the major cause of 
HCC was alcoholic liver disease and non-alcoholic liver disease, which accounted for 
71 of 130 patients, comprising 54.6% in total. This difference in demographic profile 
is likely explained by a relatively low immigrant population in the North East UK, in 
combination with a high prevalence of alcohol abuse and obesity. The emerging 
epidemic of the obesity associated metabolic syndrome in North America and 
Western Europe is believed to have contributed to the increase in non-alcoholic 
steatohepatitis, it being the liver component/sequelae of this syndrome  [247]. In a 
BCLC 
Stage 
Predicted Median 
survival (in 
months) 
Statistical 
difference (p-
value) 
 
A 
B 
C 
D 
 
48.0 
20.2 
12.1 
2.1 
 
0.001 
0.001 
0.112 
0.001 
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review in 2005, Bugianesi E et al observed that 7 – 30% of HCC develops against a 
background metabolic syndrome, which includes obesity, Type-2 diabetes and 
dyslipidaemia[248]. Obesity now appears to be increasing worldwide, especially in 
the developing countries undergoing economic transition to an open market 
economy[246]. The after effects of this growing problem in the east could be felt in 
the years to come. In the west the compulsory vaccination against hepatitis B and the 
scrupulous screening of blood before transfusion could contribute to the low incidence 
of viral hepatitis B and C (less than 10%) related HCC in our series. In the west drug 
abuse is the principal cause of hepatitis C as compared to the developing world where 
blood transfusions from unscreened donors and unsafe therapeutic practices account 
for the majority of cases [249]  
The prognosis of HCC without specific treatment is poor but the patients diagnosed 
with the disease in early stages can be offered definitive therapeutic intervention 
which has a definitive impact on survival. So early diagnosis of the disease remains 
the key goal in improving the management which also remains the goal of the NHS 
Cancer Plan. Progress has also been made in multimodality therapy which improves 
survival in patients with unresectable HCC with preserved synthetic function with no 
involvement of the portal vein. In our series of patients, 54% received TACE with or 
without radiofrequency ablation with a median survival of 18.8 months and three year 
survival of 42%, as compared to the group which did not receive any treatment 
showed a median survival of 3.4 months. This compares with the studies in the 
literature with the 2 year survival varying from 25% to 65% and all these studies also 
documented a definite improvement from the group treated expectantly [250].  
We have used Okuda, CLIP and BCLC systems of scoring. Since the Okuda system, 
based on findings from advanced tumours, is more than 20 years old and did not take 
into account important prognostic factors like tumour size, portal vein thrombosis and 
number of neoplastic lesions, we evaluated the CLIP scoring in addition.  The latter is 
widely used now, as it incorporates additional HCC tumour characteristics, and we 
wanted to evaluate its ability to predict survival.  
In our series of 130 patients the overall median survival with CLIP scores of 0 – 5/6 
were 49, 29, 9, 8, 3 and 1 months (Table 3.5 and figure 3.4), which was similar to the 
large series reported by Lin CY et al in 2009[251].  This suggests its ability to 
discriminate patients with early tumours from patients with advanced tumours  
Studies have reported accurate predictive values of CLIP score for early and advanced 
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tumours.[1, 236, 237, 240, 244, 252]. The CLIP scores of 2-4 have a total of 65 
patients showing worsening survival with increasing scores, which was not 
statistically significant Table 2.5). This group with three intermediate CLIP scores has 
poor discriminating ability. Even for patients with scores of 0 or 1 the groups are very 
heterogenous because not all patients in these groups receive definite treatment.   
There could be more than one reason to explain this lack of statistical significance in 
our cohort compared to other series. The small number of patients in our study could 
be one of the factors responsible for this finding. The validation of the CLIP score has 
been principally done in centres with hepatitis B and C being the most important 
cause of HCC, in contrast to our series which has NASH and alcoholic liver disease as 
the principal group. This suggests that thegenetic heterogeneity of a tumour make up 
due to its different aetiologies could be responsible for the difference noted. 
Alternatively, other characteristics of the patient such as co-morbid conditions, may 
account for these differences. Often with human data there is some degree of random 
variability and a model score always works best in the given set of patients within 
which it was created. This necessitates the need to validate any scoring in different 
centres with varying aetiology for HCCs. We also note that the CLIP score depends a 
lot on the human assessment of the nodularity and size of the tumour which can be 
subject to observer variability as has been suggested by Ray Kim in a recent 
review[252]. Besides, the score of 0 for <50% of liver involvement also encompasses 
lesion from 2cms to large lesions which could still be less than 50% of liver volume 
which could make this group very heterogeneous.  In a study of 3868 patients, Lin CY 
et al concluded that though the CLIP scoring system is a reasonable ordinal scale the 
clinician must be aware of this heterogeneity of mortality within a given score[251]. 
Our centre is continuing to collect data of all newly diagnosed HCC patients in to the 
database which should be able to provide more information about the discriminatory 
ability of the CLIP scoring system. 
The BCLC scoring also has limitations in our series. The overall median survival with 
scores of A,B,C and  D are 53, 24, 11 and 1 months respectively (Table 3.7 & figure 
3.7). Only 20 patients (15.4%) were diagnosed in the early curable stage. The 
intermediate stages of B and C are less discriminatory, and account for the majority 
(61.5%) of the patients. 
The independent prognostic value of AFP is not very clear and various cut-off levels 
have been used in different studies. Analysis of our prospective series of 130 patients 
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showed a correlation of increasing AFP values with poor overall survival with a 
median survival of 4 months for patients with AFP levels more than 1000 ng/ml 
compared to a median survival of 19 months for patients with AFP values less than 
400 ng/ml (Table 3.4). CLIP score takes that into account and assigns more points for 
AFP values more than 400 ng/ml, which suggests the increased risks associated with 
elevated levels of AFP. A Study by Farinati F et al separated patients into three 
groups of <20 ng/ml, 21 – 400 ng/ml and 400 ng/ml and reported that the high value 
of AFP correlated with the overall survival in untreated patients or those treated with 
transplant or loco-regional therapies, but not in those surgically treated [253]. Levels 
more than 400 ng/ml was associated with vascular invasion and HCC progression 
predicting poor outcome for these subset of patients after resection[254]. A recent 
review analysing multiple prognostic factors, reported that appropriate cut-off values 
are yet to be determined but raised levels of AFP are associated with advanced 
tumours and a poor prognosis [255].   Our series also shows an inverse relationship 
between rising AFP values and survival, but it is obvious that a uniform cut-off value 
is essential to determine its prognostic efficacy in different centres. With more 
patients being added to our dataset on a regular basis, this needs to be re-evaluated in 
future years to add more data to our initial findings of the prognostic significance of 
AFP but that is beyond the scope of this work 
The most disturbing finding from this series was that only 10% of patients diagnosed 
in this two year period could undergo definitive treatment which suggests that the 
disease continues to be detected in late stages. Comparing the previous data from Dr 
Hudson in our Hospital it appears that more cases are being diagnosed, but as 
suggested that could be a result of increased surveillance, increased incidence and / or 
increased referral from the District hospitals. However, to improve the number of 
patients to be considered for definitive treatment the following measures might need 
to be considered: 
The primary care trusts (PCTs)  need to be updated with the increased burden of HCC 
and need to identify the at risk population from their demographic profile and habits 
A robust surveillance system not only in the apex hospitals but also in the district 
hospitals, where most cases are diagnosed. 
Any suspicious lesion in the district hospital screening programme needs to be 
referred to the apex hospital for thorough evaluation and follow up. 
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From the effectiveness of district nurses in the community it might be worthwhile to 
have specialist community nurses to identify high risk patients in the community, or 
who regularly fail to make their appointment. 
To continue to use the central database for data collection and also making the 
database available to the specialists at the district hospitals to enter any patient of 
HCC enabling them to be seen at the earliest by  making referrals quicker. 
To continue to strive towards an ideal biomarker or a panel of biomarkers to suit our 
cohort of patients to identify effectively the surveillance population and also to 
identify the tumour at an early treatable stage. 
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Chapter 4  Results 2. AFP, PIVKAII, GP3, SCCA-1 and follistatin as 
surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic 
fatty liver disease 
4.1 Introduction 
Hepatocellular carcinoma (HCC) is a major health problem worldwide, with more 
than 500,000 cases diagnosed annually [1]. While the incidence of HCC has 
reportedly risen over the last 5–8 years, the survival of those affected has not changed 
significantly in the last two decades [2, 4, 6] . This is related to both its late detection 
and the lack of effective therapies for advanced stage disease [9]. Up to 80% of HCCs 
develop against a background of cirrhosis of the liver and while we believe that 
surveillance of the at risk cirrhotic population could aid earlier detection of the disease 
and decrease the cancer related mortality rate, our present success is limited by the 
lack of sensitive biomarkers. Currently, standard surveillance includes a combination 
of a 6 monthly abdominal ultrasound scan (USS) and a serum alpha-fetoprotein (AFP) 
measurement, but this strategy does not reliably detect early disease. The diagnostic 
performance of AFP is inadequate [256] as it is only elevated in 40–60% of cases, 
while abdominal USS is difficult in cirrhotic nodular livers and notoriously user 
dependent [8]. Alternative serum biomarkers are being actively sought and proposed 
candidates include Prothrombin Induced by Vitamin K Absence (PIVKA-II), 
glypican-3 (GP3), and more recently, Squamous Cell Carcinoma Antigen -1 (SCCA-
1). PIVKA-II is an abnormal prothrombin, identified as an HCC biomarker in 1984 
[7] and since reported, is elevated most notably in advanced cases with portal vein 
invasion [152, 257]. It is proposed that PIVKA-II may be useful primarily as a 
prognostic biomarker, predicting rapid tumour progression and a poorer prognosis 
[258]. The oncofetal antigen glypican3 (GP3) is a heparan sulfate proteoglycan that is 
expressed in more than 70% of HCC [164]. When combined with AFP it has a 
sensitivity of up to 82% for HCC detection on a background of viral hepatitis [163]. 
SCCA-1 is a member of the high molecular weight serine protease family called 
serpins [259] initially reported to be elevated in epithelial tumours such as the cervical 
cancer [260] and more recently in the serum of individuals with HCC and cirrhosis 
[261]. On a global scale, viral causes of chronic liver disease are the commonest 
predecessors of HCC and these proposed biomarkers [262] have largely been studied 
in this disease group. Our own HCC patients have tumours arising predominantly on a 
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background of alcoholic (ALD) and non-alcoholic fatty liver diseases (NAFLD). In 
this chapter we present the data on a cross-sectional study comparing the efficacy of 
these markers, as well as a novel candidate biomarker, Follistatin, for the diagnosis of 
HCC arising on a background of steatohepatitis related cirrhosis. Follistatin is a 
monomeric protein overexpressed in rat and human liver tumours and reportedly 
contributing to hepatocarcinogenesis by the inhibition of activins [263]. Follistatin 
mRNA was markedly overexpressed in a HCC cell line microarray study performed 
in our own (Dr Reeves’ group) laboratory (unpublished data). Our data indicate 
differences in biomarker performance in NAFLD and ALD patients compared to 
performances reported in viral hepatitis. Neither PIVKAII, GP3, SCCA-1, nor the 
novel candidate Follistatin, has a role independent of AFP in HCC surveillance in 
steatohepatitis related cirrhosis. We show that the combination of AFP and PIVKAII 
is more valuable than AFP alone and suggest this approach should be adopted as 
standard surveillance in this disease group. 
4.3 Methods 
Patient serum samples 
All patient serum and clinical information were collected with patient consent after 
approval by The Newcastle and North Tyneside Ethics Committee for our study. 
Patients were diagnosed as having HCC as per guidelines proposed by the European 
Association for the Study of the Liver [8]. Pre-treatment samples from 50 patients 
with HCC, all of whom had underlying cirrhosis, were selected for study. Of these, 31 
patients had alcoholic liver disease (ALD) and 19 patients had NAFLD. The serum 
was immediately separated by centrifugation and frozen at - 80°C as per protocol in 
2.3. As 80% of HCC develops against the background of liver cirrhosis, these serum 
samples were compared to an independent group of 41 patients with biopsy proven 
ALD or NAFLD cirrhosis. The diagnosis of NAFLD cirrhosis was made in patients 
who had clinical features and liver biopsies compatible with NAFLD. Females and 
males consuming greater than 14 or 21 units of alcohol per week respectively were 
excluded from this category, as were any individuals with viral or autoimmune liver 
diseases. The presence of steatosis was necessary for the diagnosis to be made, as was 
stage 4 fibrosis defined by the modified Brunt criteria [264]. 
The biochemical serum tests, including serum AFP, were measured using routine 
automated methods in the Biochemistry Laboratory at the Freeman Hospital, 
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Newcastle upon Tyne. No patient positive for either HBsAg or HCV were included in 
this study. 
Western blotting and serum ELISA assay  
PIVKA-II was measured using a commercially available ELISA kit (Asserachrom 
PIVKAII kit, Stago, France), according to the manufacturer's instructions (protocol 
2.4.5) . The detection limit is 1.0 ng/ml. The cut-off value was set as 20 ng/ml for 
differentiation between HCC and cirrhosis based on the findings in this study. 
Glypican-3 was measured using commercially available ELISA kit (Biomosaics 
limited) following the manufacturer's protocol (protocol 2.4.6). Serum samples for 
this study was also sent to Rome where SCCA-1 was measured in an ELISA kit 
purchased from Xeptagen (Xeptagen, Naples, Italy) and following the manufacturer's 
instructions (This study was performed in collaboration with Prof Gianelli’s group in 
Italy as they were the first group to report the importance of SCCA-1 antigen in 
HCC)[261]. 
Follistatin was selected for study based on its marked expression in HCC cell lines on 
microarray analysis and a literature review identifying it as a secretory protein with a 
previously suspected role in hepatocarcinogenesis. Ten samples each from patients 
with NAFLD, NAFLD and cirrhosis, or NAFLD with cirrhosis and HCC were 
immunedepleted by multiple affinity removal (MARS HPLC column; Agilent 
technologies) and desalted using 5K molecular weight cut off spin filters (Agilent 
technologies). Subsequently, 50 μg of protein was separated by SDS-PAGE and 
transferred to PVDF membrane (250 mA for 90 min). The membrane was then probed 
with mouse anti-follistatin antibody (R&D Systems) at 1:500 dilution at room 
temperature overnight. After washing in Tris Buffered Saline (0.1% Tween), the 
membranes were incubated with secondary peroxidase conjugated rabbit anit-mouse 
immunoglobulin and developed using ECL (Amersham) (protocol 2.4.3 for Western 
Blot)). 
Subsequently, a direct ELISA assay for quantitative analysis, was developed using 
different concentrations of serum (raw; 1:10; 1:50; 1:100: 1:1000) with serial dilution 
of the primary antibody. Optimal conditions were using a raw serum dilution of 1:10 
and an antibody dilution of 1:250 (protocol 2.4.4). 
Statistical analysis 
Quantitative variables were expressed as median, mean and standard deviation. 
Comparison between groups was by Mann-Whitney U, Pearson Chi-square, Wilcoxon 
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or Student's t-test, as appropriate. Qualitative variables were expressed as count and 
percentage and comparisons between independent groups was by Pearson Chi-squared 
test. The diagnostic accuracy of each of the candidate biomarkers was evaluated using 
receiver operating characteristic (ROC) curve analysis, reporting the area under the 
curve (AUC) and its 95% confidence interval (CI). The diagnostic cut-off and the 
related sensitivity and specificity were determined. Statistical analysis was performed 
with SAS V8.2 software for PC, MedCalc version 7.4.3.0, as well as SPPS version 14. 
4.3 Results 
Serum AFP, PIVKA-II, GP3 and SCCA-1 levels were determined in 50 patients with 
HCC arising in a background of ALD or NAFLD cirrhosis. A control group of 41 
patients with cirrhosis from ALD/NAFLD was used for comparison. The clinical 
characteristics of the patients in these groups are shown in Table 4.1 
 
Table 4.1: Clinical 
characteristics of the 
patients with 
cirrhosis and 
cirrhosis plus HCC 
 
 
 
 
 
 
 
 
 
 
 
Serum AFP and PIVKAII as biomarkers of HCC in steatohepatitis related cirrhosis 
The median AFP value determined in our patients with HCC and those with cirrhosis 
were 92.4 ng/ml and 5.9 ng/ml respectively. These data are represented using a log 
scale in Figure 4.1A (see page 102) and also summarised in Table 4.2. This difference 
Variable Cirrhosis Cirrhosis 
with HCC 
P-value 
Number 41 50  
Age (years) 54.3 + 9.62 62.67 + 12.02 0.001 
Male: 
Female 
28 : 13 40 : 10 0.205 
ALD:NAFL
D 
33 : 08 30 : 20 0.074 
Childs-Pugh 
A:B:C 
22 : 14 : 05 27 : 18 : 05 0.853 
Portal vein 
invasion 
NA 08 NA 
Single 
nodule 
NA 22 NA 
Two nodules NA 10 NA 
≥ 3 Nodules NA 18 NA 
95 
 
was statistically significant (p value 0.0004). The ROC curve analysis (Figure 4.2A) 
confirmed an area under curve of 0.71 (CI 95% 0.61 – 0.8), with a cut-off value of 15 
giving a sensitivity of 58% (CI95% 43.2% 71.8%) and a specificity of 100% (CI 95% 
91.3 – 100). 
Mean PIVKA-II levels were also significantly different between patients with HCC 
and liver cirrhosis, as shown in 4.1B and Table 4.2.  
 
Table 4.2: Levels of candidate biomarkers (ng/ml) as detected by specific ELISA 
assays 
 Cirrhosis Cirrhosis + HCC 
Mean + SD Median Mean + SD Median 
AFP 5.96 + 2.65 5.00 5934.66 + 
13025.02 
92.50 
PIVKA II 23.47 + 59.69 7.83 135.17 + 168.96 42.75 
GPC 3 125.41 + 
281.05 
29.62 161.41 + 422.33 56.57 
Follistatin 72.41 + 76.16 50.20 87.33 +  131.31 61.35 
 
The median value in the former was 42.74 ng/ml and in the latter 7.8 ng/ml 
(interquartile range: 2.8 – 17.8). The area under the ROC curve was 0.81 (CI95% 
0.715 – 0.886) with a cut-off 20.24 ng/ml. This predicted a sensitivity of 79.6%. 
(CI95% 65.7% – 89.7%) and a specificity of 80.5% (CI95% 65.1 – 91.2%). As shown 
in Figure 4.1F, the level of PIVKAII is significantly raised in patients with tumours 
>5 cm in size (n = 24) relative to those 3–5 cm in size (n = 23) (ANOVA p = 0.001). 
In fact, the level from tumours 3–5 cm in size was not significantly different from the 
level in patients with cirrhosis alone. While there was similarly a difference between 
these two size groups using AFP (7369 +/- 14361 ng/ml; n= 36 versus 2417 +/- 8889 
ng/ml; n = 13), the difference was not statistically significant. Serum AFP therefore is 
better at specifically detecting early malignant disease than PIVKAII. However, the 
combination of serum AFP and PIVKA-II in these patients is better than either alone, 
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with a combined sensitivity of 94% and a specificity of just over 80%, as shown in 
Table 4.3. 
 
Serum GP3 and SCCA-1 have no role in HCC surveillance in steatohepatitis-
related cirrhosis 
The data for GP3 and SCCA-1 in this group of ALD/NAFLD patients with and 
without HCC is also presented in Figures 4.1C, 4.1D, 4.2C and 4.2D and tables 4.2 
and 4.3. These data demonstrate that neither had any value in HCC detection in this 
group of patients. While their expression was elevated in the serum of patients with 
chronically diseased livers and HCC, there was no significant difference between the 
levels detected in cirrhotic patients with and without a cancer. 
Follistatin is raised in the serum of individuals with cirrhosis and HCC, but its 
specificity for HCC is poor. 
Levels of follistatin were studied in immune depleted serum from individuals with 
either NAFLD (n = 10), NAFLD with cirrhosis (n = 10), or NAFLD with cirrhosis 
and HCC (n = 10) by western blot analysis. Representative data from 24 of these 
individuals is presented in Figure 4.3. While there was little evidence of follistatin in 
the serum of individuals with NAFLD without significant fibrosis or HCC, it was 
detectable in all individuals with HCC as well as some individuals with cirrhosis and 
no HCC. We went on to develop an ELISA assay for more quantitative raw serum 
analysis between the latter two groups. Unfortunately, while follistatin is clearly 
increased in individuals with cirrhotic NAFLD, it fails to distinguish between those 
with and without HCC, as shown in Figures 4.1E and 4.2E.
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Table 4.3 Performance of combinations of candidate biomarkers 
Combination TP FP TN FN Sensitivity 
(HCC=50) 
Specificity 
(LC=41) 
PPV TPN LR 
AFP 28 0 41 22 56.00% 100.00% 100% 65.10% -- 
AFP+PIV 47 8 33 3 94.00% 80.50% 85.50% 91.70% 4.82 
PIV 39 8 33 11 78.00% 80.50% 83.30% 75.00% 4 
AFP+SCCA 36 11 30 14 72.00% 73.2% 76.60% 68.20% 2.68 
AFP+PIV+SCCA 45 16 25 5 90.00% 61.00% 73.80% 83.30% 2.31 
PIV+SCCA 42 16 25 8 84.00% 61.00% 72.40% 75.80% 2.15 
GCP+SCCA 36 16 25 14 72.00% 61.00% 69.20% 64.10% 1.85 
AFP+GCP 41 22 19 9 82.00% 46.30% 65.10% 67.90% 1.53 
AFP+PIV+GCP 48 27 14 2 96.00% 34.10% 64.00% 87.50% 1.46 
GCP+PIV 46 27 14 4 92.00% 34.10% 63.00% 77.80% 1.4 
All 48 31 10 2 96.00% 24.40% 60.80% 83.30% 1.27 
GCP 34 22 19 16 68.00% 46.30% 60.70% 54.30% 1.27 
GCP+PIV+SCCA 47 31 10 3 94.00% 24.40% 60.30% 76.90% 1.24 
AFP+GCP+SCCA 36 28 13 14 72.00% 31.70% 56.30% 48.10% 1.05 
SCCA 9 11 30 41 18.00% 73.20% 45.00% 42.30% 0.67 
The true and false positive (TP and FP), as well as true and false negative (TN and FN) for each candidate either alone or in combination is 
presented, along with sensitivity, specificity, Positive Predictive Value (PPV) and true percentage negative (TPN) values and the likelihood ratio 
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(LR). The LR is the ratio of true and false positives (sensitivity and 1-specificity respectively), where higher values reflect the probability of a 
better performance. 
(AFP- alpha-fetoprotein, PIV – Prothrombin induced by vitamin K absence II, GCP3 – Glypican 3, SCCA – Squamous cell carcinoma antigen 
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Figure 4.1 Levels of Candidate Biomarkers in cirrhotic patients with and without 
HCC. Box plots comparing levels of AFP, PIVKAII, GP3, SCCA-1 and Follistatin are 
shown. Levels are presented as ng/ml, except for AFP where the log data are 
presented in order to accommodate the wide range. The mean between the two groups 
is significantly different for both AFP and PIVKAII. For the latter, this is 
predominantly a result of a marked increase in levels in individuals with tumours 
greater than 5 cm in size. 
 
 
 
100 
 
 
 
Figure 4.2 
ROC Curve analyses of the candidate biomarkers. The diagnostic accuracy of each 
candidate biomarker, in terms of sensitivity and specificity, are presented after 
receiver operating characteristic (ROC) curve analysis. In figures 4.2A and 4.2B, 
corresponding to AFP and PIVKAII, the area under the curve is markedly better than 
for the other markers. 
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Figure 4.3 
Follistatin is detectable in serum in patients with NAFLD related HCC. Immune 
depleted serum samples from individuals with non-fibrotic NAFLD (N), NAFLD 
cirrhosis(Ci), and NAFLD cirrhosis with cancer (C) have been separated by SDS-
PAGE and analysed by western blot. The majority of HCC patients had detectable 
levels of follistatin in their serum, as did one or two individuals with NAFLD 
cirrhosis and no cancer 
4.4 Discussion 
The increasing incidence of HCC[3], compounded by the fact that the majority of 
these tumours are diagnosed at a late stage when curative treatments are not 
possible[19], has prompted the international community into performing regular 
surveillance of high risk individuals. Unfortunately, surveillance programmes are 
hindered by the poor performance of the commonly used serum marker, namely AFP 
[6], even in combination with abdominal USS. A tremendous amount of effort has 
been and continues to be applied to the search for improved HCC biomarkers. 
As yet, none has proved superior to AFP in performance, but in combination some 
may have complimentary roles in HCC arising on a background of viral 
hepatitis [20]. Our own particular concern relates to the marked increase in the 
prevalence of ALD and NAFLD related HCC on our own unit. 
In our study, serum AFP performs moderately well as a biomarker of HCC in 
ALD/NAFLD patients, with a sensitivity of 58% (15 ng/ml) in combination with a 
specificity of 100%. The AASLD recommended cut off level for diagnosis of HCC is 
200 ng/ml[21], although lower levels, particularly if rising, should be deemed 
suspicious and followed very carefully. In ALD/NAFLD patients, where a mild to 
moderately elevated but stable AFP level similar to that occasionally observed in 
individuals with viral hepatitis is rare, it may be possible to attach a more sinister 
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connotation to much lower levels of expression. While this data is encouraging, the 
sensitivity of AFP is not good enough for it to be used in isolation, as over a third of 
cancers will be missed. 
Both the sensitivity and specificity for PIVKAII as an HCC biomarker were in the 
order of 80% at a level of 20 ng/ml. The addition of PIVKAII serum analysis to that 
of AFP increases the combined sensitivity to 94%. While this is at the modest expense 
of the specificity (reduced to 80.5%), the combination of both AFP and PIVKAII 
analyses may well be justified in our patients. It should be noted, however, that the 
added benefit is only in the detection of more advanced disease – as indicated in 
previous viral hepatitis studies and confirmed in our own NAFLD/ALD patients -the 
encouraging performance of PIVKA-II is predominantly a result of detection of 
larger, more advanced cancers. 
Assessment of the other candidate biomarkers was disappointing. Both the sensitivity 
and specificity of GP3 were poor in our patient set, indicating that it has no role at all 
in the surveillance of HCC in individuals with steatohepatitis related cirrhosis. 
Follistatin is an expressed transcript in the foetal liver and has previously been 
identified by microarray as an up-regulated gene in HCC relative to dysplastic 
nodules [265]. Although we had high hopes for this activin antagonising protein, 
[266] based on both our preliminary microarray data and a pilot study in immune 
depleted sera, the ELISA data assessing its discriminatory function between cirrhotic 
individuals with and without HCC was poor. The discrepancy between the western 
and ELISA data is most likely a result simply of assessing a greater number of 
patients using the latter method, but it is also that follistatin, or an isoform of it, was 
enriched during the column preparation phase of the serum of HCC patients assessed 
by western blotting. Perhaps the most surprising of results, however, in this 
homogenous group of patients with steatohepatitis related HCC, was the disappointing 
performance of SCCA-1. SCCA-1 has previously shown promise, particularly as an 
AFP complementary biomarker, in viral hepatitis related HCC [182, 267]. In our 
study in NAFLD/ALD, however, there was no significant difference between levels in 
patients with and without HCC and while the combination with AFP does modestly 
improve its sensitivity (78% from 56%); this is at an unacceptable cost to specificity 
(73% from 100%). Why this serum protein should be significantly elevated in the 
serum of HCV related HCC patients relative to HCV cirrhosis alone, and not similarly 
elevated in steatohepatitis related HCC patients relative to steatohepatitis cirrhosis 
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alone is unclear. It is possible that the study of these novel candidate biomarkers 
complexed to immunoglobulins, rather than the study of their free forms, may yet 
improve their performance, as has been shown for other biomarkers [268]. Whether or 
not there is room for improvement, however, our SCCA-1 data clearly indicate that as 
we come to consider further candidate biomarkers it is important to assess HCC 
arising in different disease backgrounds independently when performing validation 
studies. 
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Chapter 5. Results 3. A Proteomic Strategy to Identify Novel Serum 
Biomarkers for Liver Cirrhosis and Hepatocellular Cancer in Fatty Liver 
Disease. 
5.1 Introduction 
Globally, viral infections such as Hepatitis B (HBV) and Hepatitis C (HCV) are the 
principal causes of chronic liver injury, while in western nations steatohepatitis 
secondary to alcoholic liver disease (ALD) or non-alcoholic fatty liver disease 
(NAFLD) contribute significantly. NAFLD is the liver manifestation of the metabolic 
syndrome, characterised by central obesity, insulin resistance, hypertension and 
atherogenic dyslipidaemia. It is now the commonest cause of chronic liver disease in 
western countries[15]. Whatever the insult, chronic injury generates a persistent 
wound healing response associated with a changing extra cellular matrix (ECM) and 
the accumulation of fibrous, type I collagen rich, scar tissue. Cirrhosis describes the 
end stages of this process and is characterised by the disruption of normal liver 
architecture by both fibrotic bands and disorganised nodules of regenerating 
hepatocytes. There is presently no medical treatment to reverse the changes of 
cirrhosis, although it is hoped that improved therapies (e.g. antiviral therapy or those 
targeting the metabolic syndrome and/or NAFLD) introduced at lesser stages of 
disease may have an impact on their rate of progression to cirrhosis. 
As well as deteriorating liver function and significant clinical morbidity, cirrhosis is 
associated with a markedly increased risk of developing hepatocellular carcinoma 
(HCC). With more than 500,000 cases diagnosed annually, HCC itself is a major 
health problem[2]. It is frequently detected at an advanced, incurable stage [9] and the 
survival of those affected has not altered significantly in the last two decades [2, 4, 6]. 
It was hoped that surveillance of cirrhotic individuals would facilitate early diagnosis 
of HCC and improve survival. Surveillance using liver imaging with abdominal 
ultrasound (USS) in combination with serum alpha fetoprotein (AFP) measurement is 
performed 6 monthly in many centres. This strategy, however, has limited value. 
There is no safe and cost-effective population-based means to identify the at risk 
cirrhotic population requiring surveillance. Liver biopsy is presently the best means of 
diagnosing cirrhosis, but it carries a significant risk and has well recognised 
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limitations such as sampling error. It is only performed if there is a clinical indication. 
There are panels of serum-based tests,[269] some in conjunction with clinical 
parameters, [270, 271] now proposed as useful in diagnosing cirrhosis. These too are 
largely aimed at individuals in the clinical setting, rather than being advocated as 
population-based screening tools. Despite the prevalence of NAFLD being 20-25% of 
the population [272], the reality is that many of those who progress and develop 
cirrhosis remain unaware of their disease until a complication, such as an HCC, 
develops. Secondly, and even more disheartening for those with known cirrhosis, the 
diagnostic performance of AFP for HCC detection is inadequate [256] as it is only 
elevated in 40-60% of positive cases. Abdominal USS is a little better as it is difficult 
in cirrhotic nodular livers and is notoriously user dependent [8]. USS in NAFLD 
patients is particularly difficult owing to the frequent association with central obesity. 
Improved non-invasive means of detecting both cirrhosis and HCC are urgently 
required if we are to have an impact on the survival of the increasing numbers of 
individuals affected by these diseases. Although a number of alternative biomarkers 
for HCC have been proposed, largely in individuals with HCV and some in 
combination with AFP, none has yet had an impact on clinical practice. Here we 
report our own pilot study in individuals with either ALD or NAFLD. We have used 
immune depleted and filtered serum from individuals with liver disease, with and 
without cirrhosis, and from cirrhotic individuals with and without cancer. This serum 
has been studied using gel-based proteomic techniques in conjunction with mass 
spectroscopy to identify novel biomarkers distinguishing the three conditions. From 
the analysis of the gels we have identified 5 candidate biomarkers capable of 
discriminating at least one or other of the patient groups. One novel serum protein, 
CD5L, was selected for further characterisation in a larger patient group. We have 
confirmed that it is an independent predictor of cirrhosis in NAFLD, and may also 
identify individuals at greater risk of HCC development. 
5.2 Methods  
Patient serum samples 
All patient serum and clinical information was collected with patient consent after 
approval by The Newcastle and North Tyneside Ethics Committee. The liver 
histology of patients with NAFLD (steatosis on biopsy and compatible clinical 
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features in the absence of an alcohol intake greater than 14 units weekly for women 
and 21 weekly for men) was staged according to the Brunt scoring system [264]. A 
fibrosis score of 4 describes cirrhosis. Serum samples from patients with chronic liver 
disease (including both ALD and NAFLD patients) were taken at the time of liver 
biopsy. Individuals with HCC were diagnosed as per guidelines proposed by the 
European Association for the Study of the Liver (mentioned in Table 2.1, Chapter2) 
[8]. The majority of these were not biopsied, but each of them had underlying clinical 
cirrhosis in association with a hypervascular lesion visible on two imaging modalities 
and compatible with the diagnosis of HCC. Serum samples from the individuals with 
HCC were pre-treatment samples taken at the time of diagnosis. Details of the HCC 
patients and controls with biopsy proven cirrhosis are included in Table 1. All serum 
samples were separated by centrifugation within 4 h and subsequently stored at -80°C. 
The standard biochemical serum tests, including serum AFP, were measured using 
routine automated methods in the Biochemistry Laboratory at the Freeman Hospital, 
Newcastle upon Tyne. No patient positive for either HBsAg or HCV were included in 
this study. 
Table 5.1 
Clinical characteristics of cirrhotic patients with and without HCC. 
 Cirrhosis HCC 
Number 49 45 
Age (years) 56.73 ± 8.9 67.8 ± 7.4 
Male: Female 35:14 37:8 
ALD:NAFLD 28:21 28:17 
Childs-Pugh 
A:B:C 
30:14:05 24:16:05 
AFP (ng/ml) 6.04 ± 2.68 
6551 ± 
13602 
Bilirubin (μmol/L) 
33.42 ± 
30.81 
22.87 ± 
22.29 
Albumin (g/l) 36.36 ± 7.76 35.71 ± 5.02 
Portal vein NA 8 
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 Cirrhosis HCC 
invasion 
Single nodule NA 19 
Two nodules NA 8 
≥ 3 nodules NA 18 
 
The difference in age between patients with cirrhosis and HCC versus those with 
cirrhosis alone was statistically significant (p < 0.001). There was no significant 
difference between sex or Child-Pugh stage between the two groups 
Proteomic studies 
Serum samples from 5 patients with NAFLD but no significant fibrosis, 5 patients 
with NAFLD and biopsy proven cirrhosis, and 5 patients with NAFLD cirrhosis and 
advanced AFP negative HCC were prepared for study. AFP negative samples were 
used hypothesising that these patients secrete other proteins. The samples were 
immunodepleted and de-salted using protocol 2.4.2 A. 500 μg of total protein was 
separated per 2-dimensional gel electrophoresis run. The prepared protein was then 
subjected to 2 dimensional electrophoresis as per protocol in 2.4.2 C.  
All samples were analysed using duplicate gels. Gel images after scanning were 
stored as TIFF files and analysed using Progenesis Software (Nonlinear Dynamics). 
Protein spots of interest were excised, destained, and digested with trypsin. Peptide 
mass fingerprinting was performed using a Voyager DE-STR MALDI-TOF mass 
spectrometer (Applied Biosystems Inc.) operated in positive ion reflectron mode with 
α-cyano-4-hydroxycinnamic acid as the matrix. Protein identifications were 
performed using the Mascot Peptide Mass Fingerprint search program (Matrix 
Science Ltd). 
Serum ELISA assay 
A direct ELISA for novel candidate CD5L was optimised using different 
concentrations of serum (raw, 1:10, 1:100, 1:500 and 1:1000), primary anti-CD5L 
antibody (R&D systems) and recombinant CD5L protein (R&D systems). Serum 
dilutions of either 1:10 or 1:100 generated a linear absorbance response over a protein 
range of 0.01 - 1.0 ng/ml using a primary antibody dilution of 1:500. This antibody 
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dilution was then used to analyse all subsequent patient serum samples in triplicate at 
a dilution of 1:10 (protocol 2.4.4). 
Liver Tissues CD5L mRNA analysis (performed by Dr HL Reeves’ group) 
Liver biopsy tissues surplus to diagnostic requirements were available from 21 
patients with histologically staged pre-cirrhotic NAFLD, collected with appropriate 
ethical approvals in either Newcastle Hospitals or the Policlinico Gemelli Hospital, 
Rome. Histological staging was as defined by Brunt [264], although no RNA yield 
sufficient for analysis was obtained from a stage 4/cirrhotic biopsy. In addition, liver 
tissues obtained at the time of liver resection or radiofrequency ablation for benign or 
malignant primary or secondary tumours was obtained in the Newcastle Hospitals, 
with ethical approval, from an additional 14 individuals. One of these had 
histologically confirmed HCC and steatohepatitis related cirrhosis. The other 13 had 
'normal livers', although mild steatosis or a mild focal mononuclear cell infiltrate were 
occasionally noted on histological assessment post resection. Semi-quantitative real 
time PCR analysis was performed as previously described [273] using GAPDH as a 
control gene and the following CD5L primers: Forward: 5' CAA CAA GCA TGC 
CTA TGG CCG AAA, Reverse: 5' TCA CAT TCG ACC CAC GTG TCT TCA. 
CD5L expression was expressed relative to the control gene GAPDH and a normal 
liver sample from an individual patient undergoing resection of a benign focal nodular 
hyperplasia. 
Statistical analysis 
Quantitative variables are expressed as mean and standard deviation. Comparison 
between groups were performed by Pearson Chi-square, Wilcoxon or Student's t-test, 
as appropriate. The diagnostic accuracy of CD5L was evaluated using receiver 
operating characteristic (ROC) curve analysis, reporting the area under the curve 
(AUC) and its 95% confidence interval (CI). Statistical analyses were performed with 
SPSS version 14. 
5.3 Results 
Novel candidate biomarkers identified using proteomic techniques 
Figure 5.1 shows representative 2D gels of each of the three groups and identifies a 
number of spots, labelled 1-5. These spots, particularly in combination, enable the 
differentiation between the three patient groups, namely NAFLD without fibrosis, 
NAFLD with cirrhosis, and NAFLD with cirrhosis and HCC.  
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Table 5.2 (below) lists the the 5 proteins with differential expression (> 2 fold change) 
in between the conditions of steatohepatitis, cirrhosis and HCC 
Spot 
number 
Accession 
code (Entrez 
protein) 
Identification 
method 
Mascot 
Score 
Sequence  
Coverage 
Protein 
description 
Mass Function 
1 CAA00975 Matrix MS 247 80% ApoA1 Protein 
(fragment) 
28061 Cholesterol 
transport to the 
liver 
2 CAA00975 Matrix MS 236 75% ApoA1 Protein 
(fragment) 
28061 Cholesterol 
transport to the 
liver 
3 CA00975 MatrixMS, 
then 
MS MS 
195 62% Pro-ApoA1 
Protein 
(fragment) 
28061  
4 AAA51748 Matrix MS 338 64% Apo A iv Protein 43358 Required for 
efficient 
activation of 
lipoprotein 
lipase 
5 AAD01446 Matrix MS 218 68% AFO11429 
(CD5L) 
38063 Apoptosis 
inhibitor 
secreted by 
macrophage 
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Figure 5.1 
Serum proteins separated by two dimensional gel electrophoresis in early and 
advanced NAFLD, with and without HCC. These are representative blots 
comparing immune depleted and desalted serum from a patient with NAFLD and no 
fibrosis, a patient with NAFLD cirrhosis, and a patient with NAFLD cirrhosis and 
cancer. Serum profiles separated by 2D gel electrophoresis from 5 patients in each 
group, run in duplicate, were compared using Progenesis software. 5 spots were 
characterised by MS after excision. Spots 1,2 and 3 were isoforms of apolipoprotein 
A1, spot 4 was apolipoprotein A4, and spot 5 was identified as CD5 antigen like, or 
CD5L 
 
Protein identification of spots 1-5 was by Mascot search after mass spectroscopy. The 
identities and Mascot scores are summarised in Table 5.2. Spots 1-3 were all 
identified after mass spectroscopy as apolipoprotein A1 (ApoA1). Spot 2 in particular 
was reduced in cirrhotic individuals relative to those with pre-cirrhotic NAFLD. In 
addition Pro-ApoA1, spot 3, was markedly present in all individuals with cirrhosis 
and HCC relative to only trace amounts in simple steatosis patients and cirrhotic 
patients without HCC. Protein spot 4 appeared lower in pre-cirrhotic NAFLD patients, 
compared to those with cirrhosis and in individuals with cirrhosis and HCC. This spot 
was identified as Apolipoprotein A4 (ApoA4). Protein spot 5 was identified as CD5 
antigen like (CD5L). Relative to pre-cirrhotic NAFLD, this protein was identified in 
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the serum of individuals with both cirrhosis and also those with cirrhosis and cancer, 
markedly so in the latter group. 
 
CD5L determined by ELISA assay was very highly expressed in the serum of 
individuals with cirrhosis and HCC 
Serum CD5L was assessed in the serum of 45 individuals with steatohepatitis-related 
HCC and compared to levels in 49 individuals with biopsy proven steatohepatitis-
related cirrhosis. Patient characteristics are shown in Table 5.1. The CD5L serum 
level was not significantly associated with age or sex. The box plots depicting the 
mean levels of the two groups of patients are shown in Figure 5.2 and are not 
significantly different (194 ± 167 without HCC versus 218 ± 221 with HCC). The 
AUC determined by ROC analysis (shown in Figure5.2B) was 0.495 and indicated a 
poor serum CD5L discriminatory capacity between cirrhotic individuals with and 
without cancer. Some individuals with HCC did have, however, particularly high 
CD5L levels. A level greater than 400 ng/ml has a specificity for HCC of 88%. The 
sensitivity at this level was unacceptably poor (20%). 
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Figure 5.2 
CD5L discriminates poorly between cirrhotic patients with and without HCC. 
Serum levels of CD5L were measured by ELISA assay in cirrhotic patients with (218 
± 221; n = 45) and without (194 ± 166; n = 49) HCC, as shown in 2A. Characteristics 
of the individuals are shown in Table 5.1. There was no significant difference between 
the two groups. ROC analyses is shown in 2B. The area under the curve is 0.495 (95% 
confidence intervals 0.376 and 0.614). A level > 400 ng/ml has a sensitivity of only 
20%, but a specificity of 88%. Levels > 500 ng/ml have a specificity of 96%, > 600 
ng/ml of 98% and > 700 ng/ml of 100%. For comparison, the mean CD5L serum level 
from patients without cirrhosis (detailed in figure 5.2A) is also shown. 
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CD5L ELISA in individuals with different stages of NAFLD was a good predictor of 
those with cirrhosis 
Serum from 77 patients, all of whom had biopsy proven NAFLD and had an alcohol 
intake of < 21 units per week for men and < 14 units for women, was studied. In this 
group of individuals the serum level of CD5L ng/ml in cirrhotic individuals (236 ± 
223) was similar to those cirrhotic individuals with and without HCC described 
above. This level for stage 4 fibrosis/cirrhosis was significantly elevated compared to 
individuals with all other pre-cirrhotic stages (ANOVA p = 0.001, Bonferroni 
correction applied). Mean levels of CD5L were not significantly different between 
any other histologically defined group (steatosis or the presence or absence of 
necroinflammation). The level of CD5L was significantly associated with fibrosis 
independently of age, sex, steatosis or necroinflammation, as assessed by General 
Linear Model analysis (GLM, SPSS). The ROC analyses of CD5L as a predictor of 
stage 4 fibrosis in this independent group of patients with NAFLD is shown in 
Figure5.3 B. The area under the curve was 0.712 (95% CI 0.534-0.889). 
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Figure 5.3 
CD5L discriminates between steatohepatitis patients with and without cirrhosis. 
Serum levels of CD5L were measured in a total of 113 patients with either ALD or 
NAFLD. Fibrosis was scored histologically on liver biopsy as per the Brunt scoring 
system. The numbers of individuals in each group are shown within the boxes of 
figure 5. 3A. The difference in CD5L levels between the different stages of fibrosis is 
statistically significant by univariate analysis (p = 0.004) controlled for both age and 
sex. This difference The ROC analyses for the identification of those individuals with 
stage 4 fibrosis (cirrhosis) is depicted in 5.3B. The area under the curve is 0.719 (95% 
confidence intervals 0.623 and 0.816), p < 0.0001. A level of CD5L 50 ng/ml has a 
sensitivity of 78% and a specificity of 46%, while a level of 100 ng/ml has a 
sensitivity of 63% and a specificity of 72%. A level greater than 200 ng/ml has a 
specificity of 95% (sensitivity 41%), and greater than 300 ng/ml of 97% (sensitivity 
27%). 
 
CD5L mRNA expression was elevated in individuals with NAFLD versus those with 
no underlying liver disease 
CD5L mRNA expression was quantified in one set of liver biopsy tissues from 
patients with histologically staged NAFLD, and a set of normal liver tissues collected 
at the time of resection for benign or secondary cancers (See methods). Data are 
expressed relative to the GAPDH control gene and a single normal liver sample from 
an individual undergoing resection for focal nodular hyperplasia. In the pre-cirrhotic 
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NAFLD biopsy tissues, there was no significant difference in association with either 
fat, inflammatory or fibrosis score, as shown in Figure 5.4. What was most notable, 
was that the liver mRNA expression of CD5L was significantly increased in the 
diseased NAFLD group as a whole (n = 21), relative to the normal liver group (n = 
13) (6.945 ± 0.722 versus1.68 ± 0.269; p = 0.000). Although some of the 'normal' 
liver samples from patients undergoing resection for secondary malignancies had a 
'mild steatosis' or a 'minimal focal mononuclear cell infiltrate' noted at the time of 
histological examination, there was no significant difference in CD5L expression in 
association with either of these minor changes (data not shown). The marked CD5L 
mRNA expression shown in the single cirrhotic tissue and HCC pair (Figure5.4C) 
were in keeping with the serum ELISA assays from the much larger patient group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
116 
 
Figure 5.4 
CD5L mRNA expression is not altered in association with either fat, 
inflammation or fibrosis scores in pre-cirrhotic NAFLD liver tissues. mRNA 
CD5L expression was quantified by real-time PCR, relative to GAPDH and a normal 
liver sample, in 21 pre-cirrhotic NAFLD biopsy tissues, 13 normal liver samples 
taken at the time of liver resection, one cirrhotic liver and one HCC. As shown in 4A-
C, there was no difference in any pre-cirrhotic NAFLD biopsy tissues in association 
with the degree of fat, inflammation or fibrosis. There was a significant increase in the 
NAFLD tissues as a group (n = 21), compared with normal liver tissues (n = 13) as 
represented in 4D (6.945 ± 0.722 versus1.68 ± 0.269; p = 0.000, ***). The elevated 
CD5L mRNA expression in one cirrhotic and HCC tissue pair, obtained at the time of 
laparoscopic radiofrequency ablation, is also presented in 4C and is in keeping with 
the elevated serum CD5L levels identified in the larger cohort of patients studied. 
5.4 Discussion 
The prevalence of chronic liver disease is increasing steadily in the UK, as is the 
population at risk of developing and dying from HCC. An increasing incidence of 
HCC has already been documented [6] and this is unfortunately compounded by the 
majority of tumours being diagnosed at a late stage when curative treatments are not 
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possible [274]. Regular surveillance of high risk individuals is recommended but is 
presently hindered by the poor performance of the commonly used serum marker, 
AFP [8], even in combination with abdominal USS. A significant effort has been and 
continues to be applied to the search for improved HCC biomarkers. As yet, none has 
proved superior to AFP in performance, but in combination some may have 
complimentary roles [275, 276]. Our particular concern relates to the marked increase 
in the prevalence of ALD and NAFLD related HCC on our own unit. These 
individuals are often over 65 years of age and have cardiovascular co-morbidities 
precluding curative resection or transplantation. Much attention has been focused on 
validating quantitative fibrosis or cirrhosis markers in these individuals, with 
combinations of serum markers [271] showing encouraging if still suboptimal 
improvements in performance. Imaging methods such as the fibroscan may improve 
the efficiency of cirrhosis detection [277-279], but presently this technique needs to 
be interpreted with caution in obese individuals [279-282]. The need for further 
improvements in serum biomarkers for early detection of both advanced fibrosis and 
HCC grows ever more pressing. 
We have applied a proteomic strategy using an optimised method of patient serum 
preparation in order to identify candidate biomarkers of either cirrhosis or HCC. This 
includes immune depletion prior to separation of serum by 2D gel electrophoresis. 
While this might remove some key biomarkers, we believe that this strategy improves 
the sensitivity of the technique applied to the remaining serum proteins. Having 
identified a number of spots able to discriminate between patients in at least one of 
our pre-defined disease groups, namely pre-cirrhotic NAFLD, cirrhotic NAFLD, and 
cirrhotic NAFLD with cancer, we selected candidates for identification by peptide 
mass spectroscopy. 
The novel serum protein CD5L was identified in the serum of cirrhotic individuals 
with and without HCC by our proteomic strategy. CD5L, also known as Sp alpha, is a 
soluble protein belonging to group B of the scavenger receptor cysteine-rich (SRCR) 
superfamily for which little functional information is available [283]. It is expressed 
by macrophages present in lymphoid tissues (spleen, lymph node, thymus, and bone 
marrow), and it binds to myelomonocytic and lymphoid cells, suggesting that it may 
play an important role in the regulation of the innate and adaptive immune systems. It 
was recently identified in the sera of individuals with liver fibrosis related to HCV 
infection and, based on its proposed role in immune system regulation, was thought 
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most likely associated with viral infection rather than cirrhosis [284]. While this may 
yet be true, as a mRNA transcript, it has been previously reported AS upregulated in 
HCC relative to dysplastic nodules [265]. We have investigated the potential of CD5L 
as a candidate biomarker for either advanced liver disease, or advanced liver disease 
and cancer. Our ELISA assay indicated a poor performance for CD5L as a 
surveillance tool for HCC, but again suggested value for cirrhosis detection. Our data 
clearly indicate, however, an association with cirrhosis in individuals without viral 
infection, which is independent of the presence or absence of histologically assessed 
inflammation. Our CD5L mRNA expression data from pre-cirrhotic NAFLD liver 
biopsies indicate an increase in association with fatty liver disease which, again, is not 
altered by the grade of either fat or inflammation. As CD5L does not increase 
incrementally with the level or stage of fibrosis, we propose that its dramatic increase 
in the serum of individuals with a background cirrhosis reflects hepatocyte 
regeneration, rather than the advanced fibrosis per se. The recent identification of 
CD5L by microarray as one of 30 mRNA transcripts expressed in patients with 
cirrhosis with a 'high risk' of HCC development [285] was one reason for our focus on 
this serum protein. Certainly some of our HCC patients had markedly high CD5L 
levels, while those with cirrhosis who had particularly high levels may be at high risk 
and may yet develop HCC. As a cirrhosis biomarker, the ROC analysis for CD5L 
indicates an accuracy of 72%. While this falls short of the accuracy of the European 
Liver Fibrosis (ELF) panel, recently validated in NAFLD patients and having an AUC 
of 0.9 for advanced fibrosis, CD5L is a single biomarker whose performance in 
conjunction with others may yet improve. In addition, it may have a value 
complementing that of AFP, which is predominantly elevated in patients with 
advanced HCC, in highlighting individuals with cirrhosis who are at greater risk of 
HCC development. At a level > 200 ng/ml, CD5L had a specificity for cirrhosis of 
96% and a specificity for cancer of 60%. 
Particularly prominent on our gel images were three spots identified as apolipoprotein 
A1 (ApoA1). ApoA1 is the major protein component of high density lipoprotein in 
plasma. It promotes cholesterol efflux from tissues to the liver for excretion and it is a 
cofactor for lecithin cholesterolacyltransferase which is responsible for the formation 
of most plasma cholesterol esters. It is not that surprising that this liver function 
associated protein alters in the serum of individuals with chronic liver disease and this 
has been previously reported in serum proteomic studies [286]. The mass of spots 1 
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and 2 (Figure 5.1) varied by approximately 30 daltons using MALDI analysis and are 
most likely attributable to post translational modification by oxidation. Notably, these 
two spots were reduced in cirrhotic individuals relative to those with pre-cirrhotic 
NAFLD, which is in keeping with previous reports and validates the clinical relevance 
of our methodology. In fact, a reduction of ApoA1 in the serum of patients with 
cirrhosis has remained a constitutive part of combined peptide panels used to predict 
fibrosis for a number of years [269, 287]. In addition, however, we identified a novel 
isoform - spot 3. The difference in mass between spots 1 and 2 and spot 3 was much 
greater and in the order of 900 daltons (Additional files 1, 3 and 5). MALDI MS 
analysis of this spot has identified it as pro-Apolipoprotein A1 (Additional files 6 and 
11), similarly detected and reported by an independent group of researchers studying 
patients with lung cancer [288]. Pro-Apolipoprotein A1 is proposed as a novel serum 
marker of brain metastases in lung cancer patients [288] and there may well be a 
rationale for its upregulation also in HCC patients. ApoA1 is secreted as the 
proprotein (pro-Apolipoprotein A1/spot 3) and is then cleaved, regulating its 
activation for lipid binding, by a metalloproteinase. One candidate metalloproteinase 
responsible is the c-terminal procollagen endoproteinase, Bone morphogenic protein 1 
(BMP-1) [289]. BMP-1 is secreted by the liver, but protease inhibitors, such as alpha-
2-macroglobulin (A2M), are also secreted by the liver, often at elevated levels in 
inflammation or chronic disease [290]. Either a reduction in BMP-1, or an increase in 
inhibitors such as A2M - as reportedly occurs in HCC [291], could block the 
maturation of pro-Apolipoprotein A1, hence contributing to relative increase in this 
isoform (spot 3). In fact, the relative decrease in mature apoA1 in cirrhotic patients 
(spot 2) may also reflect increases in protease inhibition and A2M has similarly 
contributed significantly to serum diagnostic tests for fibrosis [290-292]. Further 
investigation has yet to determine the sensitivity and specificity of pro-Apolipoprotein 
A1 as a novel candidate biomarker in patients with chronic liver disease and HCC, but 
our pilot study suggests that its up-regulation is specifically a feature in the serum of 
patients with HCC. 
5.5 Conclusion 
While non-hypothesis driven methodologies may be criticised by some as ‘fishing 
expeditions’, encouraging agreement is beginning to emerge when comparing data 
generated by proteomic techniques in the field of chronic liver disease, particularly 
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when it is interpreted in the context of the ever growing academic literature generated 
by gene expression profiling. The data presented in this pilot study have identified a 
pattern of serum apolipoproteins which, in combination CD5L, can discriminate 
between precirrhotic NAFLD, cirrhotic NAFLD, and cirrhotic NAFLD with HCC. 
These methodologies, even in small studies requiring additional validation, contribute 
significantly to this field and provide the hope that improved serum biomarkers may 
yet become available as surveillance, diagnostic and prognostic tools in patients with 
chronic liver disease. 
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Chapter 6 Results 4. Liver transplant for HCC – Newcastle experience 
6.1 Introduction 
The definitive treatment for HCC is surgical, removing the tumour either by resection 
or liver transplantation. Resection is usually only considered for patients with early 
malignant disease and with preserved liver function and no portal hypertension. For 
those in whom the liver function is poor, or in whom there is significant portal 
hypertension, liver transplantation to replace both the tumour and the diseased liver 
offers the only chance of cure. Selection of patients for liver transplantation in the UK 
is carefully governed by use of the Milan criteria, as detailed in Chapter 1.  Other 
critical limiting factors include the age of the patient and the presence of other 
significant co-morbidities.  
Unfortunately, despite careful selection of our patients by these means, the outcome 
of liver transplantation for non-malignant conditions remains superior. Recurrence of 
HCC in the transplanted liver occurs in approximately 10 - 60% of recipients, 
adversely affecting their long term survival. [111, 293-296].  The role of 
immunosuppressive drugs in HCC recurrence post liver transplant remains unclear.  
As yet there are not sufficient data to implement evidence based changes to standard 
triple therapy regimes, but many transplant centres do modify immunosuppressive 
regimes in the HCC setting. The role of adjuvant therapy, for which there is similarly 
no proven benefit in these individuals, remains an area of keen interest.  Ideally, we 
would like to be able to extend rather than further restrict the numbers of patients 
transplanted for HCC, but this is not appropriate when there are growing waiting lists 
with restricted donor organs. To achieve long term survival in HCC patients, we need 
not only to more accurately predict those individuals at higher risk of recurrent 
disease, but also to offer them an adjuvant therapy which will reduce tumour 
recurrence. 
Liver transplantation has been ongoing at the Freeman hospital (Regional centre for 
Liver diseases) in Newcastle-Upon-Tyne since 1993. We have retrospectively audited 
our patients transplanted for HCC.  A number of them have received adjuvant 
chemotherapy with Doxorubicin. Our Newcastle survival and recurrence data are 
presented.   
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6.2 Patient and methods 
Between 02/10/1993 and 18/07/2007, a total of 553 patients were transplanted on our 
unit at the Freeman Hospital, Newcastle Upon Tyne. HCC co-existent with chronic 
liver disease was present in 51 of these patients.  The pre-transplant diagnosis of HCC 
was made using a combination of contrast enhanced cross-sectional imaging by CT 
and MRI scanning, as per recommended EASL guidelines, in 38 of these individuals 
(HCC being an incidental finding in the explanted liver in 11 patients). Post 1996, 
only those individuals radiologically within the Milan criteria (a single tumour < 5cm; 
or 3 tumours none >3cm and no macrovascular invasion) were accepted onto the 
transplant list. Additional imaging included a thoracic CT scan, a bone scan, and bone 
densitometry.  Routine serum tests included the tumour markers, CA19-9, CEA and 
AFP.  Patient details are summarised in Table 6.1. The diagnosis of HCC was 
confirmed histologically in the explanted liver. Some patients received transarterial 
chemoembolisation (50mg doxorubicin mixed with 6-8ml lipiodol, followed by 
polyvinylalcohol particles) whilst on the list. 
From the time of transplantation, patients were managed according to our own 
protocols modified for the HCC setting. Postoperative immunosupression was 
modified relative to non-malignant liver diseases. Our protocol included patients with 
a preoperative diagnosis of HCC being given a perioperative dose of intravenous 
doxorubicin 20 mg/m
2
 during the anhepatic phase of the liver transplant.  
A careful pathological study of the explanted liver was performed in all cases. The 
tumour characteristics based on the pathological findings were compared to 
preoperative imaging. The recorded tumour characteristics included the number of 
tumours, unilobar/bilobar involvement, the size of the tumour(s), grade of 
differentiation and presence/absence of vascular invasion. The total tumour diameter 
was calculated as the sum of the greatest diameter of each lesion [297].  
28 days post transplant, patients (HCC diagnosed pre transplant and incidental 
tumours) who had unfavourable histology (moderately to poorly differentiated 
tumour, microvascular invasion) and multifocal tumours were considered for adjuvant 
doxorubicin chemotherapy (weekly doxorubicin of 25mg/m
2
 for a total of 200mg/m
2
).  
Peri-operative mortality was defined as patient death, irrespective of the cause, within 
28 days of the liver transplant.  Follow up of LT recipients included a CT scan and 
AFP measurement at every 4 months for the first year, six monthly for second year 
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and annually thereafter. The recurrence rate was defined as percentage of HCC 
recurrence including all HCC cases during the follow up period. All patients were 
followed up at the Freeman Hospital and no patients were lost to follow up. Follow up 
data was collected in February, 2009. 
Statistical analyses were using SPSS software version 16.0 and Graph pad prism 
version 4.02. Actuarial survival was calculated using the Kaplan-Meier method. 
Differences in survival were examined using the log rank test. Cox-proportional 
hazards regression analysis used for multivariate analysis of variables to test the 
significance of variables removing the confounding variables. Students t test, Mann-
Whitney test, Fisher exact test, and the Chi squared test were used to compare groups. 
P<0.05 was considered significant.  
6.3 Results 
6.3.1 Demographic profile of patients transplanted for HCC 
The majority of patients transplanted with HCC were male, with an underlying ALD 
or HCV related cirrhosis 
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The demographic data for the 51 patients with HCC transplanted between 1993 and 
2007 are summarised in Table 6.1. Eight were female and 43 were male, their median 
ages being 56.5 (42 – 67) and 59 years (28 - 69 ) respectively. Alcoholic liver disease 
(ALD) and Hepatitis C (HCV) were the commonest underlying aetiologies.  The 
follow-up times until 1
st
 of July, 2011 are a median of 55 months (range 03 – 202) and 
a mean of 67.6 + 50.52 months.  
6.3.2 Cross sectional imaging underestimated the stage of malignant disease 
The pathological and histological characteristics of the tumours identified are 
summarised in Table 6.2 (In one patient histopathological data was not available). Of 
these 51 patients, 11 were diagnosed of HCC in the excised liver and the preoperative 
imagings did not reveal any tumour i.e. incidental tumours.  While it is not possible to 
determine the histological grade of an HCC pre-transplant without biopsy, it is 
proposed that some pre-operative factors such as radiological (eg size or number of  
Table 6.1 Demographic data of patients who 
underwent OLT and the explant confirmed HCC 
 
Characteristics Number of patients (%) 
Male/Female 43/8 
Age (M/F) 59/56.5 
Aetiology  
20 (39.2) 
3 (5.8) 
15 (29.4) 
3 (5.8) 
2 (3.9) 
2 (3.9) 
3 (5.8) 
3 (5.8) 
ALD 
NAFLD 
HCV 
HBV 
PBC 
AIH 
Haemochromatosis 
Cryptogenic 
Follow-up (months)   
 
55 
67.6 + 50.32  
Median 
Mean 
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tumours, the presence of large vessel invasion) can be useful to predict outcome. One 
third of our patients transplanted with HCC had poorly differentiated cancers on 
explant histology, with a similar number having evidence of microvascular invasion.  
In fact, this histological grading does reflect tumour size and number, as a similar 
proportion of patients had larger or more than ideal numbers of tumours in their 
explanted liver. 
In summary, 18 (36%) of these individuals had disease at explant that would have 
been deemed beyond ‘Milan criteria’, if radiological imaging could be more sensitive.   
6.3.3 The survival of our cohort of patients who underwent liver transplant for 
HCC (including incidental tumours) was 61.3% at 5 years.  
In the first 18 years of liver transplant for HCC in this centre, 25 deaths were observed 
in 51 patients. Of these, two deaths were in the post operative period (death within 
post-operative 4 weeks), one as a result of sepsis and the other as a result of 
reperfusion syndrome. The causes of the additional 23 mortalities are shown in Table 
6.3.  
 
 
 
Table 6.2. Tumour characteristics  
Distribution Unilobar 
Bilobar 
36 
14 
Differentiation Well  
Moderate  
Poor 
17 
19 
14 
Number 1 
2-3 
4-5  
> 6 
27 
10 
05 
08 
Total size < 30 mm 
30 – 50 mm 
> 50 mm 
17 
17 
16 
Microvascular  
Invasion 
Present 
Absent 
22 
28 
Explant fitting  
Milan criteria 
Yes 
No 
32 
18 
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Figure 6.1 The overall 5 year 
survival for patients transplanted 
for HCC was 62.1%.  
 
 
 
 
 
 
 
The causes for early death are reperfusion syndrome, sepsis and coagulopathy whilst 
recurrence of HCC and graft failure accounted for deaths within 2 years of transplant. 
Lymphoproliferative disorders and recurrent cirrhosis were responsible for those 
patients who died in the long term. 
Table 6.3 Cause of death  Number of 
patients 
Median survival 
(months) 
Recurrence of HCC 
Primary lung carcinoma 
Primary gastric carcinoma 
Intracranial Haemorrhage 
Myocardial Infarction 
Status epilepticus with aspiration 
Sepsis 
Reperfusion syndrome 
Coagulopathy 
Graft failure 
Recurrent hepatitis with cirrhosis 
Post-Transplant 
Lymphoproliferative disorder 
Hodgkin’s disease 
5 
1 
1 
1 
2 
1 
2 
1 
1 
7 
1 
 
1 
1 
10 
06 
20 
06 
120 
01 
01 
0 
0 
32 
137 
 
152 
149 
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Recurrence of HCC was observed in 5 patients, occurring within two years in all 
cases. The overall survival was at 62.1% at 5 years, as shown in figure 6.1, with a 
recurrence rate in the explants or distant site of 10% (n=5). The median survival noted 
for this period of the study was 137 months. 
The survival in the incidental cohort was longer than the preoperatively diagnosed 
cohort but the difference was not statistically different as shown in Figure 6.2. 
 
 
Figure 6.2 comparing the 
survival after liver transplant 
with a known  preoperative 
diagnosis of HCC and incidental 
HCC in the explants (log rank 
0.8) 
 
 
 
 
 
 
 
6.3.4 Tumour and epidemiological characteristics in 5  year survival 
A Cox regression model was used to analyse the effect of different tumour and 
epidemiological characteristics which include aetiology of cirrhosis, number of 
tumour nodules, tumour differentiation and microvascular invasion. 19 of 39 patients 
had preoperative TACE and was also included in the analysis to assess whether it 
affects  survival after liver transplantation. The results are shown in Table 6.4 and 
Figures 6.3 and 6.4. 
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Table 6.4 Univariate and multivariate analysis of patient survival with 
tumour and epidemiological characteristics using log rank test and Cox 
regression model 
Characteristic Number Log rank    Cox regression 
Aetiology                            
                        
15                             
03 
03 
02                          1.000 
03 
02 
03 
      ALD 
      HCV 
      HBV 
      NASH 
      PBC 
Haemachromatosis 
      AIH 
     Cryptogenic 
Tumour Nodules                              
 26 
11                        0.136 
13 
     One nodule 
2-3 Nodules 
      >3 nodules 
AFP                              
40                        0.031                        0.039 
11 
<400 
>400 
Pre op TACE                              
20                        0.687 
31 
     Yes 
     No 
Lobar distribution                              
 
36                        0.058 
14 
     Unilobar 
     Bilobar 
Differentiation                              
17 
20                       0.043                    0.021 
13 
     Mild 
     Modearte 
     Poor 
Microvascular invasion                              
28                        0.003                   0.004 
22 
    Yes 
    No 
Multifocal                      
26                       0.08    Yes 
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Table 6.4 (above) shows the correlation of survival with different tumour parameters 
and the aetiology of background liver disease 
Long term survival was adversely affected by raised AFP (>400), poor differentiation 
and  tumours more than 5cms. Pre-transplant TACE showed no improvement in 
survival. 
   No 24 
Tumour diameter                       
24 
13                 0.005                  0.008 
13 
      <3cm 
     3-5 cms 
      >5cm 
130 
 
Figure 6.2 shows comparisons of survival in relation to sex (A), tumour number (B), 
AFP levels (C), pre-operative TACE (D), lobar distribution (F) and degree of tumour 
differentiation (F) 
Table 6.5 showing characteristics of the three groups of patients with HCC 
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 Group A Group B Group C 
Number of patients 13 26 12 
Age (Median) 60 59.5 57 
Sex (M:F) 09:04 24:02 10:02 
Aetiology  
a)ALD 4 10 6 
b)Hepatitis C 2 10 3 
c)Hepatitis B 0 1 2 
d)NAFLD 3 0 0 
e)AIH 0 1 2 
f)Haemachromatosis 1 2 0 
g)Cryptogenic 1 1 1 
h)PBC 2 0 0 
AFP ng/ml (Mean) 12.8 1388 133.83 
Incidental HCC 7 2 2 
Pre-op TACE 5 19 6 
Recurrent hepatitis 2 5 0 
Cause of death  
a)Graft failure 1 4 1 
b)Coagulopathy 1 0 0 
c)MI 1 0 0 
d)Sepsis 0 0 1 
eAspiration pneumonia 0 0 1 
f)Metastatic HCC 0 6 1 
g)Gastric carcinoma 0 0 1 
h)Abscess with ruptured hepatic 
artery 
0 0 1 
i)Reperfusion syndrome 0 0 1 
j)Intracranial Haemorrahge 0 1 0 
5 year survival estimate 92.3% 56.7% 36.4% 
Median survival (months) 202 78 08 
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Figure 6.3 survival in comparison with microvascular invasion (A), focality of tumour 
(B) and tumour diameter (C) 
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 6.3.5 The survival of our HCC patients receiving adjuvant chemotherapy was 
56.7% 
37 of 51 patients transplanted with an HCC had adverse pathological criteria (poorly 
differentiated; evidence of microvascular invasion) and adjuvant chemotherapy was 
administered in 26.  The reasons for not giving chemotherapy included poor graft 
function (n = 3), sepsis (n = 5), persistent chest infection (n =2) and one perioperative 
death due to reperfusion syndrome.  Three of the 26 who received it did not complete 
6 cycles, owing to sepsis / neutropenia (n = 2) and death (n = 1). The median survival 
in the chemotherapy cohort was observed to be 78 months and the five year expected 
survival was observed to be 56.7% (figure 6.4A).. 
 
Figure 6.4 shows the survival in the chemotherapy cohort (A) and then compared the 
survival versus patients not requiring chemotherapy and those which were not fit for 
chemotherapy (B). 
6.3.6 Comparison of survival of the chemotheapy cohort with a non-
chemotherapy cohort 
To attempt to compare the effect of the chemotherapy, we categorised our patients 
into three groups. Group A patients had no adverse tumour characteristics and did not 
receive adjuvant chemotherapy, group B patients had adverse tumour characteristics 
and received chemotherapy, while group C had adverse tumour characteristics but 
were not fit for chemotherapy. The characteristics of the three groups are described in  
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Table 6.5. The obvious  difference  is the mean level of AFP (more than 1000) in the 
patients receiving post-transplant chemotherapy. 
We compared the five and ten year survival of group A with that of group B       .  
The estimated five year survival for patients in group A was 92.3% compared to 56.7 
% for patients who received chemotherapy i.e group B (Figure 6.4B). The median 
survival was 202 months for patients in the no chemotherapy cohort and 78 months in 
the chemotherapy cohort with the  log rank test showing inferior survival for the 
patients in the chemotherapy cohort (log rank p=0.041). 
6.4 Discussion 
Of all the current modalities of treatment available for the treatment of HCC, liver 
transplant is the only modality which deals with the cirrhosis and the liver tumour at 
the same time. This has been further encouraged by the fact that the 5 year survival 
after liver transplantation for HCC approaching that of patients undergoing liver 
transplant for non-malignant conditions in selected group of patients [298, 299]. There 
are ongoing efforts to improve the survival in the patients who undergo liver 
transplant for HCC.  
In the retrospective review of our set of 51 patients we noted a combined 5 year 
survival of 61.3%. This is in congruence with the reported survival of 58 – 74% in 
other series [300, 301]. In our centre our protocol included the administration of 
adriamycin to all patients with known HCC during the anhepatic phase of the liver 
transplant. The aim was to kill any malignant cells shed into the systemic circulation 
while mobilising the diseased liver at the time of transplantation.  
Reviewing the literature shows limited evidence for the role of adjuvant 
chemotherapy. Stone et al in 1993 reported that in a pilot study of 20 patients with 
unresectable tumours who underwent hepatic transplantation and received 
chemotherapy preoperatively, intraoperatively and postoperatively, neo-adjuvant 
doxorubicin favourably affects  long term survival[302]. In the study the actuarial 3 
year survival of the entire cohort of patients undergoing transplantation for HCC was 
59% but for the patients with HCC measuring more than 5cm the 3 year actuarial 
survival of 63% Even in tumours larger than 5cm multi modality adjuvant 
chemotherapy with liver transplantation was shown to improve recurrence free 
interval and prolong survival[303]. Other studies have supported the role of adjuvant 
chemotherapy with liver transplantation for tumours that are not amenable to resection 
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[304, 305]. However most of these results were from small studies published in the 
early 1990s.  
Some recent studies do not have a favourable opinion of chemotherapy due to 
increased side effects of the drugs, including mortality. A study on 62 patients 
randomised into two groups with 32 patients in the protocol and 28 in the control 
group. The protocol group recieved doxorubicin as adjuvant chemotherapy after 
transplantation and no difference in survival was noted between the two groups 
(overall 5 year survival was 40% in the control group and 38% in the chemotherapy 
group) [306] Bernal E et al in 2006 concluded that post liver transplantation 
chemotherapy does not avoid tumour recurrence and has fatal consequences. 
Furthermore, the uncertain effect of adjuvant chemotherapy on recurrence of viral 
hepatitis in the graft and absence of appropriate control groups warrants this drug to 
be used only within the confines of clinical trials[307]. However, Hsieh et al reported 
that the combined use of gemcitabine and cisplatin in patients where the explant did 
not fit the Milan criteria may in fact improve disease specific survival in this select 
group of patients[308] 
In our cohort, we identified post operatively those patients with known adverse 
prognostic factors i.e poor differentiation and microinvasion. In our cohort with these 
features, 26 of 37 patients were deemed fit for our adjuvant chemotherapy regime. 
Post operative adjuvant chemotherapy was administered to nullify the adverse 
prognostic factors and reduce the chance of micrometastasis. The group with the 
known adverse factors showed a lower survival than the group which did not need 
chemotherapy (56.7% vs 92.3%), which was statistically significant. Though the 
numbers were small and the data was retrospectively collected, it can be noted that 
despite the addition of adjuvant adriamycin chemotherapy the survival remained poor 
in the group with adverse predictors for survival .  
The results from our centre are also from a small non-randomised rerospective study 
and that that the overall results of adjuvant chemotherapy is dissapointing.No 
adjuvant therapy is currently advocated in HCC [309]. Our centre has also stopped the 
use of adjuvant chemotherapy but the encouraging results of kinase inhibitors e.g 
sorafenib at liver resection in a small study in 2010[310] has renewed interest in 
adjuvant treatment post-liver transplantation.  
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SUMMARY 
The cohort of HCC patients that I recruited in a two and a half year period, followed 
up therafter for a 5 year period, has provided valuable insights in a number of areas.  
Firstly, in comparison to previous cohorts, it is clear that the numbers of referred 
patients with HCC has increased 5-10 fold in as many years.  Furthermore, the 
underlying etiologies of chronic liver disease contributing the risk for development 
has changed, with steatohepatitis secondary to either alcohol or the obesity associated 
metabolic syndrome accounting for nearly 60% of the patients. Our sub analyses 
suggest that our multidisciplinary team approach to intensive patient staging and 
follow-up is worthwhile, as increasing numbers of patients are referred to us with 
early or intermediate stage disease.  We have clearly shown a survival advantage to 
patients with tumours detected incidentally or by screening, rather than 
symptomatically, and one of our areas of focused research has been to try and 
improve the means for surveillance of HCC in at risk patients, but also to consider 
how we might identify the at risk population who would benefit from surveillance. 
At the time when we were collecting patient data, we focussed on assessing the 
efficacy of some of the suggested biomarkers and explored proteomic and genomic 
approaches to mine for novel biomarkers for HCC. Combination of alphafetoprotein 
and PIVKA II (Prothrombin Induced by Vitamin K Absence II) performed better that 
either alone but sensitivity was still low. The dismal performance of SCCA 1 
(Squamous Cell Carcinoma Antigen 1) and Glypican 3 suggested that in view of the 
heterogenous nature of HCC it would be appropriate to select biomarkers for 
surveillance according to the aetiology for the background liver disease. For serum 
proteomics we used immunodepletion to remove abundant proteins before subjecting 
the serum to 2-dimensional gel electrophoresis. Of the five proteins spots showing 
differential expression between normal, cirrhosis and HCC we further investigated 
CD5L with ELISA assays. Though its ability to distinguish non-cancer from cancer 
individuals was poor, serum CD5L was markedly elevated in individuals with patients 
with NAFLD cirrhosis as compared to individuals with pre-cirrhotic disease. The 
proteomic strategy though shows promise in identifying future biomarkers. 
The poor performance characteritistics of the CLIP and BCLC scoring systems 
suggests that urgency for more robust systems. Molecular biomarkers seem to be 
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easily affected by human factors which precludes its use in daily practice. Adjuvant 
therapy post-live transplant for HCC has showed no benefit in survival. 
 In conclusion, these data in combination highlight the need for improved 
detection methods, staging systems and treatments in this increasing and changing 
population of individuals presenting with hepatocellular cancer. 
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APPENDIX 
 
Recipes 
Recipe for 10% resolving gel 
SDS –sodium dodecyl 
sulphate 
Acryl – acrylamide 
APS = ammonium 
persulphate 
 
 
Recipe for 4% stacking 
gel 
 
 
 4% BIS-Tris gel 
Double distilled water 12.2ml 
0.5M Tris (pH6.8) 5ml 
10% SDS 200 μl 
30% Acryl BIS 2.3ml 
10% APS 100 μl 
TEMED l 
 
 
Recipe for Running buffer (stock) for SDS PAGE 
10× Running buffer 
Tris base 30.3gm 
Glycine 144g 
SDS 10g 
 
Components 10% 
 Double distilled 
water 
16ml 
1.5M Tris(pH8.8) 10ml 
10%SDS 400μl 
30% Acryl BIS 13.4ml 
10%APS 200 μl 
TEMED 20 μl 
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Recipe for transfer buffer 
Transfer buffer 1L 
Tris base 3.03g 
Glycine 14.4g 
Distilled water Upto 800ml 
Methanol 200ml 
 
10 × TBS buffer 
Constituent    Quantity 
Tris-base    61g 
NaCl     90g 
De-ionosed water    1000ml 
 Adjust pH to 7.5 
Coating buffer (TBS) 
20mM Tris 2.4228 gm 
140 Mm NaCl 8.1816 gm 
DD Water to total of 1000ml 
 
Substrate for ELISA 
Stock solution was prepared by adding 100µg of TMB (tetramethyl benzidine) to10ml 
of DMSO (dimethylsulphoxide). 
Solution B was prepared by adding 1.36 gm of sodium acetate to 100ml of DDW 
(Double Distilled Water) and pH adjusted to 6. 
Then 100µl of the stock solution was added to 10ml of solution B. Then to it was 
added 2µl of hydrogen peroxide. 
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Rehydration buffer for Isoelectric Focussing 
 Final concentration Amount 
Urea (FW 60.06) 8m 12g 
CHAPS 2% 0.5g 
Ampholye 0.5% v/v 125 μl 
Bromophenol blue 0.002% 50 μl of 1% 
solution 
Double distilled water  To 25ml 
 
Equilibration buffer 
Component Quantity Final concentration 
Tris-HCl (pH 8.8) 10ml 50Mm 
Urea (FW 60.06) 72.07g 6M 
Glycerol (87% v/v) 69ml 30%v/v 
SDS (FW 288.38) 4g 2% w/v 
Bromophenol blue 400µl of 1% solution 0.002% 
Double distilled water Add to make  total volume of 
200 ml 
 
1mm thick 12% polyacrylamide gel recipe 
Component Volume 
Protogel 30% Acryl-BIS 180ml 
Tris-HCl (Ph 8.8) 112.5ml 
10% SDS 4.5ml 
Double Distilled Water 148.05ml 
 
RT-mastermix 
Component Vol 
10×Buffer 2.5 μl 
MgCl2 10 μl 
DNTP 2.5 μl 
Random primers 1.0 μl 
RNAsin 0.5 μl 
RT 0.8 μl 
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                        RT is added last 
Primers for PCR  
AFP 
Forward primer(5’ to 3’) TCC AGG AGA GCC AAG CAT TGReverse 
primer(5’ to 3’) AGC   AAC    GAG    AAA  CGC ATT TTG 
Cytokeratin 20 
Forward primer(5’ to 3’) CTG AAT AAA GAC CTA GCT CTC CTC AAA 
  
Reverse primer(5’ to 3’) GTG TTG CCC AGA TGC TTG TG 
β-actin 
Forward primer(5’ to 3’) CCT GGC ACC CAG CAC AAT 
Reverse primer(5’ to 3’) GCC GAT CCA CAC GGA GAT CT 
Standard PCR master mix for a 20 µl reaction 
Component Volume 
10×buffer 2.0 µl 
MgCl2 1.2 µl 
10mM dNTPs 0.4 µl 
F Primer 0.16 µl 
R Primer 0.16 µl 
Taq 0.16 µl µl 
Water 15.92 µl 
cDNA 2.0 µl 
  
10× TBE buffer 
Component Amount 
Tris-base 108 gm 
Boric acid 55 gm 
EDTA (pH 8.0) 40 ml 
 
166 
 
PIVKA-II ELISA Assay 
PIVKAII Stago Diagnostics Kit components 
Six 16 well strips, precipitated with the F(ab)2 fragments of anantithrombomodulin 
monoclonal antibody. 
Calibration plasmas 
Dilution buffer 
Antithrombomodulin peroxidise 
Reference thrombomodulin 
Calibration diluents 
Washing solution 
Urea peroxide 
Ortho-phenylenediamine (OPD) substrate 
PIVKAII Assay protocol    
1. The calibration plasmas were reconstituted with the dilution buffer. The serum 
samples were diluted with the dilution buffer 1:10.  
2. 200µl of dilution buffer was added to each well and then 50µl of the 
calibration plasma or of the test sample in the dilution buffer was added to the wells. 
The wells were filled in triplicate.The microwell plate was left to incubate for 1h at 
room temperature. 
3. The wells were washed five times with the washing buffer. 200µl of antibody-
enzyme conjugate was added to each well. 
The wells were incubated for 1h at room temperature, then washed five times with the 
washing solution. As soon the washing was completed, 230µl of substrate OPD/urea 
was added to each microwell. 
The microwell plate was then incubated for exactly 5min, and then the reaction 
stopped by adding 50µl of 3M sulphuric acid to each microwell. 
The microwell plate was then left for 10min at room temperature and the absorbance 
measured at 492Nm, using a micro-ELISA plate reader. 
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GPC-3 ELISA Assay 
GPC-3 Biomosaics Kit components 
1. Component 1: Coated microtiter plate – 96 removable wells pre-coated with 
GPC-3 monoclonal antibody. 
2. Component 2: GPC-3 standard – vials containing lyophilised human GPC-3 
protein. 
3. Detector antibody: biotinylated anti-human GPC-3 antibody. 
4. 400×Conjugate: Steptavidin-Peroxidase Conjugate; concentrated solution 
5. Conjugate Diluent (30ml): buffer for dilution of 400× Conjugate 
6. Substrate: Chromogenic substrate (TMB) 
7. Sample diluent 
8. 50× Plate Wash Concentrate: 50- fold concentrate solution of Tris and 
surfactant 
9. Stop solution: 0.25N sulphuric acid 
10. Plate sealers    
GPC-3 Assay protocol 
1.  Sample preparation: Serum sample was diluted to 1:4 using sample diluents.  
GPC-3 standard was reconstituted with DDW and then serially diluted with the 
sample diluents to obtain standard concentrations of 4050, 1350, 450, 150 and 50 
pg/ml.  
2. 100µl of sample diluent was pipetted into each well prior to adding samples or 
standards. Then 100µl of standard or the diluted samples was added in duplicate to the 
wells. The plates are then covered with the plate cover and incubated overnight at 2-8
0 
C. 
3. The wells are washed with 1× wash buffer five times. 
4. 200 µl of pre-diluted biotin conjugate anti GPC-3 was  pipetted into each well. 
5. The plates were covered and incubated overnight (18 – 24 hrs) at 2-80C.The 
wells were then washed 5 times with 1× wash buffer. 
6. Sufficient quantity of 400× SA-HRP conjugate was diluted 1:400 in SA-HRP 
conjugate  diluent to provide for 200 µl of 1× solution for each sample and standard 
well. 200µL of TMB substrate solution was added to each well and the plate 
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incubated in the dark at room temperature for 30min. The wells were washed 5 times 
with 1× Wash solution and then emptied. .  
7. 200µl of of TMB Substrate Solution was added to each well and incubated in the 
dark at room temperature for 30min. 100µl of Stop solution was added to each well in 
the same order as the TMB substrate solution. The wells were  read in the spectra max 
at dual wavelength of 450/550nm within 30min . 
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PROFORMA FOR PATIENTS WITH HCC 
COMBINED TUMOUR CLINIC:ASSESSMENT AND PROGRESS 
 
Patient Name/ 
Sticky laberl 
DATE         
 Child-Pugh 
Stage 
        1 2 3 
Encephalopathy         none Grade1-2 Grade 3-
4 
Ascites         absent mild Mod 
Bilirubin 
(µmol/l) 
        17-34 35-49 >50 
Albumin (g/l)         >35 28-35 <28 
PT (secs d)         1-4 4-6 >6 
         Grade A = 5-6; Grade B = 7-9,                           
           Grade C  9 
Okuda Score         0 1 
Tumour Size         <50% >50% 
Albumin         >30 <30 
Ascites         ABSENT PRESENT 
Bilirubin         <35 >35 
         Score 0  Stage1  28 months; Score 
1/2  Stage2  8; Score 3/4  Stage3 
 1 month 
CLIP Score         0 1 2 
Child-Pugh 
Stage 
        A B C 
Tumour 
morphology 
        Uninodular 
+ 
extension 
50% 
Multinodular 
+ extension 
50% 
Massive 
or 
extension 
> 50% 
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Performance StatusTest in cancer patients used to quantify functional status, is an 
important factor in determining prognosis (Sorensen Br J Cancer 1993) 
PS 0 = normal activity; PS 1 = some symptoms but near full ambulatory; PS 2 = <50% 
time in bed; PS 3 = >50% time in bed; PS 4 = Bedridden. 
AFP (ng/l)         <400 >400  
Portal vein 
thrombosis 
        no yes  
         Median survival in months: Score 0  
42.5; Score 1  32; Score 2  16.5; 
Score 3  4.5; Score 4  2.5; Scores 
5+6  1 
PST Score 
 
        
 
CT / MRI scan 
 
 
    
Clinical comment / 
Other significant PMHx 
/ 
Medication eg. 
Metformin? 
 
    
 
Management Plan 
including dates of MDT 
Reviews 
 
 
    
 
TACE 
 
 
    
 
RFA 
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Other therapeutic 
Intervention 
- Surgery / Systemmic 
Chemo /       
mirradiation 
    
 
Other inpatient 
admission 
 
 
    
